CONSOLIDATED FINANCIAL STATEMENTS AND UNIFORM GUIDANCE REPORTS AND SCHEDULE

Vanderbilt University Medical Center Years Ended June 30, 2023 and 2022 With Reports of Independent Auditors

Ernst & Young LLP



Vanderbilt University Medical Center

Consolidated Financial Statements and Uniform Guidance Reports and Schedule

June 30, 2023 and 2022

Contents

Report of Independent Auditors	1
Consolidated Financial Statements	
Consolidated Balance Sheets	4
Consolidated Statements of Operations	5
Consolidated Statements of Changes in Net Assets	
Consolidated Statements of Cash Flows	
Supplementary Information	
Schedule of Expenditures of Federal Awards and State Financial Assistance	47 74
Uniform Guidance Reports and Schedule	
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With Government Auditing Standards	76
Report of Independent Auditors on Compliance for Each Major Federal Program and	
Report on Internal Control Over Compliance Required by the Uniform Guidance	
Schedule of Findings and Questioned Costs	81



Ernst & Young LLP Suite 2100 222 2nd Avenue South Nashville, TN 37201 Tel: +1 615 252 2000 ev.com

Report of Independent Auditors

Senior Management and the Board of Directors Vanderbilt University Medical Center

Report on the Audit of the Financial Statements

Opinion

We have audited the consolidated financial statements of Vanderbilt University Medical Center (VUMC), which comprise the consolidated balance sheets as June 30, 2023 and 2022, and the related consolidated statements of operations, changes in net assets and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of VUMC at June 30, 2023 and 2022, and the results of its operations, changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of VUMC and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about VUMC's ability to continue as a going concern for one year after the date that the financial statements are issued.

2312-4393418



Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and Government Auditing Standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to
 fraud or error, and design and perform audit procedures responsive to those risks. Such procedures
 include examining, on a test basis, evidence regarding the amounts and disclosures in the financial
 statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures
 that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
 effectiveness of VUMC's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about VUMC's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

2312-4393418



Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. We have not performed any procedures with respect to the audited financial statements subsequent to September 29, 2023. The Schedule of Expenditures of Federal Awards and State Financial Assistance as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards and the State of Tennessee Audit Manual is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated September 29, 2023, on our consideration of VUMC's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of VUMC's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering VUMC's internal control over financial reporting and compliance.

Ernst + Young LLP

September 29, 2023, except for our report on the Schedule of Expenditures of Federal Awards and State Financial Assistance for which the date is February 20, 2024

Vanderbilt University Medical Center Consolidated Balance Sheets June 30, 2023 and 2022

(\$ in thousands)	_	2023		2022
Assets				
Current assets:				
Cash and cash equivalents	\$	679,566	\$	651,720
Current investments		104,923		255,090
Patient accounts receivable		730,052		658,644
Grants and contracts receivable		148,543		88,793
Inventories		160,134		134,557
Other current assets		88,667		122,903
Total current assets		1,911,885		1,911,707
Restricted cash		95,088		18,662
Noncurrent investments		932,952		773,234
Noncurrent investments limited as to use		165,119		150,925
Property, plant, and equipment, net		1,768,649		1,679,768
Operating lease assets		845,573		826,560
Other noncurrent assets		173,687		166,734
Total assets	\$	5,892,953	\$	5,527,590
Liabilities and Net Assets Current liabilities:				
Current portion of long-term debt	\$	23,910	\$	18,193
Accounts payable and other accrued expenses		473,542		404,059
Medicare accelerated payments		_		15,956
Estimated liabilities under third-party programs		67,022		89,328
Accrued compensation and benefits		345,691		353,270
Current portion of operating lease liabilities		71,906		68,510
Current portion of deferred revenue		8,275		9,494
Current portion of medical malpractice self-insurance reserves		18,414		15,820
Total current liabilities		1,008,760		974,630
Long-term debt, net of current portion		1,854,940		1,728,263
Noncurrent portion of operating lease liabilities		800,003		783,178
Fair value of interest rate exchange agreements		33,157		45,019
Noncurrent portion of medical malpractice self-insurance reserves		72,039		65,816
Noncurrent portion of deferred revenue		758		1,560
Other noncurrent liabilities		9,741		8,856
Total liabilities		3,779,398		3,607,322
Net assets without donor restrictions:				
Net assets without donor restrictions controlled by Vanderbilt				
University Medical Center		1,774,525		1,631,068
Net assets without donor restrictions related to noncontrolling				
interests		21,929		20,768
Total net assets without donor restrictions		1,796,454		1,651,836
Net assets with donor restrictions		317,101		268,432
Total net assets		2,113,555		1,920,268
Total liabilities and net assets	\$	5,892,953		\$5,527,590
Total Habilitios arta flot accord	Ψ	3,002,000	===	+3,02.,000

The accompanying notes are an integral part of these consolidated financial statements.

Vanderbilt University Medical Center Consolidated Statements of Operations Years Ended June 30, 2023 and 2022

(\$ in thousands)	2023	2022
Operating revenues		
Patient service revenue	\$ 5,871,054	\$ 5,356,273
Academic and research revenue	765,527	705,859
Other operating revenue	224,494	278,736
Total operating revenues	6,861,075	6,340,868
Operating expenses		
Salaries, wages, and benefits	3,697,820	3,304,333
Supplies and drugs	1,533,897	1,378,316
Facilities, equipment, and technology	398,957	364,623
Services and other	921,467	909,783
Depreciation and amortization	191,046	172,999
Interest	66,192	59,930
Total operating expenses	6,809,379	6,189,984
Income from operations	51,696	150,884
Nonoperating revenues and expenses		
Income (loss) from investments	61,043	(71,057)
Gift income	24,977	21,477
Earnings of unconsolidated organizations	3,932	9,392
Unrealized gain on interest rate exchange agreements,	,	,
net of cash settlements	9,611	25,841
Other nonoperating (losses) gains	(1)	5,957
Total nonoperating revenues and expenses	99,562	(8,390)
Excess of revenues over expenses	151,258	142,494
Excess of revenues over expenses attributable to	,	,
noncontrolling interests	(8,507)	(8,886)
Excess of revenues over expenses attributable to VUMC	142,751	133,608
Other changes in net assets without donor restrictions		
Change in noncontrolling interests' net assets	1,161	12,429
Net assets released from restriction for capital	984	6,733
Other changes	(278)	(6,756)
Total changes in net assets without donor restrictions	\$ 144,618	\$ 146,014

Vanderbilt University Medical Center Consolidated Statements of Changes in Net Assets Years Ended June 30, 2023 and 2022

(\$ in thousands)	2023	2022
Net assets without donor restrictions Net assets without donor restrictions at the beginning		
of the period	\$ 1,651,836	\$ 1,505,822
Excess of revenues over expenses	142,751	133,608
Change in noncontrolling interests' net assets	1,161	12,429
Net assets released from restriction for capital	984	6,733
Other changes	(278)	(6,756)
Change in net assets without donor restrictions	144,618	146,014
Net assets without donor restrictions at the end of the period	\$ 1,796,454	\$ 1,651,836
Net assets with donor restrictions Net assets with donor restrictions at the beginning of the period	\$ 268,432	\$ 224,558
of the period	φ 200,432	φ 224,330
Contributions	60,412	73,294
Restricted investment income (loss)	6,621	(8,482)
Net assets released from restrictions for operations	(17,232)	(15,697)
Net assets released from restriction for capital	(984)	(6,733)
Other changes	(148)	1,492
Change in net assets with donor restrictions	48,669	43,874
Net assets with donor restrictions at the end of the period	\$ 317,101	\$ 268,432
Total net assets		
Beginning of the period	\$ 1,920,268	\$ 1,730,380
Change in total net assets	193,287	189,888
End of the period	\$ 2,113,555	\$ 1,920,268
Life of the period	Ψ 2,113,333	ψ 1,320,200

Vanderbilt University Medical Center Consolidated Statements of Cash Flows Years Ended June 30, 2023 and 2022

(\$ in thousands)		2023		2022
Cash flows from operating activities				
Change in total net assets	\$	193,287	\$	189,888
Adjustments to reconcile change in total net assets to net	•	,	·	,
cash provided by operating activities:				
Depreciation and amortization		191,046		172,999
Gain on acquisition of equity method investment		_		(14,669)
Investment (gains) losses		(19,371)		102,832
Purchases of trading securities		(269,291)		(289,027)
Sales of trading securities		301,430		306,081
Unrealized gain on interest rate exchange agreements		(11,862)		(31,845)
Implementation costs incurred on hosting arrangements		(23,609)		(18,108)
Restricted contributions for endowments and property,				
plant, and equipment		(24,745)		(24,323)
Noncash lease expense		74,080		76,325
Other noncash activities		(4,827)		(2,805)
(Decrease) increase in cash due to changes in:				
Patient accounts receivable		(71,408)		(102,805)
Accounts payable and other accrued expenses		54,493		51,693
Medicare accelerated payments		(15,956)		(174,428)
Other assets and other liabilities, net		(120,195)		(42,617)
Net cash provided by operating activities		253,072		199,191
Cash flows from investing activities				
Purchases of property, plant, and equipment		(255,779)		(213,532)
Acquisition of additional investment interest				(7,660)
Purchases of long-term securities		(377,616)		(399,028)
Sales and maturities of long-term securities		341,536		221,191
Proceeds on sale of property, plant, and equipment		54		_
Net cash used in investing activities		(291,805)		(399,029)
Cash flows from financing activities				
Proceeds from issuance of long-term debt		148,725		361,666
Debt issuance costs		(917)		(3,160)
Repayment of long-term debt and lines of credit		(11,576)		(359,292)
Principal payments under finance lease obligations		(10,626)		(7,333)
Restricted contributions for endowments and property, plant,		(10,020)		(1,000)
and equipment		24,745		24,323
Distributions to noncontrolling interests		(7,346)		(10,700)
Net cash provided by financing activities		143,005		5,504
Net change in cash, cash equivalents, and		_		_
restricted cash		104,272		(194,334)
Cash, cash equivalents, and restricted cash				
Beginning of the period		670,382		864,716
End of the period	\$	774,654	\$	670,382
'		,		,

1. Description of Organization

Vanderbilt University Medical Center ("VUMC") is a Tennessee not-for-profit corporation incorporated in March of 2015 to operate an academic medical center including a comprehensive research, teaching, and patient care health system (the "Medical Center"). Until April 29, 2016, the Medical Center operated as a unit within Vanderbilt University (the "University" or "VU"), as a part of the University's administrative structure, with the same governing board, legal, financial, and other shared services. VUMC began operations effective April 30, 2016, following the closing of the sale of the Medical Center by the University (the "Acquisition").

VUMC owns and operates three hospitals located on the main campus ("Medical Center Main Campus" or "MCMC") of the University in Nashville, Tennessee: Vanderbilt University Hospital ("VUH"), Monroe Carell Junior Children's Hospital at Vanderbilt ("MCJCHV"), and Vanderbilt Psychiatric Hospital ("VPH"). In addition, VUMC partially owns Vanderbilt Stallworth Rehabilitation Hospital ("VSRH"), also located on the main campus of the University, through a joint venture with Encompass Health Corp. in which VUMC holds a 50% interest, including a 1% interest held by Vanderbilt Health Services, LLC, ("VHS"), a VUMC wholly owned subsidiary. Effective August 1, 2019, VUMC acquired from Community Health Systems, Inc. ("CHS"): Tennova Healthcare – Lebanon, now known as Vanderbilt Wilson County Hospital ("VWCH"). Effective January 1, 2021, VUMC acquired from CHS: Tennova Healthcare – Shelbyville and Tennova Healthcare – Harton, now known as Vanderbilt Bedford Hospital ("VBCH") and Vanderbilt Tullahoma-Harton Hospital ("VTHH"), respectively. At the same time as the acquisition of VBCH and VTHH, VUMC acquired a noncontrolling ownership interest in CHS's affiliated Tennova Healthcare – Clarksville ("VMH"). VUH, MCJCHV, VPH, VWCH, VBCH, and VTHH are licensed for 1,661 beds, and VSRH is licensed for 80 beds.

VUMC consists of two major operating divisions and an administrative overhead division. The operating divisions include the Clinical Enterprise and Academic Enterprise divisions. The administrative overhead division is referred to as Medical Center Administration ("MCA").

The Clinical Enterprise division includes the professional clinical practice revenues and related expenses of the Vanderbilt Medical Group ("VMG"), and technical revenues and associated expenses for the operation of VUMC's hospitals and clinic facilities, including VUH, MCJCHV, VPH, VWCH, VBCH, and VTHH. The Clinical Enterprise also includes VHS.

- VUH is a quaternary care teaching hospital licensed for 790 acute care and specialty beds. VUH, a Level I trauma center, provides advanced patient care and serves as a key site for medical education and clinical research conducted by physician faculty. VUH includes a comprehensive burn center, the Vanderbilt Transplant Center, the Vanderbilt Heart and Vascular Institute, and the Vanderbilt Ingram Cancer Center. Effective April 5, 2023, VUMC was approved to increase its total permanent licensed bed capacity by 46 beds. On May 10, 2023, VUMC sunset the remaining 113 beds from the temporary license provided under the Board for Licensing Health Care Facilities ("BLHCF") Policy 82 response to COVID-19 (which was comprised of 20 observation beds and 93 double occupancy beds).
- MCJCHV is a pediatric quaternary care teaching hospital licensed for 325 beds (144 acute and specialty, 65 pediatric intensive care, and 116 neonatal intensive care). MCJCHV is the region's only full-service pediatric hospital, with over 30 pediatric specialties. MCJCHV serves as a site for medical education and clinical research conducted by pediatric physician faculty, houses the only Level IV neonatal intensive care center and the only Level I pediatric trauma center within the region, and is a regional referral center for extracorporeal membrane oxygenation (heart and lung failure).

- VPH is a psychiatric hospital licensed for 106 beds and provides inpatient care to pediatric, adolescent, adult, and geriatric patients. Also, VPH provides partial hospitalization programs to both adult and adolescent patients, psychiatric assessment services, adult intensive outpatient programs, pediatric and adult ambulatory outpatient treatment, and neuromodulation procedures through electroconvulsive therapy and transcranial magnetic stimulation.
- VWCH is a 245 licensed bed acute care facility and is a substantial provider of both inpatient
 and outpatient medical services in Lebanon, Tennessee. Services offered include an accredited
 chest pain center, a stroke center, a comprehensive weight loss center, a comprehensive total
 joint program for orthopedics, and a provisional Level III trauma center. In addition, Vanderbilt
 Ingram Cancer Center extended services to this campus in 2020, and it includes a state-of-theart linear accelerator.
- VBCH is a 60 licensed bed, Joint Commission-accredited hospital, which offers a range of inpatient and outpatient medical and surgical services, along with urgent care services.
- VTHH is a 135 licensed bed Joint Commission-accredited hospital, which offers a full range of inpatient and outpatient surgical and specialty services including interventional cardiology, orthopedics, urology, a sleep center, cardiac rehabilitation, and physical rehabilitation. The hospital also features an accredited Chest Pain Center.
- VMG is the practice group of physicians and advanced practice practitioners employed by VUMC, many of whom, when appropriate and required, have faculty appointments from the University, who perform billable professional medical services. VMG is not a separate legal entity. VMG has a board which consists of the VUMC clinical service chiefs, who also serve as clinical department chairs. Under the oversight of VUMC executive leadership, VMG sets professional practice standards, bylaws, policies, and procedures. VUMC bills for services rendered by VMG clinicians in both inpatient and outpatient locations. Collected fees derive a component of each VMG clinician's compensation. VMG includes nationally recognized physicians whose expertise spans the spectrum from primary care to the most specialized quaternary discipline. VMG members are "board certified" or eligible for board certification, as required by bylaws. All VMG members are re-credentialed every two years in accordance with the Centers for Medicare and Medicaid Services, The Joint Commission, and the National Committee for Quality Assurance Standards. Most of the specialties and subspecialties currently recognized by the various national specialty boards are represented in VMG.
- VHS serves as a holding company for 16 first tier health care related subsidiaries and joint ventures owned with various entities, including, but not limited to, VSRH, Vanderbilt Integrated Providers ("VIP") and the Vanderbilt Health Affiliated Network ("VHAN"). VHS operations primarily consist of community physician practices, walk-in and retail health clinics, imaging services, outpatient surgery centers, radiation oncology centers, a home health care agency, a home infusion and respiratory service, an affiliated health network, accountable care organizations, and a rehabilitation hospital. VIP employs providers and staff located off the main VUMC campus and affiliates with or purchases and operates physician practices in the region. VHAN contracts with other healthcare providers, including hospitals, physicians, and physician groups to jointly develop and implement a clinical integration program though a clinically integrated network of physicians and hospitals. These subsidiaries of VHS include clinics managed in multiple outpatient locations throughout middle Tennessee and southwestern Kentucky.

- Health Professional Solutions, LLC ("HPS") is a holding company that holds interest in four VUMC subsidiaries that engage in or support various health care related activities in order to improve the quality and availability of health care services in the community. These subsidiaries include businesses focused on pharmacy, supply chain, and clinically integrated support services.
- Nashville Biosciences, LLC ("NashBio") operates exclusively in support of VUMC's non-academic medical research activities. NashBio deploys the biospecimens and genomic data and de-identified medical records of VUMC known as "BioVU", along with other information, to provide commercial services and products to life science industry customers in connection with pharmaceutical, biotechnology, and medical research and development activities.

The Academic Enterprise division includes all research, research-support activities, and faculty endeavors supporting post-graduate training programs. A significant funding source for VUMC's research has historically been the federal government. Federal funding is received from the Department of Health and Human Services, the Department of Defense, the National Science Foundation, and other federal agencies. Sponsored research awards, including multi-year grants and contracts from government sources, foundations, associations, and corporations signify future research commitments. Also, core activities supporting research, including advanced computing and grant administration, are included in this division.

VUMC has entered into debt agreements further discussed below. Certain of these debt agreements contain required disclosures outlining annual and quarterly reporting requirements. In addition, certain of these debt agreements require notices of the occurrence of significant events which include but are not limited to delinquencies, bond calls, rating changes, bankruptcies, and mergers or acquisitions. The Obligated Group includes the wholly-owned hospitals located on the MCMC along with all associated on-campus and off-campus ambulatory clinics, the Academic Enterprise, MCA, VWCH, and VMG.

The terms "Company," "VUMC," "we," "our," or "us" as used herein and unless otherwise stated or indicated by context refer to Vanderbilt University Medical Center and its affiliates. The terms "facilities" or "hospitals" refer to entities owned and operated by VUMC and its affiliates, and the term "employees" refers to employees of VUMC and its affiliates.

VUMC operates on a fiscal year which ends on June 30. The term "Fiscal" preceding a year refers to a particular VUMC fiscal year.

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Based on the existence or absence of donor-imposed restrictions, VUMC classifies resources into two categories: net assets without donor restrictions and net assets with donor restrictions.

Principles of Consolidation

The consolidated financial statements include the accounts of VUMC and its wholly owned, majority-owned, and controlled organizations. Noncontrolling interests in less-than-wholly owned consolidated subsidiaries of VUMC are presented as a component of net assets to distinguish between the interests of VUMC and the interests of the noncontrolling owners. All material intercompany transactions and account balances among the various entities have been eliminated.

VUMC uses the equity method to account for its interests in unconsolidated partnerships, joint ventures, and limited liability entities over which it exercises significant influence. Investment carrying amounts are adjusted for VUMC's share of investee earnings or losses based on percentage of ownership. Distributions received from unconsolidated entities that represent returns on VUMC's investment (i.e., dividends) are reported as cash flows from operating activities in VUMC's consolidated statements of cash flows.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. These estimates affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated balance sheets and the reported amounts of revenues and expenses during the reporting periods. Actual results ultimately could differ from those estimates.

Cash and Cash Equivalents

Cash and cash equivalents are liquid assets with minimal interest rate risk and maturities of three months or less when purchased. VUMC invests operating assets in a diversified manner. At times, VUMC may have cash and cash equivalents at a financial institution in excess of federally insured limits, and therefore, bears a risk of loss. Certain cash and cash equivalents are included in investments and restricted cash on the consolidated balance sheets.

Liquidity and Availability

As of June 30, 2023, VUMC has \$2,447.6 million of financial assets available within one year of the balance sheet date to meet cash needs for general expenditures consisting of cash and cash equivalents of \$679.6 million, patient accounts receivable of \$730.1 million, and unrestricted investments of \$1,037.9 million. As of June 30, 2022, VUMC had \$2,338.6 million of financial assets available within one year of the balance sheet date to meet cash needs for general expenditures consisting of cash and cash equivalents of \$651.7 million, patient accounts receivable of \$658.6 million, and unrestricted investments of \$1,028.3 million. None of these financial assets are subject to donor or other contractual restrictions that make them unavailable for general expenditures within one year of the balance sheet date.

VUMC has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. In addition, as part of its liquidity management, VUMC invests cash in excess of daily requirements in various short-term investments, including certificates of deposit and short-term treasury instruments.

As more fully described in Note 11 Long-Term Debt, VUMC also has committed lines of credit in the amount of \$300 million, which it could draw upon in the event of an unanticipated liquidity need, with no amount drawn as of June 30, 2023 or June 30, 2022.

Revenue Recognition - Patient Services

VUMC contracts with patients to provide healthcare services that are tailored to each patient's medical needs and health conditions. VUMC recognizes patient service revenue over time as performance obligations are ultimately satisfied. Performance obligations related to inpatient services are generally satisfied as the healthcare services are rendered to the patient, which generally begins at the time of patient admission and extends through the time of patient discharge. Performance obligations for outpatient services are generally satisfied on the same day that services are rendered to the patient. VUMC uses a portfolio approach consisting of major payor classes to account for categories of patient contracts as a collective group rather than recognizing revenue on an individual contract basis. Based on historical collection trends and other analysis, VUMC believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

Patient service revenue is recognized on an accrual basis using a best estimate of the transaction price for the type of service rendered to the patient. The transaction price ultimately represents the estimated amount to be received from the patient and third-party payors in exchange for the services rendered by VUMC. VUMC estimates the transaction price based on standard charges, reduced for estimated price concessions. The price concessions include items that are explicit, such as contractual adjustments provided to third-party payors and discounts provided to uninsured and underinsured patients in accordance with VUMC policy, and also implicit in nature, such as the estimated uncollectible amounts from uninsured or underinsured patients. VUMC regularly reviews transactional data for the major revenue categories to evaluate the reasonableness of the transaction price, including any price concessions, and takes into consideration recent experience by payor category and payor agreement rate changes among other factors.

VUMC carries the value of the related patient accounts receivable balances at the transaction price, inclusive of all estimated price concessions. Given the complexities involved in determining amounts ultimately due to VUMC under reimbursement arrangements with third-party payors, which are often subject to interpretation, VUMC may receive reimbursement for healthcare services authorized and provided that differs from these estimates. If actual results differ from these estimates, a change in estimate will be recorded in the period the change is identified and such differences could be material.

VUMC has elected to apply the optional exemption provided in the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 606-10-50-14 as substantially all of its performance obligations relate to contracts with a duration of less than one year. Therefore, VUMC is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting period. Unsatisfied or partially satisfied performance obligations are primarily related to in-house patients at the end of the reporting period. The performance obligations for these contracts are generally completed when the patient is discharged, which is typically within a week.

In addition to reimbursement received in fee-for-service arrangements, VUMC participates in certain federal healthcare programs, as well as state and commercial payor programs, through which VUMC may be entitled to additional payments. These arrangements are complex and may extend over multiple accounting periods. The arrangements are subject to the interpretation of federal and state-specific reimbursement rules, new or changing legislation, and final cost report settlements. Any changes to reimbursement rules or the introduction of new or changing legislation could impact levels and timing of reimbursements received from these programs. As a participant in these programs, VUMC is also required to meet certain financial reporting requirements which include the filling of an annual cost report for each hospital. Each annual cost report is also subjected to an audit performed by the regulatory agency and may extend several years before ultimate settlement becomes known. Therefore, determining the actual amounts earned under these programs involves judgement and estimates that may extend into future periods. These estimates are frequently evaluated and subsequently may be adjusted based on new developments or the receipt of new information related to these settlements. If actual results vary from these estimates, a change in estimate will be recorded in the period the change is identified and such differences could be material.

VUMC provides care to patients who meet the criteria for charity care under its financial assistance policy for no payment or at payment amounts less than its established charge rates. VUMC does not recognize the charges that qualify as charity care as revenue because VUMC does not pursue collection of these amounts.

Revenue Recognition - Non-Patient Services

Revenue for non-patient services is recognized at an amount that reflects the consideration VUMC expects to be entitled in exchange for providing goods or services. The amounts recognized reflect considerations due from customers, the U.S. government, and others, and is recognized as performance obligations are satisfied. Primary categories of non-patient revenue include academic and research revenue as well as other miscellaneous activities as further described in Note 8 Other Relevant Financial Information.

VUMC receives funding through grants and contracts issued by departments and agencies of the U.S. government, industry, and other foundation sponsors who restrict the use of such funds to academic and research purposes. VUMC recognizes revenue from these grants and contracts in accordance with contract terms, as defined in the agreements governing that funding. VUMC recognizes facilities and administrative ("F&A") costs recovery as revenue when the allowable expenditure is incurred on the associated grant or contract. This activity represents reimbursement, primarily from the federal government, of F&A costs on sponsored activities.

Grants and contracts receivable include amounts due from these sponsors of externally funded research. These amounts have been billed or are billable to the sponsor and are recorded at the amount that reflects the consideration VUMC expects to receive.

Deferred Revenue

Deferred revenue is recorded for funds received in advance. The related revenue is recognized when the performance obligations have been met.

Gift Income and Pledges

VUMC recognizes unconditional promises to give cash and other assets, referred to as pledges, as gift income at fair value when the pledge is received. Conditional promises to give are recognized as pledges once the conditions are substantially met. Pledges are recognized as net assets with donor restrictions. Gifts received with donor stipulations limiting the use of the donated assets are reported as net assets with donor restrictions. Donor-restricted contributions whose restrictions are met within the same year as received are reported as gift income in the consolidated statements of operations.

Gift income is recognized when a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished. Gifts of cash or other assets that must be used to acquire long-lived assets are reported as net assets with donor restrictions until the assets are placed in service, at which point they are reclassified to net assets without donor restrictions.

Pledges receivable are reported net of allowances for uncollectible amounts based on an analysis of past collection experience and other judgmental factors. Pledges receivable are included in other current or other noncurrent assets in the consolidated balance sheets based on the expected timing of cash flows. VUMC discounts the noncurrent portion of pledges receivables at a rate commensurate with the scheduled timing of receipt. VUMC applied annual discount rates ranging from 0.5% to 1.5% to amounts outstanding as of June 30, 2023 and 2022.

Concentrations of Risk

VUMC grants unsecured credit to its patients, primarily residing in Nashville, Tennessee and the surrounding areas of middle Tennessee, most of whom are insured under commercial, Medicare (both traditional fee-for-service and Managed Medicare), or TennCare agreements. Medicare, Blue Cross Blue Shield ("BCBS"), and TennCare (which includes BCBS of Tennessee, United, and Amerigroup) represent VUMC's significant concentrations of credit risk from payors.

The collection of revenue and accounts receivables from Medicare, TennCare, Blue Cross, other third-party payors, and patients is a significant source of operating cash flow. The payor composition of patient service revenue and related accounts receivable portfolio may fluctuate from time to time and generally correlate to the prevailing economic conditions, such as periods of economic expansion or recession or changes in unemployment levels, and those fluctuations may impact the realization of patient service revenue and collectability of accounts receivable. Other factors such as unexpected disruptions to business office operations or trends in federal or state governmental and private employer healthcare coverage could affect the ultimate collectability of accounts receivable balances. As a result, VUMC may be exposed to gains or losses in future periods that could affect the financial position and operating cash flows of the organization and may be material to its financial position, operating income and cash flow from operations.

Inventories

VUMC reports inventories at the lower of cost or market, with cost being determined on the first-in, first-out method. Inventories consist primarily of medical supplies, surgical implants, and pharmaceuticals.

Restricted Cash

VUMC reports cash whose use is restricted at cost, which approximates fair value. The cash is primarily restricted for use in purchasing and constructing property, plant, and equipment and restricted cash associated with our self-insurance trust.

Investments

VUMC reports investments held at fair value in the consolidated balance sheets. Private equity investments, multi-strategy hedge funds, real estate mutual funds, and hedged equity funds are reported based on net asset value ("NAV"), provided by the respective fund manager, as a practical expedient to estimate fair value. VUMC records purchases and sales of securities on the trade dates, and realized gains and losses are determined based on the average historical cost of the securities sold. Interest income is recorded on the accrual basis and dividend income is recorded on the exdividend date. VUMC reports net receivables and payables arising from unsettled trades as a component of investments.

Property, Plant, and Equipment, Net

VUMC records purchases of property, plant, and equipment at cost and expenses repairs and maintenance costs as incurred. VUMC capitalizes interest cost incurred on borrowed funds during the period of construction of capital assets as a component of the cost of acquiring those assets. VUMC capitalizes donated assets at fair value on the date of donation.

Capitalized software for internal use is recorded during the application development stage. These costs include fees paid to third parties for direct costs of materials and services consumed in developing or obtaining the software; payroll related costs and capitalized interest costs. Costs for training and application maintenance in the post-implementation operation stage are expensed as incurred.

VUMC computes depreciation using the straight-line method over the estimated useful life of land improvements (5 to 18 years), buildings and leasehold improvements (2 to 40 years), and equipment (2 to 20 years). Equipment costs also include capitalized internal use software costs, which are expensed over the expected useful life, which is generally 3 to 12 years.

Software for internal use is amortized on a straight-line basis over its estimated useful life. In determining the estimated useful life, management considers the effects of obsolescence, technology, competition, contract term, other economic factors, and rapid changes that may be occurring in the development of software products, operating systems, and computer hardware. Amortization begins once the software is ready for its intended use.

Costs Associated with Hosting Arrangements under Service Contracts

Costs associated with hosting arrangements under service contracts are presented in other noncurrent assets on our consolidated balance sheets. These assets total \$40.7 million and \$18.1 million as of June 30, 2023 and June 30, 2022, respectively. The related capitalization policy is consistent with the policy described above for internal use software. Once placed into service, these assets will be amortized over the term of the associated subscription agreement. These assets largely consist of costs associated with the implementation of an enterprise resource planning system, which was placed into service in April 2023.

Impairment of Long-Lived Assets

VUMC reviews long-lived assets, such as property, plant, and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. VUMC measures the recoverability of assets to be held and used by comparing the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, VUMC recognizes an impairment charge to the extent the carrying amount of the asset exceeds its fair value.

Conditional Asset Retirement Costs and Obligations

VUMC recognizes the estimated fair value of liabilities for existing legal obligations to perform certain activities, primarily asbestos removal, in connection with the retirement, disposal, or abandonment of assets. These liabilities are included in other noncurrent liabilities on the consolidated balance sheets and total \$7.2 million and \$7.0 million as of June 30, 2023 and 2022, respectively. VUMC measures these liabilities using estimated cash flows with an inflation rate applied of 3.0% as of June 30, 2023 and 2022. VUMC discounts those cash flow estimates at a credit-adjusted, risk-free rate, which ranged from 2.9% to 4.2% as of June 30, 2023 and 2022, and adjusts these liabilities for accretion costs and revisions in estimated cash flows.

Long-Term Debt

The carrying value of VUMC's debt is the par amount adjusted for the net unamortized amount of debt issuance costs and bond premiums and discounts.

Interest Rate Exchange Agreements

VUMC reports interest rate exchange agreements at fair value, which is determined to be the present value of future net cash settlements that reflect market yields as of the measurement date and estimated amounts that VUMC would pay, or receive, to terminate the contracts as of the report date. VUMC considers current interest rates and creditworthiness of the interest rate exchange counterparties when estimating termination settlements.

Self-Insurance Reserves

VUMC elects to self-insure a portion of its medical malpractice, professional, and general liability coverage via an irrevocable self-insurance trust. For Fiscal 2023 and 2022, the maximum annual self-insurance retention was \$6.0 million per occurrence, up to \$46.0 million in the aggregate. Actuarial firms assist management in estimating expected losses on an annual basis, at which time VUMC records medical malpractice, professional, and general liability expense within the limits of the program. These liabilities are classified as current or noncurrent based on the expected timing of cash flows and are measured at the net present value of those cash flows using a discount rate of 2.5% as of June 30, 2023 and 2022. For both Fiscal 2023 and 2022, VUMC obtained excess medical malpractice, professional, and general liability coverage from commercial insurance carriers for claims exceeding the retention limits, up to \$175.0 million. These policies would also provide coverage up to \$175.0 million if any claims in the aggregate exceeded the retention limits.

VUMC also elects to self-insure for employee health and workers' compensation expenses. Actuarial firms assist management in estimating expected losses on an annual basis. The maximum retention for workers' compensation was \$0.8 million per occurrence for both Fiscal 2023 and 2022. There is no stop loss insurance on health plan claims.

Income Taxes

VUMC is a tax-exempt organization as described in Section 501(c)(3) of the Internal Revenue Code (the "Code") and is generally exempt from federal income taxes under Section 501(a) of the Code.

Excess of Revenues Over Expenses

The consolidated statements of operations include excess of revenues over expenses as a performance indicator. Excess of revenues over expenses includes all changes in net assets without donor restrictions, except for changes in noncontrolling interest holders' share of consolidated entities, net assets released from restrictions used for capital, and certain other items.

Statement of Cash Flows

For VUMC's consolidated statements of cash flows, cash, cash equivalents, and restricted cash is defined as those amounts included in the cash and cash equivalents caption and restricted cash caption on the consolidated balance sheets.

Reclassifications

Certain reclassifications have been made to the Fiscal 2022 consolidated financial statements to conform to the Fiscal 2023 presentation. The reclassifications had no effect on net assets or changes in net assets as previously reported.

Recent Accounting Pronouncements

Periodically, the FASB issues Accounting Standards Updates ("ASUs") that may impact the recognition, measurement, and presentation of balances and activity in VUMC's consolidated financial statements or the disclosures contained within those statements. As part of preparing consolidated financial statements, VUMC evaluates the effects of the ASUs and applies the updated guidance within the required effective dates.

Not Yet Adopted

• In June, 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326). This ASU introduced a new model for recognizing credit losses on financial instruments based on an estimate of the current expected credit losses. The new current expected credit losses, or CECL, model generally calls for the immediate recognition of all expected credit losses and applies to financial instruments and other assets, including accounts receivable and other financial assets measured at amortized cost, debt securities and other financial assets. The ASU is effective for fiscal years beginning after December 15, 2022. VUMC is currently assessing the impact of this ASU on the consolidated financial statements.

3. Related Parties

On April 29, 2016, VUMC acquired the assets, liabilities, rights, and obligations of the clinical enterprise, postgraduate medical training programs, and clinically related research of the University's owned and operated Medical Center through the Acquisition.

The assets acquired and liabilities assumed from the Acquisition were detailed in a Master Transfer and Separation Agreement ("MTSA"). The MTSA contains the framework for the ongoing economic relationship between VUMC and the University. The relationship is memorialized in the form of an Academic Affiliation Agreement ("AAA"), a Trademark License Agreement ("TMLA"), a Ground Lease, and a Reciprocal Master Services Agreement ("MSA"). The agreements are described below.

• The AAA outlines the ongoing academic, research, and clinical affiliation between the University and VUMC for all the University's degree-granting, certificate, and research programs. The AAA allocates responsibility between the University and VUMC for jointly administered research and academic programs and is an exclusive agreement between VUMC and VU requiring VUMC to be organized, governed, and operated in a manner that supports VU's academic and research mission. The agreement provides that VU will be the exclusive academic affiliate of VUMC, and VUMC will be the exclusive clinical affiliate of VU.

The AAA requires VUMC to pay VU an annual fee in equal monthly payments adjusted annually for inflation based upon the Biomedical Research and Development Price Index ("BRDPI") in perpetuity under certain mutually agreed-upon termination or default clauses. During Fiscal 2023 and 2022, VUMC recorded operating expense totaling \$81.4 million and \$79.8 million, respectively, in connection with fees due under the AAA.

- Under the TMLA, VU grants, subject to certain consents and approvals, a perpetual license to use various VU-owned licensed marks in connection with VUMC's fundamental activities after the Acquisition date. The licensed marks, which VUMC continues to use as its primary brands, include virtually all those previously in use by VUMC. This agreement requires VUMC to pay VU royalties consisting of a monthly payment equal to 1% of all operating revenue of VUMC and 15% of income from operations. During Fiscal 2023 and 2022, VUMC recorded operating expense totaling \$77.5 million and \$88.0 million, respectively, in connection with the 1% of operating revenue and 15% of operating income payments due under the TMLA. Also, VUMC is required to pay in equal monthly installments an annual TMLA base fee royalty, which increases 3% annually, but is also reduced by the amount of principal payments made under a subordinated note discussed in Note 11 Long-Term Debt (the "Fixed TMLA Royalty Payment"). During Fiscal 2023 and 2022, VUMC recorded operating expense totaling \$68.8 million and \$66.6 million, respectively, in connection with this base fee royalty. In Fiscal 2018, VU sold its rights to future base fee royalty payments to a third party. In Fiscal 2019, VU sold its rights to future 1% of operating revenue payments to a third party. The TMLA is in force in perpetuity under certain mutually agreed-upon termination or default clauses.
- The Ground Lease is an agreement between VU and VUMC that allows VUMC to use the land on which VUMC's campus and related buildings are located. The initial term of the Ground Lease ends June 30, 2114, with the option to extend the lease for two additional terms of up to 50 to 99 years each with agreement between VU and VUMC. The lease covers 1.7 million square feet or 38.75 acres of space, payable monthly and CPI adjusted annually. During Fiscal 2023 and 2022, VUMC recorded operating expense totaling \$22.1 million and \$20.4 million, respectively, in connection with fees due under the Ground Lease.
- The University and VUMC provide services to one another for agreed-upon consideration as outlined in the MSA. VU provides services to VUMC, such as information technology infrastructure support, utilities, and law enforcement staffing. VUMC provides various operational services for the University, such as a student health clinic and animal care. Additionally, the MSA encompasses an Employee Matters Agreement ("EMA") and specific Employee Service Agreements ("ESAs"). The EMA and ESAs govern employee transactions and ongoing sharing between VU and VUMC in various capacities, such as research, teaching, clinical, and other administrative services. Services under the MSA can be terminated by either party subject to predetermined cancellation notification periods. In connection with the MSA, during Fiscal 2023 and 2022, VUMC recognized revenue totaling \$48.6 million and \$44.5 million, respectively, and recorded operating expense totaling \$128.6 million and \$121.2 million, respectively.
- Also, as part of the Acquisition, VUMC issued to VU a \$100.0 million subordinated promissory note payable, which is further described in Note 11 Long-Term Debt, with a balance of \$64.6 million as of June 30, 2023, and \$69.6 million as of June 30, 2022. VU sold its rights to future principal and interest payments on this note to a third party.

The impact of these agreements in the consolidated statements of operations during Fiscal 2023 and 2022 is as follows:

(\$ in thousands)	2023		23 2	
Academic and research revenue Other operating revenue	\$	18,321 30,315	\$	13,540 30,958
Total operating revenues	\$	48,636	\$	44,498
Operating expenses				
Salaries, wages, and benefits	\$	9,636	\$	9,111
Facilities and equipment		66,435		58,610
Services and other		302,326		308,290
Interest		2,174		2,336
Total operating expenses	\$	380,571	\$	378,347

Other current assets include amounts receivable from VU, which totaled \$6.2 million as of June 30, 2023, and \$7.0 million as of June 30, 2022. Accounts payable and other accrued expenses include amounts payable to related parties, which totaled \$47.7 million and \$58.5 million as of June 30, 2023 and 2022, respectively.

In the normal course of business, members of VUMC's Board of Directors or VUMC employees may be directly or indirectly associated with companies engaged in business activities with VUMC. VUMC has a written conflict of interest policy that requires, among other things, that members of the VUMC community (including trustees) may not review, approve, or administratively control contracts or business relationships when (i) the contract or business relationship is between VUMC and a business in which the individual or a family member has a material financial interest, or (ii) the individual or a family member is an employee of the business and is directly involved with activities pertaining to VUMC.

Furthermore, VUMC's conflict of interest policy extends beyond the foregoing business activities in that disclosure is required for any situation in which an applicable individual's financial, professional, or other personal activities may directly or indirectly affect, or have the appearance of affecting, an individual's professional judgment in exercising any VUMC duty or responsibility, including the conduct or reporting of research.

The policy extends to all individual members of the VUMC community (including Board of Directors, VUMC officials, full-time, part-time, temporary faculty and staff). Each applicable person is required to certify compliance with the conflict of interest policy on an annual basis. This certification includes specifically disclosing whether VUMC conducts business with an entity in which he or she (or an immediate family member) has a material financial interest, as well as any other situation that could appear to present a conflict with VUMC's best interests.

When situations exist relative to the conflict of interest policy, VUMC takes active measures to appropriately manage the actual or perceived conflict in the best interests of VUMC, including periodic reporting of measures taken to the Audit and Compliance Committee of the Board of Directors.

4. Patient Service Revenue, Patient Accounts Receivable, and Estimated Third-Party Settlements

The sources of patient service revenue by payor for Fiscal 2023 and 2022 are as follows:

(\$ in thousands)	2023		_	2022
Other third-party payors, primarily commercial carriers	\$	3,533,047	5	3,307,671
Medicare/Managed Medicare		1,438,645		1,262,330
TennCare/Medicaid		834,073		724,030
Uninsured (self-pay)		65,289		62,242
	\$	5,871,054	3	5,356,273

Patient accounts receivable comprise amounts due from the following sources as of June 30, 2023 and 2022:

(\$ in thousands)	2023		2023		202		 2022
Medicare/Managed Medicare	\$	125,031	\$ 119,626				
TennCare/Medicaid		97,767	87,357				
Blue Cross		153,521	134,528				
Other third-party payors, primarily commercial carriers		293,197	260,034				
Patient responsibility ⁽¹⁾		60,536	57,099				
Patient accounts receivable	\$	730,052	\$ 658,644				

⁽¹⁾ Includes self-pay after insurance.

Estimated third-party settlements by major payor category as of June 30, 2023 and 2022 are as follows:

(\$ in thousands)	2023		2023 2022	
Receivables under third-party programs				
Tricare/Champus ⁽¹⁾	\$	5,230	\$	5,338
Total receivables under third-party programs	\$	5,230	\$	5,338
Liabilities under third-party programs	_			
TennCare/Medicaid	\$	56,997	\$	88,296
Medicare ⁽¹⁾		15,255		6,370
Total liabilities under third-party programs	\$	72,252	\$	94,666

⁽¹⁾ These two federal healthcare programs are combined for presentation purposes on the face of the consolidated balance sheets and are reflected as an obligation in Fiscal 2023 and 2022.

Certain contracts require pay for performance or episode of care settlements whereby VUMC receives additional payment or pays a penalty based on its ability to achieve certain clinical measures or manage the cost of care for patients within various thresholds. VUMC estimates and accrues these adjustments in the period the related services are rendered and adjusts these estimates in future periods as settlements are finalized.

Medicare

Amounts received under Medicare are subject to review and final determination by program intermediaries or their agents. Final settlements have been reached for program periods ended June 30, 2018. Final settlements have not been reached for subsequent years due to audit delays experienced with the Medicare Administrative Contractor, and thus, those periods remain subject to audit by program representatives.

TennCare

TennCare is a Medicaid managed care program implemented by the state of Tennessee to provide healthcare coverage to those patients eligible for Medicaid through the Federal 1115 Waiver Program. VUMC contracts with each of the three TennCare managed care organizations ("MCOs"), which offer health maintenance organization ("HMO") and Medicare Special Needs Products for Dual Eligible Enrollees. VUMC receives inpatient reimbursement through payments that are primarily based on the Medicare severity diagnostic related group system ("MS-DRG") for these plans. VUMC receives outpatient payments generally based on an ambulatory payment classification system ("APC"), and/or a payor-developed fee schedule.

In accordance with the Tennessee Hospital Assessment Act, VUMC receives a payment of a portion of its unreimbursed TennCare costs based upon VUMC's share of uninsured TennCare costs for all of the covered hospitals.

There is no assurance that this program will be continued in its current structure or will not be materially modified in the future, however, we anticipate funding will remain relatively stable over the coming year.

In Fiscal 2023 and 2022, patient service revenue includes the following supplemental amounts received in each respective period from TennCare.

(\$ in thousands)	2023		2023 2	
Directed payments	\$	60,571	\$	36,633
Charity pool	•	21,570	*	26,026
Graduate medical education		19,088		14,688
Trauma fund		1,766		1,192
Workforce development and other		591		2,621
Virtual disproportionate share		8,539		7,651
Total supplemental TennCare revenue	\$	112,125	\$	88,811

5. Charity Care Assistance, Community Benefits, and Other Unrecovered Costs

VUMC maintains a policy which sets forth the criteria under which health care services are provided to patients who have minimal financial resources to pay for medical care. Additionally, VUMC provides other services that benefit the economically disadvantaged for which little or no payment is expected.

Charity care is determined by examining patient and family income relative to the federal poverty guidelines. VUMC provides additional discounts based on the income level of the patient household using a sliding scale for those patients with a major catastrophic medical event not qualifying for full charity assistance. Tennessee law mandates that all uninsured patients receive a discount from billed charges for medically necessary services. These amounts are classified as charity care if the patient meets charity care criteria, for which no revenue is recorded, or are included as a part of price concessions.

VUMC maintains records to identify and monitor the level of charity care provided, and these records include gross charges and patient deductibles, coinsurance and copayments foregone for services furnished under its charity care policy, and the estimated cost of those services. VUMC calculates a ratio of total costs to gross charges and then multiplies the ratio by foregone charity care charges in determining the estimated cost of charity care. The gross amount of foregone charity care revenue in Fiscal 2023 and 2022 totals \$603.8 million and \$530.5 million, respectively. The estimated cost of providing care to charity patients in Fiscal 2023 and 2022 totals \$162.2 million and \$140.0 million, respectively.

In addition to the charity care services described above, TennCare/Medicaid and state indigent programs do not cover the full cost of providing care to beneficiaries of those programs. As a result, in addition to direct charity care costs, VUMC provided services related to TennCare/Medicaid and state indigent programs and was reimbursed substantially below the cost of rendering such services. VUMC also provides public health education and training for new health professionals and provides, without charge, services to the community at large for many patients with special needs.

6. Academic and Research Revenue

Academic and research revenue comprises the following for Fiscal 2023 and 2022:

(\$ in thousands)	 2023		2022
Grants and contracts revenue			
Federally funded	\$ 398,876	\$	383,592
Non-federally funded	133,139		108,904
	 532,015		492,496
Facilities and administrative costs recovery	186,339		166,468
Total grants and contracts revenue	 718,354		658,964
Other academic and research revenue	47,173		46,895
Academic and research revenue	\$ 765,527	\$	705,859

7. Pledges Receivable, Net

Pledges receivable, net of applied discounts and allowance for uncollectible pledges, as of June 30, 2023 and 2022, were as follows:

(\$ in thousands)	 2023	 2022
Amounts due		
Within one year	\$ 17,459	\$ 19,476
In one to five years	30,405	34,312
Total pledges receivable	 47,864	 53,788
Unamortized discount	(1,034)	(1,336)
	 46,830	 52,452
Allowance for uncollectible pledges	(4,787)	(6,993)
Net pledges receivable	\$ 42,043	\$ 45,459
Net pledges receivable classified as		
Current	\$ 13,579	\$ 13,349
Noncurrent	28,464	32,110
	\$ 42,043	\$ 45,459

In addition to pledges reported as pledges receivable, VUMC had cumulative bequest intentions and conditional promises to give totaling \$93.3 million and \$76.6 million as of June 30, 2023 and 2022, respectively. Due to their conditional nature, VUMC does not recognize intentions to give as assets. Pledges receivables are presented in other current assets and other noncurrent assets on our consolidated balance sheets, as shown in Note 8.

8. Other Relevant Financial Information

Other current assets comprise the following as of June 30, 2023 and 2022:

(\$ in thousands)	 2023	 2022
Prepaid expenses Other receivables Amounts due from VU (see Note 3 Related Parties)	\$ 23,227 38,045 6,159	\$ 35,547 61,043 7,017
Current pledges receivable, net (see Note 7 Pledges Receivable, Net)	13,579	13,349
Expected recoveries from commercial insurance excess coverage Total other current assets	\$ 7,657 88,667	\$ 5,947 122,903

Other noncurrent assets comprise the following as of June 30, 2023 and 2022:

(\$ in thousands)	 2023	 2022
Equity in unconsolidated organizations	\$ 65,055	\$ 62,080
Noncurrent pledges receivable, net (see Note 7 Pledges		
Receivable, Net)	28,464	32,110
Goodwill	27,028	27,028
Implementation costs incurred on hosting arrangements	40,789	18,108
Other	12,351	27,408
Total other noncurrent assets	\$ 173,687	\$ 166,734

Implementation costs incurred on hosting arrangements include accumulated amortization of \$0.9 million at June 30, 2023. Amortization expense amounted to \$0.9 million for Fiscal 2023. Amortization expense for each of the next five years is \$3.7 million.

Other operating revenues comprise the following for Fiscal 2023 and 2022

(\$ in thousands)		2023		2022
CARES funding Clinical contracts	\$	_ 50,825	\$	72,682 55,645
Amounts recognized under MSA with VU (see Note 3		20.245		20.050
Related Parties) VHS other revenue		30,315		30,958
Nonclinical contracts		26,923		22,726
Resident and house staff rotations		21,876 8.407		20,588 9.123
		40,042		9, 123 17,612
Royalty revenue Other		46,106		49,402
	ф.	224,494	\$	
Total other operating revenue	Φ	224,494	Ψ	278,736

9. Investments

VUMC investments are made up of current investments, restricted cash, noncurrent investments, and noncurrent investments limited as to use on the face of the consolidated balance sheets. VUMC investments include assets limited as to use related to the following specified purposes as of June 30, 2023 and 2022:

(\$ in thousands)	 2023	 2022
Self-insured malpractice program	\$ 50,381	\$ 49,290
Donor endowments	94,885	85,430
Split-interest trusts	8,949	8,515
Supplemental employee retirement program assets	10,904	7,690
	\$ 165,119	\$ 150,925

VUMC's endowment does not include gift annuities, interests in trusts held by others, contributions pending donor designation, or contributions receivable.

The Board of Directors' interpretation of its fiduciary responsibilities for donor-restricted endowments under the Uniform Prudent Management of Institutional Funds Act ("UPMIFA") requirements is to preserve intergenerational equity, barring the existence of any donor-specific provisions. Under this broad guideline, future endowment beneficiaries should receive at least the same level of real economic support as the current generation. The overarching objective is to preserve and enhance the real (inflation-adjusted) purchasing power of the endowment in perpetuity. VUMC invests assets to provide a relatively predictable and stable stream of earnings to meet spending needs and attain long-term return objectives without the assumption of undue risks.

Self-insured malpractice program – VUMC elects to self-insure a portion of its medical malpractice, professional, and general liability via an irrevocable self-insurance trust.

Donor endowments – Donor-restricted gifts where the principal amount is to be held in perpetuity. Distributions of earnings are restricted for use according to the donor's intent, as specified in a gift agreement. Donor endowments typically benefit specific programs in clinical departments of the Medical Center, for either, research, directorships, or general program support.

Split-interest trusts – Trusts established by donors where VUMC is named as beneficiary. Depending on the terms of the trust, VUMC may receive periodic distributions, and potentially a principal amount at some point in the future. Like donor endowments, split-interest trusts typically benefit specific programs as defined in the terms of the trust.

Supplemental executive retirement program assets – Assets set aside to fulfill obligations as they come due according to the terms of the retirement program.

Investments were as follows as of June 30, 2023 and 2022:

(\$ in thousands)	 2023	2022
Corporate bonds	\$ 307,347	\$ 345,781
Equity mutual funds	143,681	123,707
Cash and cash equivalents	162,500	17,852
Split-interest trusts	8,949	8,515
Hedged equity mutual funds	38,692	137,325
Fixed income mutual funds	177,309	167,261
Certificates of deposit	13,246	18,301
Asset-backed securities	3,614	28,022
Mortgage-backed securities	99,468	6,542
Commercial paper	6,375	22,755
Government bonds	76,885	44,126
Hedged debt mutual funds	63,453	150,056
Commodities and managed futures mutual funds	22,654	42,063
Target date mutual funds	8,279	6,422
Equity securities	 74,278	12,033
Total investments reported at fair value	 1,206,730	 1,130,761
Private equity investments recorded at net asset value	29,409	31,022
Multi-strategy hedge funds recorded at net asset value	20,870	17,055
Real estate mutual fund recorded at net asset value	22,228	-
Hedged equity fund recorded at net asset value	 18,845	19,073
Total investments	\$ 1,298,082	\$ 1,197,911

Investment returns comprise the following elements for Fiscal 2023 and 2022:

(\$ in thousands)	 2023	 2022
Interest and dividend income	\$ 52,494	\$ 23,891
Net realized (losses) gains on sales of securities	 (6,550)	 9,619
Realized investment gains	45,944	33,510
Unrealized investment gains (losses), net	 22,535	 (112,451)
Total investment returns	68,479	(78,941)
Investment manager, trustee and other fees	(815)	(598)
Restricted investment (income) loss	 (6,621)	 8,482
Total income (loss) from investments, net	\$ 61,043	\$ (71,057)

VUMC has exposure to risks, including liquidity, interest rate, counterparty, basis, regulatory, market, and credit risks, for marketable securities. Due to the level of risk exposure, it is possible that material near-term valuation changes for investment securities may occur.

VUMC manages all investments, including endowments, in various investment pools.

10. Property, Plant, and Equipment, Net

Property, plant, and equipment comprise the following as of June 30, 2023 and 2022:

(\$ in thousands)	 2023	 2022
Land and land improvements	\$ 52,999	\$ 44,230
Buildings and improvements	1,383,525	1,303,474
Equipment and software	926,739	813,736
Leasehold improvements	171,922	154,486
Construction in progress	 145,502	 98,300
Property, plant, and equipment at cost	2,680,687	2,414,226
Accumulated depreciation and amortization	 (912,038)	 (734,458)
Property, plant, and equipment, net	\$ 1,768,649	\$ 1,679,768

As part of the MTSA, VUMC acquired land and land improvements and buildings and improvements which are not allowed to be repurposed without the express consent of VU.

In Fiscal 2023 and 2022, VUMC capitalized interest of \$5.1 million and \$1.3 million, respectively, related to long-term capital projects, primarily the VUH bed tower, VUH lab expansion, and the VUH lobby and operating room renovations in Fiscal 2022.

Property, plant, and equipment balances above include the following amounts related to capitalized internal use software:

(\$ in thousands)	 2023	 2022
Equipment and software	\$ 217,568	\$ 211,790
Construction in progress	7,057	3,931
	 224,625	 215,721
Accumulated amortization	 (105,682)	 (85,071)
Internal use software, carrying value	\$ 118,943	\$ 130,650

Depreciation and amortization comprise the following amounts in Fiscal 2023 and 2022:

(\$ in thousands)	2023	 2022
Depreciation of tangible assets Amortization of finance leases, leasehold improvements,	\$ 146,362	\$ 131,677
and internal use software	44,684	41,322
Total depreciation and amortization	\$ 191,046	\$ 172,999

11. Long-Term Debt

Long-term debt comprises the following as of June 30, 2023 and 2022:

(\$ in thousands)	20232022 Carrying Carrying Amount Amount		Effective Interest Rate ⁽²⁾	Fiscal Year of Maturity
Series debt				
Fixed-rate debt				
Series 2016A	\$ 476,930	\$ 476,930	4.1%	2047
Series 2016B	300,000	300,000	4.1%	2027
Series 2017A	121,270	121,270	4.1%	2049
Series 2017	100,000	100,000	4.2%	2038
Series 2021A	57,860	57,860	1.8%	2032
Series 2021B	237,565	237,565	3.2%	2053
Total fixed-rate debt	1,293,625	1,293,625	3.8%	
Variable-rate debt				
Series 2016F	19,800	21,900	4.4%	2042
Series 2018	53,385	53,385	3.7%	2050
Series 2021C	50,000	50,000	4.5%	2047
Series 2022A	70,500	_	3.8%	2056
Series 2022B	70,500		3.7%	2056
Total variable-rate debt	264,185	125,285	4.0%	
Total series debt	1,557,810	1,418,910		
Other long-term debt				
2019 Term Loan	35,000	35,000	4.5%	2050
2019 Notes	128,600	128,600	3.9%	2055
Subordinated note payable	64,583	69,583	3.2%	2036
Product financing arrangement	16,354	20,830	4.3%	2027
Finance leases	18,499	19,388	2.6%	Various
Other	7,725		0.0%	2026
Total other long-term debt	270,761	273,401	3.7%	
Subtotal ⁽¹⁾	1,828,571	1,692,311	3.8%	
Net unamortized premiums	62,841	66,838		
Net unamortized issuance costs	(12,562)	(12,693)		
Total long-term debt	1,878,850	1,746,456		
Current portion of long-term debt	(23,910)	(18,193)		
Long-term debt, net	\$ 1,854,940	\$ 1,728,263		

⁽¹⁾ The effective interest rate of 3.8% as of June 30, 2023, is presented exclusive of interest rate exchange agreements discussed in Note 12 Interest Rate Exchange Agreements. Inclusive of these agreements, the overall portfolio effective interest rate was 4.0%.

⁽²⁾ The effective interest rate for each debt instrument is calculated by dividing each instrument's interest expense by the weighted average debt outstanding, and where applicable, interest expense is reduced by premium amortization and increased by original issue discount amortization. Interest rates per the agreements are detailed in the accompanying notes.

On April 29, 2016, VUMC issued the Series 2016 A, B, C, D, E, and F bonds ("2016 Series Debt") and notes aggregating \$1.3 billion of proceeds for the purpose of financing the Medical Center Acquisition and paying a portion of the costs of issuance associated with the 2016 Series Debt.

The bonds and notes comprising the 2016 Series Debt were issued by the Health and Educational Facilities Board of The Metropolitan Government of Nashville and Davidson County, Tennessee ("HEFB"). As a conduit issuer, the HEFB loaned the debt proceeds to VUMC. VUMC's debt service requirements under these loan agreements coincide with required debt service of the actual HEFB bonds.

- The Series 2016A tax-exempt fixed-rate revenue bonds were issued in the par amount of \$476.9 million and include an original issue premium of \$59.6 million. The Series 2016A bonds have a final maturity date of July 1, 2046, and can be optionally redeemed at par on or after July 1, 2026. The 2016A bonds were structured as serial bonds with maturities from Fiscal 2030 through 2032, as well as three term bonds maturing Fiscal 2036 through 2047, which are subject to mandatory sinking fund redemption in lots. The Series 2016A bonds bear interest at 5% per annum and pay interest semiannually on July 1 and January 1.
- The Series 2016B taxable fixed-rate revenue bonds were issued in the par amount of \$300 million, bearing interest at 4.1% per annum. Interest is paid semiannually on July 1 and January 1, and has a bullet maturity of July 1, 2026. VUMC is entitled, at its option, to redeem all or a portion of the Series 2016B bonds before April 1, 2026, at a make-whole redemption price, which equals the greater of (i) 100% of the remaining outstanding principal and (ii) the net present value of the remaining scheduled principal and interest payments to the original maturity date, using a discount rate of 0.35% above rates for U.S. Treasury securities with comparable maturities.
- The Series 2016F taxable variable-rate revenue bonds were issued in the par amount of \$75 million and were placed privately with a bank. The bonds bore interest in a variable-rate mode at a fixed spread to one-month LIBOR of 2.5% through the initial mandatory tender date of July 1, 2022. During Fiscal 2018, \$53.1 million of the Series 2016F bonds were extinguished using proceeds from the 2018 tax-exempt fixed-rate revenue bonds, discussed further below. The renegotiated interest rate on the remaining \$21.9 million of principal outstanding was a variable-rate mode at a fixed spread to one-month LIBOR of 1.2%. During Fiscal 2022, the Series 2016F taxable variable-rate revenue bonds were modified and the renegotiated interest rate is a variable-rate mode at a fixed spread to SOFR of 0.8%. The remaining principal has a mandatory tender date of December 1, 2028. Beginning on July 1, 2022, VUMC began paying required annual principal payments ranging from \$2.1 million to \$2.7 million. The remaining \$5.3 million of principal is due on December 1, 2028.
- Prior to Fiscal 2022, Series 2016 C, D and E bonds were extinguished.

On July 26, 2017, the Series 2017A Tax-Exempt and Series 2017 Taxable Corporate Bonds were issued, and on August 1, 2017, the Series 2017B Taxable Revenue Bonds were issued ("2017 Series Debt"), aggregating \$271.3 million of proceeds for the purpose of refinancing existing debt, funding capital projects related to the MCJCHV expansion and the VUH bed expansion/clinical relocation, which was a phased project, and paying a portion of the costs of issuance associated with the 2017 Series Debt.

The Series 2017A Tax-Exempt Revenue Bonds and the Series 2017B Taxable Term Loan Revenue Note were issued by the HEFB. The Series 2017 Taxable Bonds were a corporate issue with VUMC as the issuer.

- The Series 2017A tax-exempt fixed-rate revenue bonds were issued in the par amount of \$121.3 million and include an original issue premium of \$5.1 million. The final maturity date is July 1, 2048, and optional redemption at par can occur on or after July 1, 2027. The Series 2017A bonds bear interest at 4.4% per annum and pay interest semiannually on July 1 and January 1.
- The Series 2017 taxable fixed-rate corporate bonds were issued in the par amount of \$100.0 million, bearing interest at 4.2% per annum. Interest is paid semiannually on July 1 and January 1, and the bonds have a final maturity date of July 1, 2037. There is a bullet payable beginning July 1, 2026, that allows VUMC to call the debt.
- The Series 2017B taxable variable-rate term loan notes were issued in the par amount of \$50 million and placed privately with a bank. The notes bore interest initially at a fixed-spread to one-month LIBOR of 1.2%. The notes had a final maturity date of July 1, 2046, a tender date of August 1, 2024, and could be redeemed at any time. Proceeds from the issuance of the Series 2017B notes were used to extinguish the Series 2016C R-FLOATs, initially issued on April 29, 2016. During Fiscal 2022, the Series 2017B notes were extinguished using proceeds from the Series 2021C Taxable Revenue Bonds, discussed further below.

On April 20, 2018, the Series 2018 Tax-Exempt Revenue Bonds ("2018 Series Debt") aggregating \$53.4 million of proceeds were issued for the purpose of refinancing existing debt and paying a portion of the costs of issuance associated with the 2018 Series Debt. The Series 2018 Tax-Exempt Revenue Bonds were issued by the HEFB, were placed privately with a bank, and bore interest at a fixed spread to 81% of one-month LIBOR of 0.6%. The bonds have a final maturity date of July 1, 2049. Proceeds from the issuance of the Series 2018 bonds were used to extinguish a portion of the Series 2016F taxable variable-rate bonds. During Fiscal 2023, the Series 2018 bonds were modified and the renegotiated interest rate is a fixed spread of 79% of SOFR plus 0.76%.

On July 30, 2019, VUMC entered into a term loan agreement ("2019 Term Loan") with a lender for \$35 million to pay for the acquisition of Tennova – Lebanon (now VWCH) hospital facilities, near term capital expenditures, and costs of issuance. The term loan bore interest at a variable rate plus a fixed spread to one-month LIBOR of 0.50% through the maturity date of August 1, 2029. Due to LIBOR being sunset as the benchmark rate, the interest rate was modified during Fiscal 2023 to SOFR plus a fixed spread of 0.60%. VUMC has the option to prepay all or a portion of the loan at any time, subject to notice. The 2019 loan is subject to principal amortization commencing on July 1, 2024 and ending July 1, 2049, as defined in the 2019 loan agreement between VUMC and the lender.

On October 22, 2019, the 2019 Taxable Fixed Private Placement Notes ("2019 Notes") aggregating \$128.6 million of proceeds were issued for the purpose of refinancing existing debt and paying a portion of the costs of issuance associated with the 2019 Notes. The 2019 Notes were placed privately with a bank, and bear interest at a fixed rate of 3.9% per annum. The notes have a final maturity date of July 1, 2054.

On April 9, 2021, the 2021 Short-Term Loan was issued in the par amount of \$200 million for the purpose of refinancing the 2020 Loan. The debt bore interest at a fixed spread to LIBOR of 0.4% and had a maturity of April 8, 2022. During Fiscal 2022, the 2021 Short-Term Loan was extinguished using proceeds from the Series 2021A Tax-Exempt and Series 2021B Taxable Revenue Bonds discussed further below.

On November 4, 2021, the Series 2021A Tax-Exempt and Series 2021B Taxable Revenue Bonds were issued, and on December 1, 2021, the Series 2021C Taxable Revenue Bonds were issued ("2021 Series Debt"), aggregating \$345.4 million of proceeds for the purpose of refinancing existing debt, funding capital projects, and paying a portion of the costs of issuance associated with the 2021 Series Debt. The 2021 Series was issued by the HEFB.

- The Series 2021A tax-exempt fixed-rate revenue bonds were issued in the par amount of \$57.9 million and include an original issue premium of \$16.2 million. The Series 2021A bonds have a bullet maturity of July 1, 2031, and can be optionally redeemed at par on or after January 1, 2031. The Series 2021A bonds bear interest at 5% per annum and pay interest semiannually on July 1 and January 1.
- The 2021B taxable fixed-rate revenue bonds were issued in the par amount of \$237.6 million, bearing interest at 3.2% per annum, which is paid semiannually on July 1 and January 1. The 2021B bonds have a final maturity of July 1, 2052 and are subject to mandatory sinking fund redemption in lots. VUMC is entitled, at its option, to redeem all or a portion of the Series 2021B bonds before January 1, 2052, at a redemption price, which equals the greater of (i) 100% of the remaining outstanding principal and (ii) the net present value of the remaining scheduled principal and interest payments to the original maturity date, using a discount rate of 0.20% above rates for U.S. Treasury securities with comparable maturities.
- The 2021C taxable variable-rate revenue bonds were issued in the par amount of \$50 million and were placed privately with a bank. The bonds bore interest in a variable-rate mode at a fixed spread to one-month LIBOR of 0.5%. Due to LIBOR being sunset as the benchmark rate, the interest rate was modified during Fiscal 2023 to SOFR plus a fixed spread of 0.63%. The bonds have a final maturity date of July 1, 2046, a tender date of December 1, 2027, and may be redeemed at any time. Proceeds from the issuance of the Series 2021C bonds were used to extinguish the Series 2017B notes.

On December 7, 2022, the Series 2022A Tax-Exempt and Series 2022B Tax-Exempt Revenue Bonds were issued for \$70.5 million each. The proceeds were used to fund capital projects, and to pay a portion of the costs of issuance. The bonds bear interest at SIFMA plus a fixed spread of 0.70% and 0.67%, respectively. The 2022 Series was issued by the HEFB.

Each of the bonds, notes, and loans represent separate obligations under a Master Trust Indenture ("MTI") structure. The MTI provides the flexibility for multiple parties to participate in debt issuances as part of an obligated group; presently, VUMC has no other third-party members participating in the obligated group. All debt issued under the MTI is a general obligation of the obligated group. Under the provisions of the Leasehold Deed of Trust, Security Agreement, Assignment of Rents and Leases, and Fixture Filing (the "Security Agreement") within the MTI, gross receivables of the obligated group are pledged as collateral. Additionally, the Security Agreement established a mortgage lien on (i) the leasehold interest of the land subject to the Ground Lease; (ii) the buildings, structures, improvements, and fixtures now or hereafter located on the land subject to the Ground Lease; and (iii) certain other collateral.

Trust indentures for certain bond issues contain covenants and restrictions, the most material of which include limitations on the issuance of additional debt, maintenance of a specified debt service coverage ratio, and a minimum amount of days cash on hand. VUMC complied with such covenants and restrictions as of June 30, 2023 and 2022.

On April 29, 2016, VUMC delivered a secured subordinated promissory note in the amount of \$100 million to VU to finance the Acquisition (the "subordinated note"). In July of 2018, VU sold its rights to future principal and interest payments on this note to a third party. The note was issued at a fixed rate of 3.25% with monthly principal payments totaling \$5 million annually commencing on May 31, 2016, for a period of 20 years ending on April 30, 2036. VUMC may, at any time and from time to time, without premium or penalty, prepay all or any portion of the unpaid principal amount of the subordinated note. This note is secured by the gross receivables and mortgaged property described in the Security Agreement subject to the requirements of the 2016 Series Debt and the MTI.

As part of the Acquisition, VUMC assumed a 10-year, unsecured, noninterest-bearing product financing arrangement with a vendor for the purchase and implementation of internal use software. The annual payment of \$5.3 million is payable in monthly installments, is considered principal and imputed interest, and continues through Fiscal 2027. The balance due under the Product Financing Arrangement is \$16.4 million and \$20.8 million as of June 30, 2023 and 2022, respectively. At June 30, 2023 and 2022, \$4.7 million and \$4.5 million, respectively, was included in the current portion of long-term debt caption, with the remaining balance in long-term debt, net of current portion.

In Fiscal 2023 and 2022, noncash investing and financing activities totaled \$9.7 million and \$10.5 million, respectively, related to finance leases.

VUMC has an agreement with a bank to provide a general use line of credit with a maximum available commitment totaling \$100 million, which bore interest at a fixed spread to one-month LIBOR of 0.65% and has no maturity date if the line of credit is renewed annually. The line of credit accrued a commitment fee of 0.15% per annum on any unused portion of the line of credit. Effective April 4, 2023, the agreement was amended to modify the interest rate and commitment fee and extend the maturity date. The line of credit bears interest at a fixed spread to SOFR of 0.50%, accrues a commitment fee of 0.10% on any unused portion of the line of credit, and has a final maturity date of April 3, 2024.

VUMC established an additional \$50 million line of credit with a bank in Fiscal 2021. The line of credit bore interest at a fixed spread to one-month LIBOR of 0.45%, maturing in Fiscal 2022 with a commitment fee of 0.2% on any unused portion of the line of credit. Effective April 7, 2023, the agreement was amended to modify the interest rate and extend the maturity date. The line of credit bears interest at a fixed spread to SOFR of 0.60%, accrues a commitment fee of 0.18% on any unused portion of the line of credit, and has a maturity date of April 4, 2025

During Fiscal 2023, VUMC established an additional \$50 million line of credit, which bears interest at a fixed spread to SOFR of 0.75%, accrues a commitment fee of 0.125% on any unused portion of the line of credit, and has a maturity date of May 8, 2026.

During Fiscal 2023, VUMC established an additional \$100 million line of credit, which bears interest at a fixed spread to SOFR of 0.62%, accrues a commitment fee of 0.15% on any unused portion of the line of credit, and has a maturity date of May 1, 2026.

There are no outstanding balances on lines of credit as of June 30, 2023 or 2022. Commitment fees for the lines of credit totaled \$0.2 million and \$0.3 million in Fiscal 2023 and Fiscal 2022, respectively.

Interest paid on all obligations, including interest rate swap settlements, net of amounts capitalized, was \$69.9 million and \$62.6 million in Fiscal 2023 and 2022, respectively.

Principal retirements and scheduled sinking fund requirements based on maturity schedules for long-term debt due in subsequent fiscal years ending June 30 are as follows:

(\$ in thousands)

2024	\$ 23,910
2025	19,893
2026	22,786
2027	317,402
2028	14,987
Thereafter	 1,429,593
	\$ 1,828,571

12. Interest Rate Exchange Agreements

Key features of VUMC interest rate exchange agreements are summarized below:

Notional Amount	Pay Fixed Rate	Receive Variable Rate	Mandatory Termination Date
\$75.0 million	4.24%	68% of one-month LIBOR	May 2, 2025
\$75.0 million	4.28%	68% of one-month LIBOR	April 29, 2026

VUMC incorporates these interest rate exchange agreements into its debt portfolio management strategy. There are no collateral pledging requirements. The agreements terminate automatically on May 2, 2025 and April 29, 2026, if not renegotiated or extended, at which point the exchange agreements will be settled at fair value.

VUMC recorded the following activity related to the interest rate exchange agreements during Fiscal 2023 and 2022:

(\$ in thousands)	2023		2022	
Mark-to-market adjustments Cash settlements	\$	11,862 (2,251)	\$	31,845 (6,004)
Unrealized gain on interest rate exchange agreements, net of cash settlements	\$	9,611	\$	25,841

13. Leases

VUMC has operating and finance leases for real estate, personal property and equipment. VUMC determines if an arrangement is a lease at the inception of a contract. Leases with an initial term of twelve months or less are not recorded in the consolidated balance sheets.

VUMC has lease agreements which require payments for lease and non-lease components and has elected to account for these as a single lease component. For leases that commenced before the effective date of ASU 2016-02, VUMC elected the permitted practical expedients to not reassess the following: (i) whether any expired or existing contracts contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases.

Right-of-use assets represent VUMC's right to use an underlying asset during the lease term, and lease liabilities represent VUMC's obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the commencement date, based on the net present value of fixed lease payments over the lease term. VUMC's lease terms include options to extend or terminate the lease when it is reasonably certain that the options will be exercised. As most of VUMC's operating leases do not provide an implicit rate, VUMC uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. VUMC considers recent debt issuances, as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates. Finance lease agreements generally include an interest rate that is used to determine the present value of future lease payments. Operating fixed lease expense and finance lease depreciation expense are recognized on a straight-line basis over the lease term. Variable lease costs consist primarily of common area maintenance and other index adjustments.

Operating and finance lease right-of-use assets and lease liabilities as of June 30, 2023 and 2022, are as follows:

(\$ in thousands)	Balance Sheet Classification	2023		 2022	
Assets:					
Operating leases Finance leases	Operating leases Property, plant, and	\$	845,573	\$ 826,560	
i mance leases	equipment, net		18,704	19,412	
Total lease assets		\$	864,277	\$ 845,972	
Liabilities:					
Current:					
Operating leases	Current portion of operating lease liabilities	\$	71,906	\$ 68,510	
Finance leases	Current portion of long-term debt		9,483	6,618	
Noncurrent:			,	,	
Operating leases	Noncurrent portion of operating lease liabilities		800,003	783,178	
Finance leases	Long-term debt, net of		,		
	current portion		9,016	 12,770	
Total lease liabilities		\$	890,408	\$ 871,076	
Weighted-average remaining term	:				
Operating leases			54.8 years	56.3 years	
Finance leases			2.8 years	3.4 years	
Weighted-average discount rate:					
Operating leases			3.7%	3.7%	
Finance leases			3.2%	2.7%	

Included in the tables above is the Ground Lease with VU expiring in 2114 discussed below. Excluding this lease, the weighted average remaining lease term for VUMC's operating leases is 8.2 years as of June 30, 2023 and 7.5 years as of June 30, 2022. As of June 30, 2023 and 2022, the land lease comprises \$488.1 million and \$488.7 million, respectively, of the operating lease asset and \$490.8 million and \$491.4 million, respectively, of the operating lease liability detailed above.

Lease expense for finance and operating leases for the years ended June 30, 2023 and 2022, are as follows:

(\$ in thousands)	 2023	 2022
Finance lease expense:		
Amortization of leased assets	\$ 10,489	\$ 8,431
Interest on lease liabilities	497	467
Operating lease expense (1)	109,049	107,551
Short-term lease expense (1)	3,195	4,551
Variable lease expense (1)	16,944	15,665
	\$ 140,174	\$ 136,665

⁽¹⁾ Expense is included in "Facilities, equipment, and technology" in the consolidated statements of operations.

The following table presents supplemental cash flow information for the years ended June 30, 2023 and 2022:

(\$ in thousands)	 2023	 2022
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases Operating cash flows for finance leases Financing cash flows for finance leases	\$ 106,246 497 10,626	\$ 105,366 467 7,333

The following table reconciles the undiscounted minimum lease payments to the operating and financing lease liabilities recorded in the consolidated balance sheet at June 30, 2023:

(\$ in thousands)		perating Leases		Finance Leases
2024	\$	101,251	\$	9,800
2025		92,436		4,487
2026		77,956		1,844
2027		61,935		1,859
2028		53,100		659
Thereafter		1,824,915		816
Total minimum lease payments		2,211,593		19,465
Less: amount of lease payments representing interest		(1,339,684)		(966)
Present value of future minimum lease payments	,	871,909	<u></u>	18,499
Less: current lease obligations		(71,906)		(9,483)
Long-term lease obligations	\$	800,003	\$	9,016

Essential provisions of leases considered by management to be material are as follows:

- On April 29, 2016, VUMC entered into a Ground Lease with VU for approximately 1.7 million square feet of land for an initial term ending June 30, 2114, and an option to extend for up to two additional terms of 50 to 99 years each upon agreement by VU and VUMC. The annual base rent is payable monthly, and is CPI adjusted annually. VUMC made rental payments totaling \$22.1 million and \$20.4 million in Fiscal 2023 and 2022, respectively. The Ground Lease allows VUMC to use the land on which its campus and related buildings are located. Included in the table above are \$1.8 billion in ground lease payments representing future minimum rentals based on the initial annual base rent of \$19.4 million, excluding annual CPI adjustments.
- In July 2007, VU entered into an agreement to lease approximately 50% of the space in the 850,000 square foot One Hundred Oaks shopping center located approximately five miles from the main campus ("100 Oaks Lease"). VU redeveloped this leased space primarily for medical and office uses. In October 2014, VU agreed to an amendment which extends the original lease term to November 30, 2035, with an option to renew the lease further for four additional 10-year periods. As part of the lease agreement, the lessee also has first rights on leasing additional space in the shopping center and first rights on purchasing if the landlord desires to sell. On April 29, 2016, the 100 Oaks Lease was assigned to VUMC. On June 10, 2023, the lease was amended to add an additional 84,750 square feet of leased space within the facility. VUMC included minimum property rental payments totaling \$116.1 million related to this space in the above minimum lease payments table.
- On April 29, 2016, VU assigned to VUMC a lease for approximately 231,000 square feet of office space at 2525 West End Avenue with expiration dates ranging from 2026 through 2030, with options to renew for two additional five-year periods. VUMC included minimum lease payments totaling \$57.7 million related to this space in the above minimum lease payments table.
- On April 29, 2016, VUMC and VU entered into certain lease agreements for the use of space in buildings separately owned by each entity. As of June 30, 2023, VUMC's estimated future minimum lease payments to VU totaled \$31.2 million. Estimated future lease receipts from VU for the fiscal year ended June 30, 2024, are \$8.8 million, subject to annual renewal.
- On November 1, 2022, VUMC entered into a lease agreement for office space at 431 Great Circle Road, located approximately five miles from the main campus. The lease provided for initial occupancy of approximately 94,000 square feet, with occupancy of an additional 16,000 square feet of space commencing on February 16, 2023, for a total of 110,000 square feet. The lease expiration date is October 31, 2042. VUMC included minimum lease payments totaling \$48.3 million related to this space in the above minimum lease payments table.

14. Net Assets

Net asset restrictions relate to the following purposes as of June 30, 2023 and 2022:

(\$ in thousands)	 2023	 2022
Donor-restricted – time or purpose Property, plant, and equipment Research and education Operations	\$ 18,839 166,396 12,818	\$ 14,534 150,086 5,335
Total donor-restricted – time or purpose	\$ 198,053	\$ 169,955
Donor restricted – perpetuity Research and education	\$ 119,048	\$ 98,477

Net assets without donor restrictions are free of donor-imposed restrictions. This classification includes all revenues, gains, and losses not restricted by donors. VUMC reports all expenditures in net assets without donor restrictions since the use of restricted contributions in accordance with donors' stipulations results in the release of the restriction.

Donor restricted – time or purpose contain donor-imposed stipulations that expire with the passage of time or that can be satisfied by the action of VUMC. These net assets may include restricted gifts including unconditional pledges, split-interest agreements, interests in trusts held by others, and accumulated appreciation on donor-restricted endowments not yet appropriated by the Board of Directors for distribution. Donor gifts that are restricted for funding capital projects are considered released from restriction once related capital expenditures have been made and the asset is placed in service.

Donor restricted – perpetuity contains amounts held in perpetuity as requested by donors. These net assets may include unconditional pledges, donor-restricted endowments, split-interest agreements, and interests in trusts held by others. Generally, the donors of these assets permit VUMC to use a portion of the income earned on related investments for specific purposes.

UPMIFA specifies that unless stated otherwise in a gift instrument, donor-restricted assets in an endowment fund are restricted assets until appropriated for expenditure. Barring the existence of specific instructions in gift agreements for donor-restricted endowments, VUMC reports the historical value of such endowments as donor restricted – perpetuity and the net accumulated appreciation as donor restricted – time or purpose. In this context, the historical value represents the original value of initial contributions restricted as permanent endowments plus the original value of subsequent contributions and, if applicable, the value of accumulations made in accordance with the direction of specific donor gift agreements.

15. Fair Value Measurements

Fair value measurements represent the amount at which the instrument could be exchanged in an orderly transaction between market participants at the measurement date. VUMC utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels:

- Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that VUMC has the ability to access.
- Level 2 Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the assets or liabilities, and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
- Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement. Unobservable inputs reflect VUMC's assumptions about the inputs market participants would use in pricing the asset or liability, including assumptions about risk. Unobservable inputs are developed based on the best information available in the circumstances and may include VUMC's own data.

VUMC's principal assets and liabilities are cash and cash equivalents, investments, patient accounts receivable, estimated receivables and liabilities under third-party programs, grants and contracts receivable, pledges receivable, operating lease assets, accounts payable and other accrued expenses, self-insurance reserves, operating lease liabilities, long-term debt, and interest rate exchange agreements. Except for long-term debt, the carrying amount of these assets and liabilities approximates fair value.

As of June 30, 2023, the carrying value and estimated fair value of total long-term debt totaled \$1.9 billion and \$1.7 billion, respectively. As of June 30, 2022, the carrying value and estimated fair value of total long-term debt totaled \$1.7 billion and \$1.7 billion, respectively. VUMC bases estimated fair value of long-term debt on market conditions prevailing at fiscal year-end reporting dates. Besides potentially volatile market conditions, fair value estimates typically reflect limited secondary market trading. The fair values of the fixed-rate Series Debt, as defined in Note 11 Long-Term Debt, were based on a Level 2 computation using quoted prices for similar liabilities in active markets as of June 30, 2023 and 2022, as applicable. The carrying amounts related to VUMC's variable-rate Series Debt and other long-term debt obligations approximate their fair values as of June 30, 2023 and 2022. As of June 30, 2023 and 2022, the fair values of the subordinated note payable and the product financing arrangement were based on a Level 2 discounted cash flow approach applying a risk-adjusted spread for issuers of similar credit quality to U.S. Treasury yields for securities with comparable maturities.

For financial instruments measured at fair value on a recurring basis, the following tables summarize valuation hierarchy levels as of June 30, 2023 and 2022, determined by the nature of the financial instrument and the least observable input significant to the fair value measurement:

	Fair Value Measurements as of June 30, 2023										
								Total			
							(Carrying			
(\$ in thousands)	Level 1			Level 2		evel 3		Amount			
Assets											
Corporate bonds	\$	_	\$	307,347	\$	_	\$	307,347			
Equity mutual funds	Ψ	22,887	Ψ	120,794	Ψ	_	Ψ	143,681			
Cash and cash equivalents		162,500		120,734		_		162,500			
Beneficial interests in		102,300		_		_		102,500			
split-interest trusts		_		8,949		_		8,949			
Hedged equity mutual funds		_		38,692		_		38,692			
Fixed-income mutual funds		83,055		94,254		_		177,309			
Certificates of deposit		-		13,246		_		13,246			
Asset-backed securities		_		3,614		_		3,614			
Mortgage-backed securities		_		99,468		_		99,468			
Commercial paper		_		6,375		_		6,375			
Government bonds		_		76,885		_		76,885			
Hedged debt mutual funds		_		63,453		_		63,453			
Commodities and managed				00, 100				00, 100			
futures mutual funds		8,628		14,026		_		22,654			
Target date mutual funds		_		8,279		_		8,279			
Equity securities		74,278		-		_		74,278			
Total assets in the		,						,			
fair value hierarchy	\$	351,348	\$	855,382	\$		\$	1,206,730			
Investments measured at net											
asset value								91,352			
Total assets reported								,			
at fair value							\$	1,298,082			
Liabilities											
Interest rate exchange											
agreements	\$	_	\$	33,157	\$	_	\$	33,157			
Total liabilities reported					-						
at fair value	\$		\$	33,157	\$		\$	33,157			

	Fair Value Measurements as of June 30, 2022										
						-		Total Carrying			
(\$ in thousands)	Level 1			Level 2	Lev	vel 3		Amount			
Assets											
Corporate bonds	\$	_	\$	345,781	\$	_	\$	345,781			
Equity mutual funds	,	19,887	,	103,820	•	_	,	123,707			
Cash and cash equivalents		17,852		-		_		17,852			
Beneficial interests in		,						,			
split-interest trusts		_		8,515		_		8,515			
Hedged equity mutual funds		_		137,325		_		137,325			
Fixed-income mutual funds		80,697		86,564		_		167,261			
Certificates of deposit		· _		18,301		_		18,301			
Asset-backed securities		_		28,022		_		28,022			
Mortgage-backed securities		_		6,542		_		6,542			
Commercial paper		_		22,755		_		22,755			
Government bonds		_		44,126		_		44,126			
Hedged debt mutual funds		_		150,056		_		150,056			
Commodities and managed						_					
futures mutual funds		8,135		33,928				42,063			
Target date mutual funds		_		6,422		_		6,422			
Equity securities		12,033		_		_		12,033			
Total assets in the				_							
fair value hierarchy	\$	138,604	\$	992,157	\$		\$	1,130,761			
Investments measured at net											
asset value								67,150			
Total assets reported											
at fair value							\$	1,197,911			
Liabilities											
Interest rate exchange											
agreements	\$	<u> </u>	\$	45,019	\$		\$	45,019			
Total liabilities reported							-				
at fair value	\$		\$	45,019	\$		\$	45,019			

Certain of the investments are reported using a calculated NAV per share. These investments are not expected to be sold at amounts that are materially different from NAV. The following table identifies attributes relating to the nature and risk of investments for which fair value is determined using a calculated NAV as of June 30, 2023 and 2022:

June 30, 2023

		04110 00	,							
\$ 29,409 20,870 22,228 18,845 91,352	\$	2,000 5,000 - - 7,000	None Quarterly Semi-annual Quarterly	None 65-95 Days 90 Days 90 Days						
 June 30, 2022										
Carrying Amount			Redemption Frequency	Redemption Notice Period						
\$ 31,022 17,055 19,073	\$	3,500 8,000 ———————————————————————————————	None Quarterly Quarterly	None 65-95 Days 90 Days						
\$ \$	20,870 22,228 18,845 \$ 91,352 Carrying Amount \$ 31,022 17,055 19,073	Amount Cor \$ 29,409 \$ 20,870 22,228 18,845 \$ \$ 91,352 \$ Carrying Amount Cor \$ 31,022 \$ 17,055 19,073	Carrying Amount Unfunded Commitments \$ 29,409 \$ 2,000 20,870 5,000 22,228 - 18,845 - \$ 91,352 \$ 7,000 June 30 Carrying Amount Unfunded Commitments \$ 31,022 \$ 3,500 17,055 8,000 19,073 -	Amount Commitments Frequency \$ 29,409 \$ 2,000 None 20,870 5,000 Quarterly 22,228 — Semi-annual 18,845 — Quarterly \$ 91,352 \$ 7,000 Redemption Carrying Amount Unfunded Commitments Redemption Frequency \$ 31,022 \$ 3,500 None 17,055 8,000 Quarterly 19,073 — Quarterly						

VUMC employs derivatives, primarily interest rate exchange agreements, to help manage interest rate risks associated with variable-rate debt. In addition to the credit risk of the counterparty owing a balance, VUMC calculates the fair value of interest rate exchange agreements based on the present value of future net cash settlements that reflect market yields as of the measurement date.

Parties to interest rate exchange agreements are subject to risk for changes in interest rates, as well as the risk of credit loss in the event of nonperformance by the counterparty. VUMC deals only with high-quality counterparties that meet rating criteria for financial stability and credit-worthiness.

16. Retirement Plan

VUMC's full-time employees participate in a 403(b) defined contribution retirement plan administered by a third party. For eligible employees with one year of continuous service, this plan requires employer matching of employee contributions up to 5% of eligible compensation. The employee immediately vests in these contributions.

VUMC funds the obligations under this plan through monthly transfers to the respective retirement plan administrator with the corresponding expense recognized in the year incurred. During Fiscal 2023 and 2022, VUMC recognized \$96.2 million and \$86.4 million, respectively, of expense in connection with this plan.

17. Functional Expense

(\$ in thousands)

Interest

Total operating expense

VUMC provides general health care services primarily to residents within its geographic location and supports research and education programs. Total operating expense by nature and function for Fiscal 2023 and 2022 were as follows:

For the Year Ended June 30, 2023

	Healthcare Services	Academic Research and Education	Administrative and Other	Total
Salaries, wages, and benefits Supplies and drugs Facilities, equipment, and technology	\$ 2,716,045 1,469,828 206,222	\$ 691,294 55,983 69,358	\$ 290,481 8,086 123,377	\$ 3,697,820 1,533,897 398,957
Services and other	675,532	141,880	104,055	921,467
Depreciation and amortization	165,904	7,868	17,274	191,046
Interest	56,032	9,977	183	66,192
Total operating expense	\$ 5,289,563	\$ 976,360	\$ 543,456	\$ 6,809,379
(\$ in thousands)		For the Year Er	nded June 30, 2022	!
	Healthcare Services	Academic Research and Education	Administrative and Other	Total
Salaries, wages, and benefits Supplies and drugs	\$ 2,454,835	\$ 608,296 64,759	\$ 241,202	\$ 3,304,333
Facilities, equipment, and	1,310,567		2,990	1,378,316
technology	200,785	55,369	108,469	364,623
· · · · · · · · · · · · · · · · · · ·				

Certain expense categories are attributable to more than one function. Therefore, these expenses require an allocation on a reasonable basis that is consistently applied. The expenses that are allocated include salaries, wages, and benefits, and services and other.

9,527

875,583

\$

12

477,416

59,930

\$ 6,189,984

50,391

\$ 4,836,985

18. Commitments and Contingencies

Management has policies, procedures, and an organizational structure to enforce and monitor compliance with government statutes and regulations. VUMC's compliance with such laws and regulations is subject to future government review and interpretations, as well as regulatory actions unknown or unasserted at this time.

- Litigation; Payor Disputes. VUMC is a defendant in certain medical professional liability lawsuits and other civil actions, none of which are anticipated to have a material effect on VUMC's consolidated financial position. In addition, VUMC from time to time pursues claims and appeals of adverse payment decisions by third parties, including governmental and commercial payors. These include but are not limited to appeals relating to Medicare reimbursements matters before the Provider Reimbursement Review Board, payments for drugs purchased and dispensed through the 340B discounted drug purchasing program, and payments received under commercial payor reimbursement agreements. The outcomes of these claims and appeals are not expected to have a material effect on VUMC's consolidated financial position.
- Compliance Program. Through the operation of its compliance program, VUMC from time to time
 initiates the review of billing for clinical services provided by VUMC and its affiliated providers.
 VUMC has established a liability reserve relating to certain matters under review as of June 30,
 2023 and 2022, which is not material to VUMC's consolidated financial position.
- Regulatory Reviews. VUMC is subject to the regulation and oversight of various state and federal
 government agencies and may from time to time receive subpoenas, requests for documents or
 other information, civil investigative demands or other legal process related to VUMC's business
 and operations (including its billing practices). VUMC's compliance with regulations and laws is
 subject to future government reviews and interpretations, as well as regulatory actions unknown
 at this time. VUMC believes that the liability, if any, from such reviews will not have a material
 effect on VUMC's consolidated financial position.
- Medical Malpractice Self-Insurance. The consolidated balance sheets include reserves for medical malpractice, professional, and general liability coverage totaling \$90.5 million as of June 30, 2023, and \$81.6 million as of June 30, 2022. These liabilities are measured at the net present value of those cash flows using a discount rate of 2.5% at both dates and are classified as current or noncurrent based on the expected timing of cash flows. Other current assets include expected recoveries from commercial insurance carriers under excess coverage arrangements totaling \$7.7 million as of June 30, 2023, and \$5.9 million as of June 30, 2022. During Fiscal 2023 and 2022, VUMC recorded expenses for medical malpractice self-insurance of \$24.4 million and \$30.4 million, respectively.
- Employee Health and Workers' Compensation Insurance. Accrued compensation and benefits included actuarially determined liabilities for employee health and workers' compensation claims totaling \$36.1 million and \$5.7 million, respectively, as of June 30, 2023, and \$23.0 million and \$5.7 million, respectively, as of June 30, 2022. During Fiscal 2023 and 2022, VUMC recorded expenses for self-insured employee health benefit plans, net of employee premiums, totaling \$310.7 million and \$261.4 million, respectively. During Fiscal 2023 and 2022, VUMC recorded expenses for self-insured workers' compensation plans of \$4.6 million and \$4.9 million, respectively.

- Federal and State Contracts and Other Requirements. Expenditures related to federal and state
 grants and contracts are subject to adjustment based upon review by the granting agencies.
 Amounts of expenditures that granting agencies might disallow cannot be determined at this
 time. These amounts affect government grants and contracts revenue, as well as facilities and
 administrative costs recovery. VUMC does not expect these costs to impact the consolidated
 financial position by material amounts.
- Health Care Services. In Fiscal 2023 and 2022, 86% and 84%, respectively, of VUMC's operating revenue was generated by providing health care services, where revenue is affected by reimbursement arrangements with federal and state healthcare programs, commercial insurance, and other managed care payors. If reimbursement rates from third-party payors decrease or if contract terms become less favorable in future periods, VUMC's operating revenues may decline. See Note 4 Patient Service Revenue, Patient Accounts Receivable, and Estimated Third-Party Settlements, for further information regarding healthcare revenues and related receivables.
- HIPAA Compliance. Under the Health Insurance Portability and Accountability Act of 1996
 ("HIPAA") and related regulations, the federal government has authority to investigate potential
 breaches of federal requirements for the privacy and security of patient health information to
 impose substantial fines and penalties in connection with violations. VUMC maintains policies,
 procedures, and organizational structures to enforce and monitor compliance with HIPAA, as
 well as other related federal and state laws, rules, and regulations.
- Construction. VUMC had contractual commitments under major construction and equipment contracts totaling \$243.9 million and \$53.5 million as of June 30, 2023 and 2022, respectively.

19. Other Events

COVID-19

In March of Fiscal 2020, COVID-19, a disease caused by the novel strain of the coronavirus, was designated by the World Health Organization as a global pandemic. A state of emergency was subsequently announced by the State of Tennessee, quickly followed by "stay at home" orders and orders for hospitals and outpatient surgical facilities to stop non-essential procedures. This global health crisis negatively impacted many facets of the business, including lower patient volumes and related revenues, significant increases in certain supply costs (in particular personal protective equipment) as well as difficulties sourcing these supplies, and volatility in the U.S. and global financial markets impacting VUMC's investment portfolios.

Sources of pandemic relief include the federal stimulus package known as The Coronavirus Aid, Relief, and Economic Security ("CARES") Act, signed into law on March 27, 2020, the Coronavirus Response and Consolidated Appropriations Act ("CRCA") signed into law on December 27, 2020, and the American Rescue Plan ("ARP"), signed into law on March 11, 2021. These laws include a number of provisions: most importantly providing funding through the Public Health and Social Services Emergency Fund ("Provider Relief Fund") to reimburse eligible health care providers for health care-related expenses or lost revenues not otherwise reimbursed that are directly attributable to COVID-19. These provider relief funds included amounts distributed to providers based on their share of the Medicare fee-for-service reimbursement ("General Distributions"). The funds also included for certain targeted distributions ("Targeted Distributions") to qualifying providers (primarily rural and high impact areas). In Fiscal 2022, VUMC recognized as revenue approximately \$44.8 million in General Distributions and \$23.4 million in Targeted Distributions, for a total of \$68.2 million, under the Provider Relief Fund. There were no Provider Relief Funds received in Fiscal 2023. These amounts are presented in other operating revenue in the consolidated statements of operations.

In addition, the CARES Act provides for an expansion of the Medicare Accelerated and Advance Payment Program ("MAAPP") whereby inpatient acute care hospitals and other eligible providers may request an advance payment of up to 100% of their Medicare payment amount for a sixmonth period to be repaid through withholding of future Medicare fee-for-service payments beginning 120 days after receipt.

On October 1, 2020, the Continuing Appropriations and Other Extensions Acts amended the repayment terms for the funds received under the MAAPP. Under the revised repayment terms, the Centers for Medicare and Medicaid Services ("CMS") began to automatically recoup the advance payments one year from the original date of issuance by offsetting the payments against newly submitted Medicare claims. Once the recoupment period began, for the first eleven (11) months, Medicare automatically recouped payments at a rate of 25% of the Medicare claims amount otherwise owed to VUMC. After the first recoupment period of eleven (11) months, and continuing for the following six (6) months, Medicare automatically recoups payments at a rate of 50% of the Medicare claims amount otherwise owed to VUMC. After this repayment term concludes, any balance that remains outstanding will be subject to interest at a rate of four percent (4%) per annum. In accordance with the repayment terms, CMS recouped \$173.4 million of VUMC's MAAPP funds during Fiscal 2022 and recouped the remaining liability of \$16.0 million during Fiscal 2023. There is no MAAP liability as of June 30, 2023.

The CARES Act also allows for deferred payment of the employer portion of certain payroll taxes between March 27, 2020 and December 31, 2020, with 50% due December 31, 2021 and the remaining 50% due December 31, 2022. As of June 30, 2022, VUMC had deferred payroll tax payments of \$37.9 million included in accrued compensation and benefits in the consolidated balance sheet. This balance was paid during Fiscal 2023 and no balance remains at June 30, 2023.

In addition, the CARES Act suspended the sequestration payment adjustment percentage of 2% applied to all Medicare Fee-for-Service claims from May 1, 2020 through December 31, 2020, with subsequent acts extending through March 31, 2022. Upon conclusion of the suspension period, CMS applied a 1% payment adjustment for the period April 1, 2022 through June 30, 2022, at which time CMS reverted to the 2% payment adjustment for sequestration. This suspension positively impacted patient service revenue in the consolidated statements of operations by approximately \$14 million for Fiscal 2022. Beginning, September 1, 2020, the CARES Act also provided for a 20% Medicare supplement for Medicare patients diagnosed with COVID-19 that are admitted to the hospital, reflecting the additional costs of treating a patient with this diagnosis. During Fiscal 2022, VUMC recognized an additional \$6 million in patient service revenue in the consolidated statements of operations related to this supplement. There was no revenue recognized in Fiscal 2023 related to this supplement.

During Fiscal 2022, VUMC received \$73.2 million of supplemental payments directed from the State of Tennessee which covered a uniform increase for inpatient and outpatient services performed for the period January 1, 2022 through December 31, 2022. VUMC recognized \$36.6 million as patient service revenue related to the services performed for the period January 1, 2022 through June 30, 2022. The remaining \$36.6 million of payments received was recognized during Fiscal 2023. An additional tranche of supplemental payments directed from the State of Tennessee was received and recognized in Fiscal 2023 in the amount of \$23.9M.

During Fiscal 2022, VUMC recognized as other operating revenue \$4.5 million for Tennessee staffing grants. No staffing grants were received in Fiscal 2023.

Business Combination of Cool Springs Surgery Center

Effective July 1, 2021, VUMC amended the operating agreement related to the noncontrolling ownership interest held in the Cool Springs Surgery Center ("CSSC"). This amendment constituted a change in control event for CSSC and is now consolidated into the financial statements of VUMC. Prior to the change in control event date, VUMC accounted for its noncontrolling ownership interest in CSSC as an equity method investment. In accordance with FASB ASC 805, Business Combinations, the acquisition method was applied to account for this consolidation and CSSC was recorded at its fair value. The acquisition-date fair value of the previous equity interest was \$18.0 million. VUMC recognized a gain of \$14.7 million during Fiscal 2022 as a result of remeasuring its previous equity interest to fair value, which is presented in other nonoperating gains in the consolidated statements of operations.

20. Subsequent Events

Management evaluated events after June 30, 2023 through September 29, 2023, the date on which the consolidated financial statements were issued. During this period, there were no subsequent events requiring recognition or disclosure in the consolidated financial statements that have not been recorded or disclosed.

Supplementary Information

Schedule of Expenditures of Federal Awards and State Financial Assistance

Fiscal Period 7/1/2022 - 6/30/2023

	Federal Assistance Listing	Additional Award	Name of Funder Pass-Through	Identifying Number Assigned By Funder Pass-Through	Total Amount Provided to	Federal	Federal Program Cluster	Cluster
Federal Awarding Agency/Program Title	Number	Identification	Entity	Entity	Sub-Recipients	Expenditures	Total Name	Total
DEPARTMENT OF AGRICULTURE AGRICULTURAL RESEARCH, BASIC AND APPLIED RESEARCH	10.001	59-0210-6-004				\$104,631	\$336,401 RESEARCH AND DEVELOPMENT	\$543.888.056
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-6-004				\$104,631	\$336,401 RESEARCH AND DEVELOPMENT	\$543,888,056
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-8-184	CRDF Global (Civilian Research and Development Foundation)	59-0210-8-184		\$9,512	\$336,401 RESEARCH AND DEVELOPMENT	\$543,888,056
AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH	10.001	59-0210-8-184	CRDF Global (Civilian Research and Development Foundation)	59-0210-8-184		\$5,176	\$336,401 RESEARCH AND DEVELOPMENT	\$543,888,056
AGRICULTURAL RESEARCH, BASIC AND APPLIED RESEARCH	10.001	59-0210-8-184	CRDF Global (Civilian Research	59-0210-8-184		\$116.977	\$336.401 RESEARCH AND DEVELOPMENT	\$543.888.056
1890 INSTITUTION CAPACITY BUILDING GRANTS	10.216	2022-38821-27352	and Development Foundation) Tennessee State University	2022-38821-27352		\$37.315	\$37.315 RESEARCH AND DEVELOPMENT	\$543,888,056
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI) TOTAL DEPARTMENT OF AGRICULTURE	10.310	VUMC94491(2017-68001-34846)	University of Kentucky	VUMC94491(2017-68001-34846)		\$175,087 \$548,803	\$175,087 RESEARCH AND DEVELOPMENT	\$543,888,056
DEPARTMENT OF DEFENSE								
Basic and Applied Scientific Research NAVAL MEDICAL RESEARCH AND DEVELOPMENT	12.300 12.340	N00014-22-1-2184 N3239822P0407			\$22,000	\$226,813 \$29,997	\$226,813 RESEARCH AND DEVELOPMENT \$29,997 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
BASIC SCIENTIFIC RESEARCH - COMBATING WEAPONS OF MASS DESTRUCTION	12.351	W15QKN-16-9-1002	Emory University	W15QKN-16-9-1002		\$182,399	\$182.399 RESEARCH AND DEVELOPMENT	\$543.888.056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT94252310003	.,,			\$24,336	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420 12.420	HT94252310004 HT9425-23-1-0070				\$13,917 \$64,201	\$11,237,544 RESEARCH AND DEVELOPMENT \$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0070				\$29,465	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543.888.056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT94252310410				\$26,624	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420 12.420	W81XWH-17-1-0442 W81XWH-17-1-0503				\$109,610 \$9.065	\$11,237,544 RESEARCH AND DEVELOPMENT \$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0005 W81XWH-17-2-0055			\$15,134	\$64.878	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543.888.056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0029				\$6,653	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420 12.420	W81XWH-18-1-0149 W81XWH-18-1-0536				\$481,356 \$120.561	\$11,237,544 RESEARCH AND DEVELOPMENT \$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0683				\$676	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0810			\$984,671	\$1,281,144	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420 12.420	W81XWH-19-1-0415 W81XWH-19-1-0580				\$204,742 \$4,633	\$11,237,544 RESEARCH AND DEVELOPMENT \$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0580 W81XWH-19-1-0640			\$13,338	\$4,633 \$37.645	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0782			* ,	\$6,248	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0812				\$306,203	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420 12.420	W81XWH-20-1-0269 W81XWH-20-1-0475			\$395 \$902	\$89,913 \$5,370	\$11,237,544 RESEARCH AND DEVELOPMENT \$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0542			\$39,126	\$521,637	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0593				\$1,011	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420 12.420	W81XWH-20-1-0648 W81XWH-20-1-0691				\$313,844 \$7,787	\$11,237,544 RESEARCH AND DEVELOPMENT \$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0701			\$95,084	\$248,343	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0910				\$165,130	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420 12.420	W81XWH-20-2-0046 W81XWH-21-1-0051			\$110,428 \$59.879	\$256,114 \$238,788	\$11,237,544 RESEARCH AND DEVELOPMENT \$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0441			455,015	\$376,731	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0617				\$365,167	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420 12.420	W81XWH-21-1-0694 W81XWH-21-1-0765			\$25,356 \$109.529	\$112,610 \$488,397	\$11,237,544 RESEARCH AND DEVELOPMENT \$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0786			\$109,529	\$220.891	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-2-0025				\$510,039	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420 12.420	W81XWH-21-BCRP-BTA12 W81XWH-22-1-0090				\$221,054 \$374,942	\$11,237,544 RESEARCH AND DEVELOPMENT \$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0090 W81XWH-22-1-0418				\$390,881	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0419				\$161,140	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420 12.420	W81XWH-22-1-0484 W81XWH2210635				\$437,714 \$44,290	\$11,237,544 RESEARCH AND DEVELOPMENT \$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH2210635 W81XWH-22-1-1008				\$201,273	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-1033				\$508,817	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420 12.420	W81XWH2211087 W911QY2310001				\$100,305 \$18,388	\$11,237,544 RESEARCH AND DEVELOPMENT \$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	VUMC103522(W81XWH2210308)	Vanderbilt University	VUMC103522(W81XWH2210308)		\$21,778	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543.888.056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	VUMC104827(W81XWH2210475)	Baylor College of Medicine	VUMC104827(W81XWH2210475)		\$56,218	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	VUMC106865(W81XWH2211122)	Vanderbilt University	VUMC106865(W81XWH2211122)		\$12,504	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420 12.420	VUMC107111(W81XWH2211121) VUMC107987(W81XWH22-1-0201)	Vanderbilt University University of Iowa	VUMC107111(W81XWH2211121) VUMC107987(W81XWH22-1-0201)		\$52,072 \$18,304	\$11,237,544 RESEARCH AND DEVELOPMENT \$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	VUMC107967(W61XWH22-1-0201) VUMC108122(W81XWH2210301)	Boston Childrens Hospital	VUMC107987(W81XWH22-1-0201)		\$1,954	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	VUMC108473(W81XWH2210367)	Vindhya Data Science Inc	VUMC108473(W81XWH2210367)		\$5,397	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	VUMC109197(W81XWH2210304)	Carnegie Mellon	VUMC109197(W81XWH2210304)		\$89,106	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420 12.420	VUMC109328(W911NF2120078) VUMC109357(W81XWH2210818)	Civil-military Innovation Institute, In- Meharry Medical College	VUMC109328(W911NF2120078) VUMC109357(W81XWH2210818)		\$71,770 \$3,389	\$11,237,544 RESEARCH AND DEVELOPMENT \$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	VUMC109357(W81XWH2210818) VUMC109716(W81XWH2210661)	Vanderbilt University	VUMC109357(W81XWH2210818) VUMC109716(W81XWH2210661)		\$3,389	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	VUMC110627	Civil-military Innovation Institute, In- Johns Hopkins University School of			\$81,656	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	VUMC62614(W81XWH-16-2-0060)	Medicine University of California-San	VUMC62614(W81XWH-16-2-0060)		\$5,072	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	VUMC82342(W81XWH-17-1-0631)	Francisco	VUMC82342(W81XWH-17-1-0631)		\$12,753	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420 12.420	VUMC84144(W81XWH2020001) VUMC86328(W81XWH-20-2-0032)	University of Colorado Denver Coalition for National Trauma Research	VUMC84144(W81XWH2020001) VUMC86328(W81XWH-20-2-0032)		\$152,490 \$49,526	\$11,237,544 RESEARCH AND DEVELOPMENT \$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	VUMC95835(W81XWH-20-2-0032) VUMC95835(W81XWH-16-D-0024, W81XWH20F0383)	University of Pittsburgh	VUMC95835(W81XWH-20-2-0032) VUMC95835(W81XWH-16-D-0024, W81XWH20F0383)		\$49,526 \$126 484	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	VUMC96620(W81XWH2110591)	Carnegie Mellon	VUMC96620(W81XWH2110591)		\$52,545	\$11,237,544 RESEARCH AND DEVELOPMENT	\$543,888,056

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

	Federal Assistance		Name of Funder	Identifying Number Assigned By Funder	Total Amount		Federal		
Federal Awarding Agency/Program Title	Listing Number	Award Identification	Pass-Through Entity	Pass-Through Entity	Provided to Sub-Recipients E	Federal Evnenditures	Program Total	Cluster Name	Cluster Total
Todala Anatang Aganoph Togram Tito	натьс	racination .		Linky	oub recipients 2	Experientares	7000	Nume	70107
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-10-2-0090	Johns Hopkins University Bloomberg School of Public Health			\$40,675	\$11,237,544 RESEARC	H AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0067	Johns Hopkins University School o Medicine Johns Hopkins University School o	W81XWH-15-2-0067		\$6,012	\$11,237,544 RESEARC	H AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0074	Medicine Medicine	W81XWH-15-2-0074		\$3,136	\$11,237,544 RESEARC	H AND DEVELOPMENT	\$543.888.056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-2-0003	Florida State University	W81XWH-16-2-0003		\$7,504	\$11,237,544 RESEARC		\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-D-0024 VUMC# 74579	University of Pittsburgh University of California-San	W81XWH-16-D-0024 VUMC# 74579		\$96,770	\$11,237,544 RESEARC	H AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12 420	W81XWH-17-1-0631	Francisco	W81XWH-17-1-0631		\$231.822	\$11 237 544 RESEARC	H AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0702	University of Maryland	W81XWH-17-1-0702		\$12.632	\$11,237,544 RESEARC		\$543.888.056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0790	University of Rochester Johns Hopkins University School o	W81XWH-18-1-0790		\$326,701	\$11,237,544 RESEARC		\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12 420	W81XWH-18-1-0815	Medicine University School of	W81XWH-18-1-0815		\$9.723	\$11.237.544 RESEARC	H AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0090	Homology Medicines, Inc	W81XWH-19-1-0090		\$23,423	\$11,237,544 RESEARC		\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0821	Rutgers University	W81XWH-19-1-0821		\$18,927	\$11,237,544 RESEARC	H AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0848	University of Maryland	W81XWH-19-1-0848		\$12,912	\$11,237,544 RESEARC		\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-2-0010	McGill University Johns Hopkins University School o	W81XWH-19-2-0010		\$17,856	\$11,237,544 RESEARC	H AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-2-0062	Medicine	W81XWH-19-2-0062		\$5,375	\$11,237,544 RESEARC		\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0540	Epitracker Inc.	W81XWH-20-1-0540		\$26,650	\$11,237,544 RESEARC		\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0620	Iowa State University Johns Hopkins University School o	W81XWH-20-1-0620 of		\$686	\$11,237,544 RESEARC	H AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-2-0063	Medicine	W81XWH-20-2-0063		\$15,006	\$11,237,544 RESEARC		\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0160	Case Western Reserve University	W81XWH-21-1-0160		\$864	\$11,237,544 RESEARC	H AND DEVELOPMENT	\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0160	Emory University	W81XWH-21-1-0160		\$12,889	\$11,237,544 RESEARC		\$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420 12.420	W81XWH-21-1-0273 W81XWH-21-1-0833	University of Kentucky University of Kentucky	W81XWH-21-1-0273 W81XWH-21-1-0833		\$165,610 \$202,140	\$11,237,544 RESEARC \$11,237,544 RESEARC		\$543,888,056 \$543,888,056
MILITARY MEDICAL RESEARCH AND DEVELOPMENT MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0833 W81XWH-21-2-0053	The Metis Foundation	W81XWH-21-1-0833 W81XWH-21-2-0053		\$202,140	\$11,237,544 RESEARC		\$543,888,056 \$543,888,056
COMMUNITY INVESTMENT	12.600	W81XWH-15-9-001	University of Colorado Denver	W81XWH-15-9-001		\$125.524		H AND DEVELOPMENT	\$543,888.056
UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS	12.750	HU000-12-1-20002	Vanderbilt University	HU000-12-1-20002		(\$1,505)		H AND DEVELOPMENT	\$543,888,056
AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM	12.800	FA8650-16-2-6G02	University of Cincinnati	FA8650-16-2-6G02		\$20,385		H AND DEVELOPMENT	\$543,888,056
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	HR0011-18-2-0001			\$1,961,474	\$2,474,727	\$2,512,387 RESEARC		\$543,888,056
RESEARCH AND TECHNOLOGY DEVELOPMENT Department of Defense	12.910 12.RD	HR0011-21-2-0011 ID07200010-301	Vanderbilt University University of Colorado Denver	HR0011-21-2-0011 ID07200010-301		\$37,660 \$81,519		H AND DEVELOPMENT H AND DEVELOPMENT	\$543,888,056 \$543,888,056
Department of Defense	12.RD	VUMC99211(47QFWA20C0012)	University of Colorado Denver	VUMC99211(47QFWA20C0012)		\$206.752		H AND DEVELOPMENT	\$543,888,056
Department of Defense	12.RD	VUMC99217(47QFWA20C0012)	University of Colorado Denver	VUMC99217(47QFWA20C0012)		\$162,465		H AND DEVELOPMENT	\$543,888,056
Department of Defense	12.RD	VUMC99580(2021-ARL-TRACA-PP-VANDY-001)	Vanderbilt University	VUMC99580(2021-ARL-TRACA-PP-VA	ANDY-001)	\$36,921	\$586,439 RESEARC	H AND DEVELOPMENT	\$543,888,056
Department of Defense	12.RD	W81XWH-20-C-0027	Triton Systems, Inc. Henry M. Jackson Foundation for the Advancement of Military	W81XWH-20-C-0027		(\$6,264)	\$586,439 RESEARC	H AND DEVELOPMENT	\$543,888,056
Department of Defense	12 RD	W81XWH-20-C-0031	Medicine	W81XWH-20-C-0031		\$97.916	\$586 439 RESEARC	H AND DEVELOPMENT	\$543.888.056
Department of Defense TOTAL DEPARTMENT OF DEFENSE	12.RD	W909MY-21-C-0023	Camgian Microsystems	W909MY-21-C-0023	\$3,437,316	\$7,130 \$14,919,983	\$586,439 RESEARC	H AND DEVELOPMENT	\$543,888,056
DEPARTMENT OF JUSTICE									
CRIME VICTIM ASSISTANCE	16.575	DOJ-TN HOSP ASSOC	Tennessee Hospital Association, Inc.	DOJ-TN HOSP ASSOC		\$19,312	\$22,059 N/A		
			State of Tennessee Department of						
CRIME VICTIM ASSISTANCE	16.575	VUMC75581(Edison ID 63811)	Children's Services Tennessee Department of Health	VUMC75581(Edison ID 63811)		\$2,747	\$22,059 N/A		
HAROLD ROGERS PRESCRIPTION DRUG MONITORING PROGRAM	16.754	64793:ST TN	Services	64793:ST TN		\$11,194	\$11,194 RESEARC	H AND DEVELOPMENT	\$543,888,056
COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	16.838 16.838	72816:ST TN 72929:ST TN	State of Tennessee State of Tennessee	72816:ST TN 72929:ST TN		\$24,364 \$16,860		H AND DEVELOPMENT H AND DEVELOPMENT	\$543,888,056 \$543,888,056
COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM COMPREHENSIVE OPIOID ABUSE SITE-BASED PROGRAM	16.838	72929:S1 TN 72930:ST TN	State of Tennessee	72929:S1 TN 72930:ST TN		\$16,860 \$506		H AND DEVELOPMENT	\$543,888,056 \$543.888.056
DEPARTMENT OF JUSTICE	16.RD	15JC1V22P00000040	Clair or Territorio	72000.01 114		\$188,751		H AND DEVELOPMENT	\$543,888,056
TOTAL DEPARTMENT OF JUSTICE						\$263,734			
NATIONAL AERONAUTICS & SPACE ADMINISTRATION									
EXPLORATION	43.003	80NCCS19M0161	National Council on Radiation Protection and Measurements	80NCCS19M0161		\$250,733	\$250,733 RESEARC	H AND DEVELOPMENT	\$543,888,056
TOTAL NATIONAL AERONAUTICS & SPACE ADMINISTRATION						\$250,733			
INSTITUTE OF MUSEUM AND LIBRARY SERVICES OR NATIONAL ENDOWMENT FOR THE ARTS OR NATIONAL ENDOWMENT FOR THE HUMANITIES									
PROMOTION OF THE ARTS_GRANTS TO ORGANIZATIONS AND INDIVIDUALS PROMOTION OF THE ARTS_GRANTS TO ORGANIZATIONS AND INDIVIDUALS	45.024 45.024	1863278-38-20 1906827-38				\$44,438		H AND DEVELOPMENT H AND DEVELOPMENT	\$543,888,056 \$543.888.056
TOTAL INSTITUTE OF MUSEUM AND LIBRARY SERVICES OR NATIONAL ENDOWMENT FOR	45.024	1906827-38				\$68,171	\$112,009 RESEARC	H AND DEVELOPMENT	\$543,888,056
THE ARTS OR NATIONAL ENDOWMENT FOR THE HUMANITIES						\$112,609			
NATIONAL SCIENCE FOUNDATION						_			
ENGINEERING	47.041	2050252				\$139,963	\$220,533 RESEARC	H AND DEVELOPMENT	\$543,888,056
ENGINEERING ENGINEERING	47.041	2124002 2124872	Vanderbilt University PragmaDx, Inc.	2124002 2124872		\$66,643 \$13,927		H AND DEVELOPMENT H AND DEVELOPMENT	\$543,888,056 \$543,888,056
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.041 47.070	2124872 2050895	PragmaDx, Inc.	2124872		\$13,927 \$79,018		H AND DEVELOPMENT	\$543,888,056 \$543,888,056
BIOLOGICAL SCIENCES	47.074	2147467				\$112,846		H AND DEVELOPMENT	\$543,888,056
BIOLOGICAL SCIENCES	47.074	NSF-2011291				\$172,985		H AND DEVELOPMENT	\$543,888,056
BIOLOGICAL SCIENCES	47.074	1814520	University of Tennessee	1814520		\$10,349	\$507,766 RESEARC	H AND DEVELOPMENT	\$543,888,056
BIOLOGICAL SCIENCES	47.074	1845634	University of Massachusetts Bosto	n 1845634		\$1,478	\$507.766 RESEARC	H AND DEVELOPMENT	\$543,888,056
BIOLOGICAL SCIENCES	47.074	2120084	University of Pittsburgh	2120084		\$210,108	\$507,766 RESEARC	H AND DEVELOPMENT	\$543,888,056
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075	2033896				\$32,934		H AND DEVELOPMENT	\$543,888,056
EDUCATION AND HUMAN RESOURCES EDUCATION AND HUMAN RESOURCES	47.076 47.076	DUE1926794 2116026	Oregon State University	2116026	\$24,215	\$13,370 \$43.618		H AND DEVELOPMENT H AND DEVELOPMENT	\$543,888,056 \$543,888,056
EDGG TOTA AND HUMAN NEGODINOES	47.076	2.10020	2.3gon Oute Offiverally	25020		φτ3,010	φου,σοο RESEARU	VD DEVELOFINEINI	9040,000,000

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	e Additional Award Identification	Name of Funder Pass-Through Entity	ldentifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Cluster Total Name	Cluster Total
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079	9531011				\$83,651	\$105,139 RESEARCH AND DEVELOPMENT	\$543,888,056
OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING	47.079 47.079	G-202105-67817 INT-9531011				\$13,064 \$8,424	\$105,139 RESEARCH AND DEVELOPMENT \$105,139 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
TOTAL NATIONAL SCIENCE FOUNDATION					\$24,215	\$1,002,378		
ENVIRONMENTAL PROTECTION AGENCY								
SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM	66.509 66.509	83950101-1 83950401	Vanderbilt University	83950401	\$58,853	\$80,495 \$1,902	\$82,397 RESEARCH AND DEVELOPMENT \$82,397 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
TOTAL ENVIRONMENTAL PROTECTION AGÉNCY					\$58,853	\$82,397		
DEPARTMENT OF EDUCATION						402,000		
SPECIAL EDUCATION, GRANTS TO STATES	84 027	45237: ST TN	Tennessee Department of Education	45237: ST TN	(\$4,521)	(\$4,519)	\$3,113,855 SPECIAL EDUCATION CLUSTER (IDEA)	\$3,113,855
			Tennessee Department of					
SPECIAL EDUCATION_GRANTS TO STATES	84.027	71077:ST TN	Education Tennessee Department of	71077:ST TN	\$21,147	\$1,791,474	\$3,113,855 SPECIAL EDUCATION CLUSTER (IDEA)	\$3,113,855
SPECIAL EDUCATION_GRANTS TO STATES SPECIAL EDUCATION_GRANTS TO STATES	84.027 84.027	71430:ST TN VUMC112145(33101-23073GRF5)(PAVE)	Education State of Tennessee	71430:ST TN VUMC112145(33101-23073GRF5)(PAVE	\$25,083)	\$1,295,235 \$31,665	\$3,113,855 SPECIAL EDUCATION CLUSTER (IDEA) \$3,113,855 SPECIAL EDUCATION CLUSTER (IDEA)	\$3,113,855 \$3,113,855
REHABILITATION SERVICES_VOCATIONAL REHABILITATION GRANTS TO STATES	84.126	69455:ST TN-VU	Vanderbilt University Tennessee Department of	69455:ST TN-VU		\$7,223	\$7,223 N/A	\$0
SPECIAL EDUCATION-GRANTS FOR INFANTS AND FAMILIES SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS	84.181	70785:ST TN	Education	70785:ST TN		\$1,449,096	\$1,449,096 N/A	\$0
FOR CHILDREN WITH DISABILITIES SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS	84.325	H325K190046				\$278,941	\$695,678 N/A	\$0
FOR CHILDREN WITH DISABILITIES	84.325	H325K190064			\$19,780	\$204,668	\$695,678 N/A	\$0
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	H325K190068			\$39,726	\$180,013	\$695,678 N/A	\$0
SPECIAL EDUCATION - PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.325	VUMC109047(H325D220072)	Vanderbilt University	VUMC109047(H325D220072)		\$32,056	\$695,678 N/A	\$0
SPECIAL EDUCATION-TECHNICAL ASSISTANCE AND DISSEMINATION TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES	84.326	H326T180048				\$249.923	\$249.923 N/A	\$0
TOTAL DEPARTMENT OF EDUCATION					\$101,215	\$5,515,775		•
DEPARTMENT OF HEALTH AND HUMAN SERVICES			Lawrence Livermore National					
Department of Energy GLOBAL AIDS	81.RD 93.067	VUMC110413(DE-AC52-07NA27344) 6NU2GGH002367-01-08	Laboratory	VUMC110413(DE-AC52-07NA27344)		\$110,348 \$2.011.898	\$110,348 RESEARCH AND DEVELOPMENT \$2,011.898 N/A	\$543,888,056 \$0
Public Health Emergency Preparedness	93.069	VUMC56952(34349-86423)(Edison ID 75941)	State of Tennessee	VUMC56952(34349-86423)(Edison ID 759	941)	\$247,298	\$247,298 N/A	\$0
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077 93.077	5R21DA052026-02 VUMC87075(U54HL120163)	American Heart Association	VUMC87075(U54HL120163)	\$50,546	\$217,098 \$47,261	\$264,359 RESEARCH AND DEVELOPMENT \$264,359 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
Strengthening Emergency Care Delivery in the United States Healthcare System through Health Information and Promotion	93.078	6HITEP220063-01-01				\$51,653	\$51,653 RESEARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	VUMC57787(NU27DD000020)	University of North Carolina-Chape Hill	el VUMC57787(NU27DD000020)		\$18,301	\$72,210 RESEARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH FOOD AND DRUG ADMINISTRATION RESEARCH	93.080 93.103	VUMC89441(NU58DD000019) 1R01FD007627-01	University of Memphis	VUMC89441(NU58DD000019)	\$8.412	\$53,909 \$167,495	\$72,210 RESEARCH AND DEVELOPMENT \$1,008,243 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	5R01FD006649-03			\$106,457	\$387,629	\$1,008,243 RESEARCH AND DEVELOPMENT	\$543,888,056
FOOD AND DRUG ADMINISTRATION RESEARCH FOOD AND DRUG ADMINISTRATION RESEARCH	93.103 93.103	75F40119D10037 75F40119D10037	Harvard Pilgrim Health Care Harvard Pilgrim Health Care	75F40119D10037 75F40119D10037		\$107,087 \$268,519	\$1,008,243 RESEARCH AND DEVELOPMENT \$1,008,243 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	R01 FD006003	Boston Childrens Hospital	R01 FD006003		\$7,019	\$1,008,243 RESEARCH AND DEVELOPMENT	\$543,888,056
FOOD AND DRUG ADMINISTRATION RESEARCH FOOD AND DRUG ADMINISTRATION RESEARCH	93.103 93.103	R01 FD006371 R01 FD007290	Cumberland Pharmaceuticals Inc. Mayo Clinic Hospital	R01 FD006371 R01 FD007290		\$18,489 \$52,005	\$1,008,243 RESEARCH AND DEVELOPMENT \$1,008,243 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
	33.103	K011 2007290	TN Dept of Mental Health and	1011 2007230		432,003	\$1,000,245 RESERVOITAND DEVELOT WENT	4545,000,030
COMPREHENSIVE COMMUNITY MENTAL HEALTH SERVICES FOR CHILDREN WITH SERIOUS EMOTIONAL DISTURBANCES (SED)	93.104	72274:ST TN	Substance Abuse Services (Changed 2012)	72274:ST TN		\$151,077	\$151,077 N/A	\$0
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	5T73MC30767-08-00	,		\$218,294	\$737,393	\$4,037,985 RESEARCH AND DEVELOPMENT	\$543,888,056
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110 93.110	6H6MMC33236-04-03 T73MC30767-05				\$361,653 (\$2,105)	\$4,037,985 RESEARCH AND DEVELOPMENT \$4,037,985 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	H30 MC24045	Childrens Hospital Los Angeles	H30 MC24045		\$1,047	\$4,037,985 RESEARCH AND DEVELOPMENT	\$543,888,056
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110 93.110	U24 GM132217 U24 GM132217 VUMC76308	University of North Texas HSC University of North Texas HSC	U24 GM132217 U24 GM132217 VUMC76308		\$3,113 \$374,769	\$4,037,985 RESEARCH AND DEVELOPMENT \$4,037,985 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	UC4 MC28042	American College of Obstetricians and Gynecologists	UC4 MC28042		\$7,792	\$4.037.985 RESEARCH AND DEVELOPMENT	\$543,888,056
			University of Colorado Anschutz				. , ,	
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110 93.110	VUMC104627(UA6MC31101) VUMC40097(H30MC24046)	Medical Center Hemophilia of Georgia, Inc.	VUMC104627(UA6MC31101) VUMC40097(H30MC24046)	\$10,000	\$30,944 \$2,523,379	\$4,037,985 RESEARCH AND DEVELOPMENT \$4,037,985 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ENVIRONMENTAL HEALTH	93.113	5R01ES031401-03		, , , , , , , , , , , , , , , , , , , ,	\$172,021	\$550,578	\$708,298 RESEARCH AND DEVELOPMENT	\$543,888,056
ENVIRONMENTAL HEALTH ENVIRONMENTAL HEALTH	93.113 93.113	R01 ES027845 R01 ES029846	Columbia University University of Louisville	R01 ES027845 R01 ES029846		\$8,684 \$19,244	\$708,298 RESEARCH AND DEVELOPMENT \$708,298 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ENVIRONMENTAL HEALTH ENVIRONMENTAL HEALTH	93.113	VUMC103156(T32ES007028)	Vanderbilt University	VUMC103156(T32ES007028)		\$3,133	\$708,298 RESEARCH AND DEVELOPMENT	\$543,888,056
ENVIRONMENTAL HEALTH	93.113	VUMC78863(R01ES010563)	Purdue University	VUMC78863(R01ES010563)		\$72,118	\$708,298 RESEARCH AND DEVELOPMENT	\$543,888,056
ENVIRONMENTAL HEALTH ENVIRONMENTAL HEALTH	93.113 93.113	VUMC87289(R01ES019217) VUMC89278(T32ES007028)	University of Louisville Vanderbilt University	VUMC87289(R01ES019217) VUMC89278(T32ES007028)		\$14,907 \$39,634	\$708,298 RESEARCH AND DEVELOPMENT \$708,298 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5K23DE028010-04	various or voidity	VOMC03270(13223007020)		\$55,056	\$458,750 RESEARCH AND DEVELOPMENT	\$543,888,056
ORAL DISEASES AND DISORDERS RESEARCH	93.121	5R01DE027749-05	University of Texas Health Science	es .	\$35,399	\$151,414	\$458,750 RESEARCH AND DEVELOPMENT	\$543,888,056
ORAL DISEASES AND DISORDERS RESEARCH	93.121	R56 DE028302	Center at Houston	R56 DE028302		(\$2,943)	\$458,750 RESEARCH AND DEVELOPMENT	\$543,888,056
ORAL DISEASES AND DISORDERS RESEARCH ORAL DISEASES AND DISORDERS RESEARCH	93.121 93.121	VUMC91537(R01DE029650) VUMC96314(R01DE029650)	University of Kentucky University of Kentucky	VUMC91537(R01DE029650) VUMC96314(R01DE029650)		\$169,658 \$85,565	\$458,750 RESEARCH AND DEVELOPMENT \$458,750 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.121	2H33MC31540-07-00	Graversity of Rentucky	VOINC40314(RUIDE023030)		\$85,565 \$47,664	\$150,850 N/A	\$543,888,056
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	6H33MC31540-06-02				\$98,525	\$150,850 N/A	\$0
EMERGENCY MEDICAL SERVICES FOR CHILDREN EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127 93.127	VUMC88889(U03MC00001) VUMC88889(U03MC00001)	University of California, Davis University of California, Davis	VUMC88889(U03MC00001) VUMC88889(U03MC00001)		\$574 \$4,087	\$150,850 N/A \$150,850 N/A	\$0 \$0
Centers for Research and Demonstration for Health Promotion and Disease Prevention	93.127	SAMSHA-UNIV OF PENN	University of Pennsylvania	SAMSHA-UNIV OF PENN		\$4,087	\$150,850 N/A \$26,333 N/A	\$0 \$0

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Federal Sub-Recipients Expenditures	Federal Program Cluster Total Name	Cluster Total
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY			Tennessee Department of Health	•	,,		
BASED PROGRAMS	93.136	72944:ST TN	Services	72944:ST TN	\$228,490	\$249,719 RESEARCH AND DEVELOPMENT	\$543,888,056
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	74108:ST TN	Tennessee Department of Health Services	74108:ST TN	\$16,529	\$249,719 RESEARCH AND DEVELOPMENT	\$543,888,056
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	R01 CE003009	University of North Carolina-Chapel	R01 CE003009	\$4.700	\$249,719 RESEARCH AND DEVELOPMENT	\$543,888,056
GLOBAL AIDS	93.067	6NU2GGH002367-01-08	• • • • • • • • • • • • • • • • • • • •	NOT GEOGGOGS	\$294,498	\$294,498 N/A	\$0
GLOBAL AIDS	93.067	6NU2GGH002367-01-08			\$1,675,260	\$1,675,260 N/A	\$0
GLOBAL AIDS AIDS EDUCATION AND TRAINING CENTERS	93.067 93.145	5NU2GGH002367-03-00 5U1OHA30535-08-01			\$3,610,819 \$33,845,765 \$3,128,122 \$4,857,737	\$33,845,765 N/A \$4,953,578 RESEARCH AND DEVELOPMENT	\$0 \$543.888.056
AIDS EDUCATION AND TRAINING CENTERS	93.145	UHA30535-03-00			\$4,141	\$4,953,578 RESEARCH AND DEVELOPMENT	\$543,888,056
AIDS EDUCATION AND TRAINING CENTERS COVID-19 COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN,	93.145	U1S HA46532	Columbia University	U1S HA46532	\$91,700	\$4,953,578 RESEARCH AND DEVELOPMENT	\$543,888,056
INFANTS, CHILDREN, AND YOUTH	93.153	2H12HA30750-06-00			\$441,675	\$482,701 N/A	\$0
COVID-19 COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN,							
INFANTS, CHILDREN, AND YOUTH HUMAN GENOME RESEARCH	93.153 93.172	5H12HA30750-05-01 2T32HG008341-06			\$41,026 \$268.271	\$482,701 N/A \$12,016,742 RESEARCH AND DEVELOPMENT	\$0 \$543,888,056
HUMAN GENOME RESEARCH	93.172	4R00HG010493-03			\$230,367	\$12,016,742 RESEARCH AND DEVELOPMENT	\$543,888,056
HUMAN GENOME RESEARCH	93.172	5R00HG010904-04			\$257,975	\$12,016,742 RESEARCH AND DEVELOPMENT \$12,016,742 RESEARCH AND DEVELOPMENT	\$543,888,056
HUMAN GENOME RESEARCH HUMAN GENOME RESEARCH	93.172 93.172	5R00HG011367-04 5R01HG009694-04			\$148,529 \$39,075 \$51,387	\$12,016,742 RESEARCH AND DEVELOPMENT \$12.016,742 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
HUMAN GENOME RESEARCH	93.172	5R01HG010863-04			\$15,728 \$646,425		\$543,888,056
HUMAN GENOME RESEARCH	93.172	5R01HG011138-04			\$255,896	\$12,016,742 RESEARCH AND DEVELOPMENT	\$543,888,056
HUMAN GENOME RESEARCH HUMAN GENOME RESEARCH	93.172 93.172	5R01HG011405-03 5R01HG012262-02			\$195,639 \$471,770 \$567,950 \$905,836	\$12,016,742 RESEARCH AND DEVELOPMENT \$12,016,742 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
HUMAN GENOME RESEARCH	93.172	5R01HG012657-02			\$367,930 \$903,636	\$12,016,742 RESEARCH AND DEVELOPMENT	\$543,888,056
HUMAN GENOME RESEARCH	93.172	5R21HG010652-02			\$6,344	\$12,016,742 RESEARCH AND DEVELOPMENT	\$543,888,056
HUMAN GENOME RESEARCH HUMAN GENOME RESEARCH	93.172 93.172	5R35HG010718-05 5RM1HG009034-08			\$445,181 \$278,184 \$1,019,129	\$12,016,742 RESEARCH AND DEVELOPMENT \$12,016,742 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
HUMAN GENOME RESEARCH	93.172	5U01HG010232-05			\$1.512.570 \$2.629.788	\$12,016,742 RESEARCH AND DEVELOPMENT	\$543.888.056
HUMAN GENOME RESEARCH	93.172	5U01HG011166-03			\$428,813 \$2,350,995	\$12,016,742 RESEARCH AND DEVELOPMENT	\$543,888,056
HUMAN GENOME RESEARCH HUMAN GENOME RESEARCH	93.172 93.172	5U01HG011181-04 THG008341-04			\$1,100,129 (\$4.167)	\$12,016,742 RESEARCH AND DEVELOPMENT \$12,016,742 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
HUMAN GENOME RESEARCH	93.172	THG008341-04 THG008341-05			(\$4,381)	\$12,016,742 RESEARCH AND DEVELOPMENT	\$543.888.056
HUMAN GENOME RESEARCH	93.172	U01 HG011723	Broad Institute of MIT and Harvard		\$256,029	\$12,016,742 RESEARCH AND DEVELOPMENT	\$543,888,056
HUMAN GENOME RESEARCH	93.172	U24 HG010262	Broad Institute of MIT and Harvard		\$358,796	\$12,016,742 RESEARCH AND DEVELOPMENT	\$543,888,056
HUMAN GENOME RESEARCH	93.172	VUMC100777(R01HG011598)	University of Louisville University of North Carolina-Chapel	VUMC100777(R01HG011598)	\$70,000	\$12,016,742 RESEARCH AND DEVELOPMENT	\$543,888,056
HUMAN GENOME RESEARCH	93.172	VUMC95052(U01HG011720)	Hill	VUMC95052(U01HG011720)	\$159,552	\$12,016,742 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1R01DC020194-01A1			\$9,223 \$202,536	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173 93.173	1R13DC020098-01 1R25DC020728-01			\$35,216 \$13.746	\$7,291,253 RESEARCH AND DEVELOPMENT \$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	1R56DC019113-01A1			\$38,855 \$128,912	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	3R21DC016723-03S1			\$10,988	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173 93.173	3R21DC019280-01A1S1 5F32DC020347-02			\$1,090 \$217,732 \$68,431	\$7,291,253 RESEARCH AND DEVELOPMENT \$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5K08DC019683-03			\$202,051	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC013270-09			\$184,935 \$483,442	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173 93.173	5R01DC015388-06 5R01DC015988-05			\$134,671 \$98.983 \$347.054	\$7,291,253 RESEARCH AND DEVELOPMENT \$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC016977-05			\$43,476 \$537,367	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC017175-05			\$68,663 \$739,203	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173 93.173	5R01DC017683-05 5R01DC017926-03			\$53,088 \$486,815 \$257,470 \$945,395	\$7,291,253 RESEARCH AND DEVELOPMENT \$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC019088-04			\$45,651 \$259,636	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R01DC019648-02			\$55,550 \$248,081	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173 93.173	5R01DC020186-02 5R01DC020311-02			\$307,918 \$272.508	\$7,291,253 RESEARCH AND DEVELOPMENT \$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	5R21DC020017-03			\$108,015	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173 93.173	5T35DC008763-16 5U01DC016033-04			\$26,482 \$33,495 \$499,806	\$7,291,253 RESEARCH AND DEVELOPMENT \$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	7R21DC018656-04			\$499,806 \$1,994 \$31,704	\$7,291,253 RESEARCH AND DEVELOPMENT \$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	7R21DC019382-02			\$104,238	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	RDC013270-04	Massachusetts Eve and Ear		(\$65)	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	P50 DC015857	Infirmary Research Foundation for Mental	P50 DC015857	\$1,249	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	R01 DC015780	Hygiene, Inc.	R01 DC015780	\$6,471 \$42,906	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173 93.173	R01 DC018171 R44 DC016780	Vanderbilt University Mimosa Acoustics, Inc	R01 DC018171	\$25,617 \$171,269	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	R44 DC016780 R44 DC018491	Intelligent Hearing Systems Corporation	R44 DC016780 R44 DC018491	\$171,269	\$7,291,253 RESEARCH AND DEVELOPMENT \$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	U01 DC014706	University of Utah	U01 DC014706	(\$11,428)	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	U01 DC018920	Ohio State University	U01 DC018920	\$3,758	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173 93.173	U01 DC018920 VUMC111082(U24DC020857)	Ohio State University Stanford University	U01 DC018920 VUMC111082(U24DC020857)	\$70,138 \$22.756	\$7,291,253 RESEARCH AND DEVELOPMENT \$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	VUMC111300(R01DC019787)	Vanderbilt University	VUMC111300(R01DC019787)	\$4.998	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	VUMC66370(R01DC015997)	University of Iowa	VUMC66370(R01DC015997)	\$91,789	\$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
DECEMBED TO DESCRIPTION AND CONSTRUCTION DICORDED	00	\(\(\) \(\	Boys Town National Research Hospital	M IMOZOGE (DOADOO ()		67 004 000 DECEMBOULAND DEVELOR	6540.000
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173 93.173	VUMC72055(R01DC016643) VUMC75320(R01DC016680)	Hospital Creighton University	VUMC72055(R01DC016643) VUMC75320(R01DC016680)	\$39,597 \$174,208	\$7,291,253 RESEARCH AND DEVELOPMENT \$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	VUMC86859(R01DC014037)	Vanderbilt University	VUMC86859(R01DC014037)	\$123,763	\$7,291,253 RESEARCH AND DEVELOPMENT \$7,291,253 RESEARCH AND DEVELOPMENT	\$543,888,056
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND			-				
EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND	93.185	1U01IP001156-01-00			\$1,246,777	\$2,109,316 RESEARCH AND DEVELOPMENT	\$543,888,056
EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	1U01IP001156-01-00			\$307,364	\$2,109,316 RESEARCH AND DEVELOPMENT	\$543,888,056

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND									
EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND	93.185	6U01IP001156-02-01	labora Handina Habaratha Oabarda			\$208,098	\$2,109,316 RESEARCH A	ND DEVELOPMENT	\$543,888,056
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93.185	U01 IP001116	Johns Hopkins University School o Medicine	U01 IP001116		\$39,555	\$2,109,316 RESEARCH A	ND DEVELOPMENT	\$543,888,056
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS	93 185	U01 IP001116	Johns Hopkins University School o Medicine	of U01 IP001116		\$189,471	\$2,109,316 RESEARCH A		\$543,888,056
IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND	93.185		Johns Hopkins University School of			\$189,471	\$2,109,316 RESEARCH A	IND DEVELOPMENT	\$543,888,056
EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.185	VUMC90573(U01IP001116) 5K23AT011569-03	Medicine	VUMC90573(U01IP001116)		\$118,051 \$127,144	\$2,109,316 RESEARCH A \$998,933 RESEARCH A		\$543,888,056 \$543.888.056
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213 93.213	5R01AT011456-03				\$288,913	\$998,933 RESEARCH A	ND DEVELOPMENT	\$543,888,056
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213 93.213	R01 AT009680 R01 AT010462	Rush University Medical Center Massachusetts General Hospital	R01 AT009680 R01 AT010462		\$426,638 \$59,731	\$998,933 RESEARCH A \$998.933 RESEARCH A		\$543,888,056 \$543.888.056
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	RAT009685-03	NORTHWESTERN UNIVERSITY			(\$12)	\$998,933 RESEARCH A		\$543,888,056
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	U01 AT010598	Case Western Reserve University	U01 AT010598		\$65,479	\$998,933 RESEARCH A	ND DEVELOPMENT	\$543,888,056
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	UG3 AT012257	Oregon Health & Science Universit	ty UG3 AT012257		\$31,040	\$998,933 RESEARCH A	ND DEVELOPMENT	\$543,888,056
NATIONAL RESEARCH SERVICE AWARDS_HEALTH SERVICES RESEARCH TRAINING RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.225 93.226	5T32HS026122-05 1K01HS029042-01			\$57,530	\$475,613 \$87,187	\$475,613 RESEARCH A \$2,747,906 RESEARCH A		\$543,888,056 \$543,888,056
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	1R01HS029331-01				\$49,231	\$2,747,906 RESEARCH A	ND DEVELOPMENT	\$543,888,056
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226 93.226	5K12HS026395-05 5R01HS025976-04			\$40,577 \$53,140	\$450,967 \$163,885	\$2,747,906 RESEARCH A \$2,747,906 RESEARCH A	ND DEVELOPMENT ND DEVELOPMENT	\$543,888,056 \$543,888,056
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	5R01HS028430-02 5R18HS025910-05			\$93,783 \$10,381	\$331,587 \$446,450	\$2,747,906 RESEARCH A \$2,747,906 RESEARCH A	ND DEVELOPMENT	\$543,888,056 \$543,888,056
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226 93.226	5R18HS025910-05 5R18HS025931-05			\$10,381 \$105,640	\$446,450 \$229,237	\$2,747,906 RESEARCH A \$2,747,906 RESEARCH A		\$543,888,056 \$543,888,056
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226 93.226	5R18HS026158-05 5R18HS026616-04			\$113,132 \$51.460	\$317,012 \$297,711	\$2,747,906 RESEARCH A \$2,747,906 RESEARCH A		\$543,888,056 \$543.888,056
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	R01 HS026742	Washington University	R01 HS026742	\$31,400	\$4,126	\$2,747,906 RESEARCH A		\$543,888,056
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	R01 HS029153	Denver Health and Hospital Authority	R01 HS029153		\$14.545	\$2.747.906 RESEARCH A	ND DEVELOPMENT	\$543.888.056
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	R01 HS029159	University of Michigan	R01 HS029159		\$15,478	\$2,747,906 RESEARCH A	ND DEVELOPMENT	\$543,888,056
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	R18 HS028578	University of Colorado	R18 HS028578		\$46,678	\$2,747,906 RESEARCH A	ND DEVELOPMENT	\$543,888,056
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	VUMC104366(R18HS028579)	Oregon Health & Science Universit			\$84,456	\$2,747,906 RESEARCH A		\$543,888,056
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226 93.226	VUMC108018(R01HS029011) VUMC108918(R01HS028007)	University of Maryland Brigham and Women's Hospital	VUMC108018(R01HS029011) VUMC108918(R01HS028007)		\$56,349 \$45,477	\$2,747,906 RESEARCH A \$2,747,906 RESEARCH A		\$543,888,056 \$543,888,056
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	VUMC112760(R21HS028880)	Parkview Hospital, Inc.	VUMC112760(R21HS028880)		\$10,519	\$2,747,906 RESEARCH A	ND DEVELOPMENT	\$543,888,056
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226 93.226	VUMC86935 VUMC86935(R01HS027417)	University of Colorado Denver University of Colorado Denver	VUMC86935 VUMC86935(R01HS027417)		\$60,395 \$36,616	\$2,747,906 RESEARCH A \$2,747,906 RESEARCH A		\$543,888,056 \$543,888,056
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	5R01HL161635-02	University of Colorado Deriver	VOMC00333(NOT113027417)	\$64,553	\$803,703	\$803,703 RESEARCH A	ND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	1K23MH131852-01 1R01MH132022-01			\$3,432	\$69,755 \$65.084	\$14,840,006 RESEARCH A \$14,840,006 RESEARCH A		\$543,888,056 \$543.888.056
MENTAL HEALTH RESEARCH GRANTS	93.242	1R21MH126272-01				\$169,011	\$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	1R21MH128790-01 1R21MH132040-01			\$7,525	\$197,197 \$35,439	\$14,840,006 RESEARCH A \$14,840,006 RESEARCH A	ND DEVELOPMENT ND DEVELOPMENT	\$543,888,056 \$543.888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242	1R34MH127975-01A1 1RF1MH123201-01A1 (Yr 3)			\$12,463 \$380.881	\$72,030 \$539.561	\$14,840,006 RESEARCH A \$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056 \$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	4R33MH122464-03			******	\$394,991	\$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	4R33MH123029-03 5K18MH122755-02			\$134,539 \$33.840	\$375,179 \$58,623	\$14,840,006 RESEARCH A \$14,840,006 RESEARCH A		\$543,888,056 \$543.888.056
MENTAL HEALTH RESEARCH GRANTS	93.242	5K23MH116339-06			\$4,969	\$110,515	\$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	5K23MH122737-03 5K23MH126313-03				\$162,902 \$213,350	\$14,840,006 RESEARCH A \$14.840,006 RESEARCH A		\$543,888,056 \$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	5K24MH126280-02				\$115,024	\$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	5R01MH070560-14 5R01MH102272-10			\$68,373	\$820,630 \$459,377	\$14,840,006 RESEARCH A \$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056 \$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	5R01MH111599-05 5R01MH111877-04				\$70,582 (\$1,058)	\$14,840,006 RESEARCH A \$14,840,006 RESEARCH A		\$543,888,056 \$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	5R01MH113362-05			\$30,397	\$109,899	\$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	5R01MH113438-03 5R01MH113478-05			\$27,626 \$160,578	\$80,138 \$529,166	\$14,840,006 RESEARCH A \$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056 \$543.888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	5R01MH114906-04			\$161,744	\$395,268	\$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	5R01MH115000-04 5R01MH116058-05			\$16,815 \$295,159	\$166,361 \$612,776	\$14,840,006 RESEARCH A \$14,840,006 RESEARCH A		\$543,888,056 \$543.888.056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	5R01MH116269-04 5R01MH118273-05			\$257.032	\$310,588 \$767,991	\$14,840,006 RESEARCH A \$14,840,006 RESEARCH A		\$543,888,056 \$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	5R01MH119817-03				(\$104)	\$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	5R01MH121438-04 5R01MH121455-04			\$400,977	\$681,691 \$464,518	\$14,840,006 RESEARCH A \$14,840,006 RESEARCH A		\$543,888,056 \$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	5R01MH121620-03			\$47,221	\$1,136,264	\$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	5R01MH123563-04 5R01MH123662-04			\$81,193 \$33.537	\$416,522 \$893,316	\$14,840,006 RESEARCH A \$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056 \$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	5R01MH124496-02			\$95,487	\$185,634	\$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	5R01MH127018-03 5R01MH127228-03			\$28,791 \$602,836	\$545,550 \$1,025,129	\$14,840,006 RESEARCH A \$14,840,006 RESEARCH A		\$543,888,056 \$543.888.056
MENTAL HEALTH RESEARCH GRANTS	93.242	5R33MH120149-03				\$404,031	\$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	5R56MH120736-02 5R56MH128747-02			\$18,267 \$146,545	\$23,705 \$433,219	\$14,840,006 RESEARCH A \$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056 \$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	5R61MH122464-02 RMH111776-01:04			\$11,712	\$255,622 (\$829)	\$14,840,006 RESEARCH A \$14,840,006 RESEARCH A		\$543,888,056 \$543.888.056
MENTAL HEALTH RESEARCH GRANTS	93.242	R01 HM118233	Massachusetts General Hospital	R01 HM118233		\$298,842	\$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	R01 MH120122 R01 MH120588	University of Colorado Denver Indiana University	R01 MH120122 R01 MH120588		\$117,999 \$118,947	\$14,840,006 RESEARCH A \$14,840,006 RESEARCH A		\$543,888,056 \$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	R01 MH123262	City University of Newyork (CUNY)) R01 MH123262		\$73,690	\$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	R01 MH124671	Vanderbilt University Cleveland Clinic Lerner College of	R01 MH124671		\$39,320	\$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	R21 MH121165	Medicine	R21 MH121165		\$3,304	\$14,840,006 RESEARCH A		\$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	R34 MH123584	University of Illinois Adaptive Technology Consulting,	R34 MH123584		\$13,145	\$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS			LLC	R44 MH115528		\$8,602	\$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	RF1 MH123971	Vanderbilt University	RF1 MH123971		\$6,753	\$14,840,006 RESEARCH A	ND DEVELOPMENT	\$543,888,056

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MENTAL HEALTH RESEARCH GRANTS	93.242	T32 MH065215	Vanderbilt University	T32 MH065215		\$49,238	\$14,840,006 RESE	ARCH AND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	U01 MH112913	University of Wisconsin	U01 MH112913		\$33,593		ARCH AND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	UG3 MH120102	California Institute of Technology Vanderbilt University	UG3 MH120102		\$162,733		ARCH AND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS		VUMC100105(RF1MH125933) VUMC100392(R01MH127317)	University of Texas, Southwestern	VUMC100105(RF1MH125933)		\$36,799 \$25,458		ARCH AND DEVELOPMENT	\$543,888,056
	93.242	,	Med Center University of Texas, Southwestern	VUMC100392(R01MH127317)		,		ARCH AND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	VUMC100934(R01MH115932)	Med Center SUNY Upstate Medical University	VUMC100934(R01MH115932)		\$16,656		ARCH AND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	VUMC102507(R01MH126459)	Hospital, Downtown Campus	VUMC102507(R01MH126459)		\$108,577	. ,,	ARCH AND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	VUMC106896(R01MH130581) VUMC107559(R01MH112847)	University of California Los Angeles University of Pennsylvania	VUMC106896(R01MH130581) VUMC107559(R01MH112847)		\$19,809 \$8.390		ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	VUMC112622	Vanderbilt University	VUMC112622		\$5,192		ARCH AND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	VUMC113077(T32MH065215)	Vanderbilt University	VUMC113077(T32MH065215)		\$11,681	\$14,840,006 RESE	ARCH AND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	VUMC81905(R01MH121407)	Portland State University	VUMC81905(R01MH121407)		\$52,016		ARCH AND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS	93.242	VUMC83132(R56MH120826)	University of New Mexico	VUMC83132(R56MH120826)		\$83		ARCH AND DEVELOPMENT	\$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242 93.242	VUMC92769(R01MH123155) VUMC93056(R01MH123687)	Yale University Vanderbilt University	VUMC92769(R01MH123155) VUMC93056(R01MH123687)		\$44,056 \$132,942		ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MENTAL HEALTH RESEARCH GRANTS MENTAL HEALTH RESEARCH GRANTS	93.242	VUMC94579(R01MH124851)	Massachusetts General Hospital	VUMC93056(R01MH123687) VUMC94579(R01MH124851)		\$132,942 \$87.534		ARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES PROJECTS OF REGIONAL	00.E-4E	701100-107 0(101111112-1001)	American Academy of Addiction	VOINGS-1075(11011111112-1001)		407,004	\$14,040,000 TREOE	atorrato devecor merti	ψο-ιο,οσο,οσο
AND NATIONAL SIGNIFICANCE	93.243	H79 TI081358	Psychiatry	H79 TI081358		\$85		ARCH AND DEVELOPMENT	\$543,888,056
ADVANCED NURSING EDUCATION GRANT PROGRAM	93.247	T14 HP33119	Vanderbilt University	T14 HP33119		\$225,418		ARCH AND DEVELOPMENT	\$543,888,056
EARLY HEARING DETECTION AND INTERVENTION COVID-19 POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.251 93.253	VUMC79629 (34347-75420)(Edison ID 65942) 6H4BHS30752-07-01	State of Tennessee	VUMC79629 (34347-75420)(Edison ID 6	5942)	\$82,685 \$466,447	\$82,685 RESE \$466,447 N/A	ARCH AND DEVELOPMENT	\$543,888,056
COVID-19 POISON CENTER SUPPORT AND ENHANCEMENT GRANT	93.253	6H4BHS30752-07-01	COM Affiliation, Inc. (Albert Einstein	n		\$466,447	\$466,447 N/A		\$0
OCCUPATIONAL SAFETY AND HEALTH PROGRAM	93.262	U01 OH012271	College of Medicine managed by Montefiore)	U01 OH012271		\$190	\$100 PESE	ARCH AND DEVELOPMENT	\$543.888.056
IMMINIZATION COOPERATIVE AGREEMENTS	93.268	VUMC107135(NH23IP922617)	Cumberland Pediactric Foundation			\$71.554		ARCH AND DEVELOPMENT	\$543,888,056
ALCOHOL RESEARCH PROGRAMS	93.273	1R03AA030100-01				\$50,136	\$1,754,734 RESE	ARCH AND DEVELOPMENT	\$543,888,056
ALCOHOL RESEARCH PROGRAMS	93.273	3P01AA029542-02S1			\$606,514	\$1,176,743	\$1,754,734 RESE	ARCH AND DEVELOPMENT	\$543,888,056
ALCOHOL RESEARCH PROGRAMS	93.273	5R01AA026186-05			6000 400	\$1		ARCH AND DEVELOPMENT	\$543,888,056
ALCOHOL RESEARCH PROGRAMS ALCOHOL RESEARCH PROGRAMS	93.273 93.273	5U01AA026222-05 R01 AA025337	University of Florida	R01 AA025337	\$226,139	\$422,423 \$39.602		ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALCOHOL RESEARCH PROGRAMS	93.273	R01 AA027654	University of Iowa	R01 AA027654		\$40,582		ARCH AND DEVELOPMENT	\$543,888,056
ALCOHOL RESEARCH PROGRAMS	93.273	U01 AA026209	University of Bristol	U01 AA026209		\$19,118	\$1,754,734 RESE	ARCH AND DEVELOPMENT	\$543,888,056
ALCOHOL RESEARCH PROGRAMS	93.273	U01 AA026224	Yale University	U01 AA026224		\$6,129		ARCH AND DEVELOPMENT	\$543,888,056
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279 93.279	1K01DA057391-01A1 1K23DA057387-01				\$4,933 \$47,544	\$3,268,870 RESE	ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	3R01DA045729-04S1			\$40.246	\$111,974		ARCH AND DEVELOPMENT	\$543.888.056
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5K01DA050740-04			Q-10,E-10	\$173,967	\$3,268,870 RESE	ARCH AND DEVELOPMENT	\$543,888,056
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5K01DA051683-03				\$157,114	\$3,268,870 RESE	ARCH AND DEVELOPMENT	\$543,888,056
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279 93.279	5K23DA047476-04 5R01DA040630-08			\$34.349	\$145,281 \$500.126		ARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5R01DA040630-08 5R01DA050334-03			\$34,349 \$137,128	\$500,126 \$558.335		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	5R34DA054483-02			\$79,460	\$168,040	\$3,268,870 RESE	ARCH AND DEVELOPMENT	\$543,888,056
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	R01 DA057204	Meharry Medical College	R01 DA057204		\$65,136		ARCH AND DEVELOPMENT	\$543,888,056
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	U01 DA055347	Vanderbilt University	U01 DA055347		\$496,678		ARCH AND DEVELOPMENT	\$543,888,056
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279 93.279	VUMC108900(P50DA054071) VUMC108919(U24DA055325)	RTI International Vanderbilt University	VUMC108900(P50DA054071) VUMC108919(U24DA055325)		\$29,153 \$22.680		ARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	VUMC84383(UG1DA015831)	Yale University	VUMC84383(UG1DA015831)		\$273,332		ARCH AND DEVELOPMENT	\$543,888,056
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	VUMC84383(UG1DA015831)	Yale University	VUMC84383(UG1DA015831)		\$107,534		ARCH AND DEVELOPMENT	\$543,888,056
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	VUMC84487(UG1DA013732)	University of Cincinnati	VUMC84487(UG1DA013732)	\$12,375	\$407,043		ARCH AND DEVELOPMENT	\$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	2T32EB001628-21				\$540	\$4,007,652 RESE	ARCH AND DEVELOPMENT	\$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286 93.286	5K01EB030039-04 5K01EB032898-02				\$164,236 \$117,026		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5R01EB032696-02 5R01EB018992-07			\$126,636	\$321.589		ARCH AND DEVELOPMENT	\$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5R01EB024525-04				\$30,239	\$4,007,652 RESE	ARCH AND DEVELOPMENT	\$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5R01EB026991-02			\$50,676	\$57,684		ARCH AND DEVELOPMENT	\$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286 93.286	5R01EB029443-02 5R01EB031078-02			\$13,066 \$15,035	\$611,447 \$155,312		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5R01EB031076-02 5R01EB031954-02			\$23,740	\$315,260		ARCH AND DEVELOPMENT	\$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5R01EB033676-02				\$203,710		ARCH AND DEVELOPMENT	\$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5R03EB029078-02				\$33,924	\$4,007,652 RESE	ARCH AND DEVELOPMENT	\$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286 93.286	5R21EB025258-03 5R21EB029639-03			\$53,058	\$99,048 \$174,976		ARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5R21EB029039-03 5R21EB032916-02			\$33,036	\$164.086		ARCH AND DEVELOPMENT	\$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5T32EB001628-19			\$59,147	\$221,878	\$4,007,652 RESE	ARCH AND DEVELOPMENT	\$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	5U18EB029351-03			\$148,730	\$807,197		ARCH AND DEVELOPMENT	\$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	R01 EB026901	Vanderbilt University Vanderbilt University	R01 EB026901		\$48,661		ARCH AND DEVELOPMENT	\$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286 93.286	R01 EB027498 R01 EB028690	Vanderbilt University Vanderbilt University	R01 EB027498 R01 EB028690		\$23,975 \$16,158		ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	R01 EB030414	Vanderbilt University	R01 EB020090		\$15,387		ARCH AND DEVELOPMENT	\$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	R01 RB033385	Vanderbilt University	R01 RB033385		\$234,071	\$4,007,652 RESE	ARCH AND DEVELOPMENT	\$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	VUMC106040(R01EB032382)	Vanderbilt University	VUMC106040(R01EB032382)		\$56,139		ARCH AND DEVELOPMENT	\$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	VUMC109503(R01EB033822)	Vanderbilt University	VUMC109503(R01EB033822)		\$9,747		ARCH AND DEVELOPMENT	\$543,888,056
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286 93.286	VUMC80654(R01EB028615) VUMC97445(R01EB017230)	Vanderbilt University Vanderbilt University	VUMC80654(R01EB028615) VUMC97445(R01EB017230)		\$23,138		ARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
NATIONAL PUBLIC HEALTH IMPROVEMENT INITIATIVE	93.286	K01 MH125073	Vanderbilt University	K01 MH125073		\$102,224 \$5.632		ARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
······································	55.252		COM Affiliation, Inc. (Albert Einsteil	n		ψ0,002	\$100,721 NEOLI		40-10,000,000
			College of Medicine managed by						
NATIONAL PUBLIC HEALTH IMPROVEMENT INITIATIVE MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.292 93.307	VUMC96527(U01OHO12271) 3U54MD010722-05S1	Montefiore)	VUMC96527(U01OHO12271)	\$113.592	\$133,089 \$286,843		ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	3U54MD010722-05S1 5P50MD017347-03			\$113,592 \$1.824.582	\$286,843 \$2,256,663		ARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
	55.557				ψ1,02-1,002	11,200,000	\$0,00E,E11 NEOE1	DETECT MENT	40-10,000,000

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Part		Federal Assistance Listing	Additional Award	Name of Funder Pass-Through		Total Amount Provided to	Federal	Federal Program	Cluster	Cluster
Marche M	Federal Awarding Agency/Program Title	Number	Identification	Entity	Entity S	ub-Recipients		Total	Name	Total
Month Mont	MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	5R01MD015396-03	NYU Langone Hospital - Long			\$839,927	\$3,602,271 RESEA	RCH AND DEVELOPMENT	\$543,888,056
Montre M				Island						
Modern M										
March Marc				Med Center		\$6,726		,,		
MANY PACE MANY	MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93 307	VUMC108664/R01MD016838)		VLIMC108664/R01MD016838)		\$56.229	\$3.602.271 RESEA	RCH AND DEVELOPMENT	\$543,888,056
March Marc	MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	VUMC110094(U54MD007586)	Meharry Medical College	VUMC110094(U54MD007586)		\$20,914	\$3,602,271 RESEA	RCH AND DEVELOPMENT	\$543,888,056
March Marc				Duke Clinical Research Institute	VUMC70882(R01MD013493)					
Transfer and segment S	TRANS-NIH RESEARCH SUPPORT	93.310	1DP5OD033412-01				\$348,892	\$23,891,004 RESEA	RCH AND DEVELOPMENT	\$543,888,056
March Marc			1U54CA280915-01 3U01HG007674-09S4			\$33,408		\$23,891,004 RESEA \$23,891,004 RESEA	RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MACHINESSAME SERVICE	TRANS-NIH RESEARCH SUPPORT	93.310	3U2COD023196-05S1				\$14,412,758	\$23,891,004 RESEA	RCH AND DEVELOPMENT	\$543,888,056
March All Miller March All M						\$365 596				
March Marc	TOANO ANU DECEADOU OUDDODT	22.242	OTO ODOSOTO	National Alliance against Disparities	OTO ODOODEOL		6044.575	\$00.004.004 BEOFA	DOLLAND DEVELOPMENT	6540 000 050
Trigger 1999										
TAMAS AND RESERVED REPORT STATE										
Date Content Date Content Date Content Con										
TRANSPORT SEPTION SEPTION SEPTION SERVICE SCHOOL	TRANS-NIH RESEARCH SUPPORT	93.310	U2C OD023375	Duke Clinical Research Institute	U2C OD023375		\$56,437	\$23,891,004 RESEA	RCH AND DEVELOPMENT	\$543,888,056
Professor Prof										
Machine Mach				University of Washington				\$23,891,004 RESEA	RCH AND DEVELOPMENT	
TAMES AND RESERVED SAPPORT 1971										
MacComman MacC	TRANS NILL DESEADOLI SUDDODT	02 240	\(\(\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\) // IMC10E427// IE4HC012E40\			\$22 801 004 BESEA	DOLLAND DEVELOPMENT	
TAMAS AND RESERVOYS SUPPORT S. 1.0 VALIDO TENER (TENER CONCOUNTS) VALIDO TENER (TENER CONCOUNTS) S. 1.0 S. 1	TRANS-NIH RESEARCH SUPPORT	93.310	VUMC107540(OT2OD032581)	University of North Texas HSC	VUMC107540(OT2OD032581)		\$589,249	\$23,891,004 RESEA	RCH AND DEVELOPMENT	\$543,888,056
March Marc										
Part										
Manual M	TRANS-NIH RESEARCH SUPPORT	93.310	VUMC60166(UG3OD023282)	University of Wisconsin COM Affiliation, Inc. (Albert Einstein		\$16,839	\$469,103	\$23,891,004 RESEA	RCH AND DEVELOPMENT	\$543,888,056
### PART NAME OF TRANSPORT OF T				Montefiore) COM Affiliation, Inc. (Albert Einstein	n					
### 543.88.00 ##										
ARE DISCORDERS, RESEARCH, SURVELLANCE, HEALTH PROMOTION, AND EDUCATION 5.13 5.10	TRANS-NIH RESEARCH SUPPORT		VUMC96155(OT2OD032581)					\$23,891,004 RESEA	RCH AND DEVELOPMENT	
ABLE PROTECTION AND INTERVENTION SCURPTY STATE AND INTERVENTIO										
PROTECTING AND IMPROVING HEALTH GLOBALLY: BUILDING AND STRENGTHENING PUBLIC HEALTH IMPACT 93.18 6NL3HCK000006-01-01 93.24 \$229.09 \$303.55 RESEARCH AND DEVELOPMENT \$543.88,056 \$75.07 \$20.25			DD01075-03	Tennessee Department of Health			\$80,815			
SYSTEMS, CAPACITY AND SECURITY STOCK STO		93.317	VUMC07131(34349-1218)(Edison ID 59293)	Services	VUMC07131(34349-1218)(Edison ID 59293)	\$3,830,947	\$3,830,947 RESEA	RCH AND DEVELOPMENT	\$543,888,056
SYSTEMS, CAPACITY AND SECURITY PROTECTION AND IMPROVING HEALTH GLOBALLY: BUILDING AND STRENGTHENING PUBLIC HEALTH ARROLD STRENGTH ARROLD STRENGTHENING PUBLIC HEALTH ARROLD STRENGTH	SYSTEMS, CAPACITY AND SECURITY	93.318	6NU3HCK000006-01-01				\$75,071	\$303,555 RESEA	RCH AND DEVELOPMENT	\$543,888,056
##ACT, SYSTEMS, CAPACITY AND SECURITY 93.18 84.005(0000586 50.05) 50.05(000586 50.05(00586	SYSTEMS, CAPACITY AND SECURITY	93.318	6NU3HCK000006-02-01	A		\$624	\$229,090	\$303,555 RESEA	RCH AND DEVELOPMENT	\$543,888,056
ANTONIAL CENTER FOR ADVANCING TRANSLATIONIAL SCIENCES 93.30 1U24TR004437-01 543.88 0.05 520.91.38 350.093.28 RESEARCH AND DEVELOPMENT 543.88 0.05 540.00000000000000000000000000000000000		93.318	6NU50CK000586		6NU50CK000586		(\$606)	\$303,555 RESEA	RCH AND DEVELOPMENT	\$543,888,056
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 9.3.50 21 LTRO02244-06 9.3.50 51 LTRO02245-05 9.3.50 9.	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350					\$209,913	\$25,039,284 RESEA	RCH AND DEVELOPMENT	\$543,888,056
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 9.3 56.42 78.002245-07 54.388,056 54.388,056 54.388,056 54.388,056 54.388,056 54.388,056 54.388,056 54.388,056 54.388,056 54.388,056 54.388,056 54.388,056 54.372 54.388,056 54.372 54.388,056 54.372 54.388,056 54.372 54.388,056 54.372 54.388,056 54.372 54.388,056 54.372 54.372 54.388,056 54.388,056	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	1U24TR004437-01				\$84,134	\$25,039,284 RESEA	RCH AND DEVELOPMENT	\$543,888,056
ANTIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.506 562.1TR002245-07 554.388.056 562.2TR002245-07 562.2T		93.350	2TL1TR002244-06			61 614				\$543,888,056
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.500 11/478027167907 544.381.081.081.081.081.081.081.081.081.081.0	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5KL2TR002245-07				\$1,138,981	\$25,039,284 RESEA	RCH AND DEVELOPMENT	\$543,888,056
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.500 5147.211 5543.888.056 5147.211 5543.888.056 5147.211 5543.888.056 5147.211 5543.888.056 5147.211 5543.888.056 5147.211 5543.888.056 5147.211 5443.888.056 5147	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES					£42 E72		\$25,039,284 RESEA	RCH AND DEVELOPMENT	
MATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.500 U24 TR001608 93.550 U24 TR001608 U24	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	5U24TR001579-07			\$147,211	\$6,381,962	\$25,039,284 RESEA	RCH AND DEVELOPMENT	\$543,888,056
MATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.500 U24 TR001608 \$1,68.3.93 \$25,039.284 RESEARCH AND DEVELOPMENT \$543,880.056 MATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.500 U24 TR001608 \$1,68.2.93 \$25,039.284 RESEARCH AND DEVELOPMENT \$543,880.056 MATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.500 U24 TR001608 \$1,60.2.73 \$25,039.284 RESEARCH AND DEVELOPMENT \$543,880.056 MATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.500 U24 TR001608 \$1,60.2.73 \$25,039.284 RESEARCH AND DEVELOPMENT \$543,880.056 MATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.500 U44 TR001608 \$1,60.2.73 \$25,039.284 RESEARCH AND DEVELOPMENT \$543,880.056 MATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.500 UMC108091 UNC108091 UNC108				Manufact States and to	Hot Theorem	\$609,492				
MATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.500 U24 TR001608 Duke University U24 TR001608 \$2.562,739,224 RESEARCH AND DEVELOPMENT \$543,888,056 MATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.500 U24 TR001608 Duke University U24 TR001608 \$2.562,739,224 RESEARCH AND DEVELOPMENT \$543,888,056 MATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.500 U24 TR001608 U24										
MATOMAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES \$3.50 \$24 \$1.000 \$25.038.284 \$8.586.056 \$54.164 \$54.388.056 \$3.500 \$25.038.284 \$8.586.056 \$3.580	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES		U24 TR001608		U24 TR001608		\$146,823	\$25,039,284 RESEA	RCH AND DEVELOPMENT	\$543,888,056
MATONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 9.3.50 UH3 TR0.0297 Vanderbilt University WB3 1600.02976 MATONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 9.3.50 MATONAL MICROSIAN T										
MATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 VUMC10881(U01TR002764) Washington University VUMC10881(U01TR002764) \$70.214 \$25,098.284 RESEARCH AND DEVELOPMENT \$543,888,056 MATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 VUMC111272(F01TR003844) The Hastings Center VUMC11272(F01TR003844) \$55,581 \$55,098.284 RESEARCH AND DEVELOPMENT \$543,888,056 MATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 VUMC40400 Rockefeller University VUMC84000 \$134,976 \$25,098.284 RESEARCH AND DEVELOPMENT \$543,888,056 RESEARCH HINDREASTRUCTURE PROGRAMS \$3.351 15100D025095-0141 \$543,888,056 RESEARCH HINDREASTRUCTURE PROGRAMS \$50,007.30 \$2,687,766 RESEARCH AND DEVELOPMENT \$543,888,056 RESEARCH HINDREASTRUCTURE PROGRAMS \$50,007.30 \$2,887,766 RESEARCH AND DEVELOPMENT \$543,888,056 RESEARCH HINDREASTRUCTURE PROGRAMS \$50,007.30 \$2,887,766 RESEARCH AND DEVELOPMENT \$543,888,056 RESEARCH HINDREASTRUCTURE PROGRAMS \$50,007.30 \$2,887,766 RESEARCH AND DEVELOPMENT \$543,888,056 RESEARCH HINDREASTRUCTURE PROGRAMS \$50,007.30 \$2,887,766 RESEARCH AND DEVELOPMENT \$543,888,056 RESEARCH HINDREASTRUCTURE PROGRAMS \$2,007.00 \$2,887,766 RESEARCH AND DEVELOPMENT \$543,888,056 RESEARCH HINDREASTRUCTURE PROGRAMS \$2,007.00 \$2,887,766 RESEARCH AND DEVELOPMENT \$543,888,056 RESEARCH HINDREASTRUCTURE PROGRAMS \$2,007.00 \$2,887,766 RESEARCH AND DEVELOPMENT \$543,888,056 RESEARCH AND DE	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	UH3 TR002097	Vanderbilt University	UH3 TR002097		\$54,164	\$25,039,284 RESEA	RCH AND DEVELOPMENT	\$543,888,056
### APTOWAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES \$3.350 VUNC84000 Rockefeller University VUNC84000 \$3.34976 \$25,039.284 RESEARCH AND DEVELOPMENT \$543,888,056 RESEARCH INFRAST RUCTURE PROGRAMS \$3.351 \$15100D025085-01A1 \$5100D025085-01A1 \$540,0000 \$2.887,766 RESEARCH AND DEVELOPMENT \$543,888,056 RESEARCH INFRAST RUCTURE PROGRAMS \$3.351 \$15100D023092-01A1 \$540,0000 \$2.887,766 RESEARCH AND DEVELOPMENT \$543,880,056 RESEARCH INFRAST RUCTURE PROGRAMS \$3.351 \$15100D033089-01 \$540,0000 \$2.887,766 RESEARCH AND DEVELOPMENT \$543,880,056 RESEARCH INFRAST RUCTURE PROGRAMS \$3.351 \$15100D033089-01 \$540,0000 \$2.887,766 RESEARCH AND DEVELOPMENT \$543,880,056 RESEARCH AND DEVELOPMEN	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350					\$70,214	\$25,039,284 RESEA	RCH AND DEVELOPMENT	\$543,888,056
RESEARCH INFRASTRUCTURE PROGRAMS 93.561 151000025085-01A1 5543,88,0656 RESEARCH AND DEVELOPMENT S543,88,0656	NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES							\$25,039,284 RESEA	RCH AND DEVELOPMENT	
RESEARCH INFRASTRUCTURE PROGRAMS 93.551 15100003039-01 \$543.288.056 93.551 15100003039-01 \$543.288.056 21ST CENTURY QUEES ACT - BEAU BIDEN CANCER MOONSHOT 93.553 1100003239-01 (7' 5) 93.553 11000032	RESEARCH INFRASTRUCTURE PROGRAMS	93.351	1S10OD025085-01A1				\$45,558	\$2,687,766 RESEA	RCH AND DEVELOPMENT	\$543,888,056
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT 93.53 1ULOCA232829-01 (Y, 4) \$367.918 \$1,04.861 \$5.088.50 RESEARCH AND DEVELOPMENT \$543.88.058 21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT 95.50 1ULCCA232829-01 (Y, 75) \$87.04 PM \$5,088.50 RESEARCH AND DEVELOPMENT \$543.88.058 21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT \$9.353 1ULCCA254323-03S1 \$10.04.254332-03S1 \$10.04.25432-03S1 \$10.04.254332-03S1 \$10.04.254										
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT 93.535 1U2CA233291-01 (Yr. 5) \$875,218 \$3,079,411 \$5,088,590 RESEARCH AND DEVELOPMENT \$543,888,056 1 RESEARCH AND DEVELOPMENT \$543,888,056 RESEARCH AND DEVELOPMENT \$4,088,056 RESEARCH AND DEVELO						600=				
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT 93.563 3UUICA254832-03S1 \$59,949 \$974.318 \$5,088.500 RESEARCH AND DEVELOPMENT \$543,888,056 RUNGSING RUN	21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	1U2CCA233291-01 (Yr 5)			\$875,218	\$3,079,411	\$5,088,590 RESEA	RCH AND DEVELOPMENT	\$543,888,056
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT		3U01CA254832-03S1			\$197,949	\$974,318	\$5,088,590 RESEA	RCH AND DEVELOPMENT	\$543,888,056
						\$12,329				

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

	Federal Assistance	Additional	Name of Funder	Identifying Number Assigned By Funder	Total Amount		Federal		
Forder I American American Title	Listing	Award Identification	Pass-Through	Pass-Through	Provided to	Federal	Program	Cluster	Cluster
Federal Awarding Agency/Program Title	Number	Identification	Entity	Entity	Sub-Recipients	Expenditures	Total	Name	Total
			University of California-San						
NURSING RESEARCH 21st Century Cures Act - Precision Medicine Initiative	93.361 93.368	R01 NR017622 3OT2OD035404-01S1	Francisco	R01 NR017622	\$4 538 263	\$3,506 \$26,298,744	\$526,959 RE	SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
21st Century Cures act - Precision Medicine Initiative CANCER CALISE AND PREVENTION RESEARCH	93.368	1R01CA269589-01A1			\$4,538,263	\$44,030		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1R01CA276352-01A1				\$94.876		SEARCH AND DEVELOPMENT	\$543,888.056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	1R37CA273318-01A1				\$8,287		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	3R37CA227130-05S1			\$107,652	\$915,149		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5K00CA253718-04				\$91,632		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH CANCER CAUSE AND PREVENTION RESEARCH	93.393 93.393	5P01CA028842-34 5P01CA116087-16			\$52,232	\$52,034 \$1,249.891		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA077955-25			\$168,257	\$290.879		SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA198482-06				\$1.645		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA202981-05			\$18,045	\$703,642	\$16,059,217 RE	SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA203012-05				\$13,044		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA204819-05			\$57,228	\$246,185		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH CANCER CAUSE AND PREVENTION RESEARCH	93.393 93.393	5R01CA207466-04 5R01CA225005-06			\$259,923	\$97,897 \$576.966	\$16,059,217 RE \$16,050,217 RE	SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA230352-05			\$298,628	\$621.178		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA232516-05			\$17,449	\$624,838	\$16,059,217 RE	SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA235553-05				\$382,167		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA237895-04				\$755,871		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH CANCER CAUSE AND PREVENTION RESEARCH	93.393 93.393	5R01CA240093-05 5R01CA247987-03			\$151,871 \$93,800	\$702,057 \$749.041	\$16,059,217 RE	SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA247987-03 5R01CA249863-02			\$50,207	\$749,041		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA251758-03			\$270,690	\$539.017	\$16.059.217 RE	SEARCH AND DEVELOPMENT	\$543.888.056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R01CA275082-02			\$214,417	\$526,503	\$16,059,217 RE	SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R21CA243036-02				\$335		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5R37CA227130-04			\$1,282 \$54,095	\$120,366		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH CANCER CAUSE AND PREVENTION RESEARCH	93.393 93.393	5R37CA237452-04 5U01CA202979-08			\$54,095 \$44,318	\$355,408 \$1,287,586		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5U01CA202979-08 5U01CA262678-02			\$44,310	\$299,305	\$16,059,217 RE \$16,059,217 RE	SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5UG3CA260318-02				\$1,396,913	\$16,059,217 RE	SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	5UG3CA265846-02			\$75,242	\$1,221,432		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	HHSN261201200035I	Northwestern University	HHSN261201200035I		\$400		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH CANCER CAUSE AND PREVENTION RESEARCH	93.393	HHSN261201200035I P01 CA138336	Northwestern University University of Hawaii	HHSN261201200035I P01 CA138336		\$172,800 \$48,490		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH CANCER CAUSE AND PREVENTION RESEARCH	93.393	P01 CA138336 R01 CA132823	Dana Farber Cancer Institute	R01 CA138336 R01 CA132823		\$48,490 \$27.575		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA152823 R01 CA157823	Trustees of Indiana University	R01 CA152623 R01 CA157823		\$92,722		SEARCH AND DEVELOPMENT	\$543.888.056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA164605	Vanderbilt University	R01 CA16/625		\$25.870		SEARCH AND DEVELOPMENT	\$543,888.056
			Baptist Memorial Healthcare				*,,		4-1-,,
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA172253	Corporation	R01 CA172253		\$11,195	\$16,059,217 RE	SEARCH AND DEVELOPMENT	\$543,888,056
			New York University School of						
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA204113	Medicine	R01 CA204113		(\$637)	\$16,059,217 RE	SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH CANCER CAUSE AND PREVENTION RESEARCH	93.393 93.393	R01 CA207401 R01 CA209798	University of Kentucky University of Southern California	R01 CA207401 R01 CA209798		\$18,495 \$6,235		SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	RU1 CA209798	University of Southern California	R01 CA209798		\$6,235	\$16,059,217 RE	SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA226086	Medical University of South Carolin	na R01 CA226086		\$14,407	\$16.059.217 RE	SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93,393	R01 CA228156	Duke University	R01 CA228156		\$216,378		SEARCH AND DEVELOPMENT	\$543.888.056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA240274	Vanderbilt University	R01 CA240274		\$2,132		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA251112	The Hospital for Sick Children	R01 CA251112		\$12,196	\$16,059,217 RE	SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH CANCER CAUSE AND PREVENTION RESEARCH	93.393 93.393	R01 CA255016 R01 CA255318	Oregon Health & Science Universi University of Wisconsin Madison	R01 CA255016 R01 CA255318		\$22,517 \$67,772		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA255318 R01 CA260615	University of Visconsin Madison University of California	R01 CA255318 R01 CA260615		\$8,497		SEARCH AND DEVELOPMENT	\$543,888,056
CANCEL CAUGE AND THE VENTION RESEARCH	83.383	NOT CA200013	University of California-San	101 CA200013		40,437	\$10,035,217 IXL	SEARCH AND DEVELOR MENT	\$343,000,030
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA262540	Francisco	R01 CA262540		\$40,816		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R01 CA267842	Duke University	R01 CA267842		\$25,534		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R37 CA246175	Washington University	R37 CA246175		\$45,357		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	R37 CA262299	Brigham and Women's Hospital	R37 CA262299		\$6,541	\$16,059,217 RE	SEARCH AND DEVELOPMENT	\$543,888,056
			COM Affiliation, Inc. (Albert Einste College of Medicine managed by	нп					
CANCER CAUSE AND PREVENTION RESEARCH	93.393	U01 CA242740	Montefiore)	U01 CA242740		\$51,892	\$16.059.217 RF	SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	U01 CA259208	Brigham and Women's Hospital	U01 CA259208		\$6,541		SEARCH AND DEVELOPMENT	\$543,888,056
			International Agency for Research				,		
CANCER CAUSE AND PREVENTION RESEARCH	93.393	U19 CA203654	Cancer	U19 CA203654		\$8,460		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	U24 CA248010	Boston Childrens Hospital	U24 CA248010		\$17,862	\$16,059,217 RE	SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	UG1 CA189824	Wake Forest University Health Sciences	UG1 CA189824		\$39.830	\$16.050.247 DE	SEARCH AND DEVELOPMENT	\$543.888.056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC103470(U01CA167552)	Harvard School of Public Health	VUMC103470(U01CA167552)		\$17,133		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC103470(U01CA167552)	Brigham and Women's Hospital	VUMC103470(001CA167332)		\$4.764		SEARCH AND DEVELOPMENT	\$543,888,056
O WOLL OF OLD THE	00.000	VOIII 010001 1(00101212402)	Memorial Sloan-Kettering Cancer	10M0100071(00101E7E40E)		\$4,704	ψ10,000,E17 11E	SECULOTIVIA DE VECO INICIA	\$0.10,000,000
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC109694(R37CA264253)	Center	VUMC109694(R37CA264253)		\$9,960		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC110000(R01CA269223)	Washington State University	VUMC110000(R01CA269223)		\$13,751		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC110335(R01CA263770)	Duke University	VUMC110335(R01CA263770)		\$18,016		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC112490(R03CA273625)	University of Florida Vanderbilt University	VUMC112490(R03CA273625)		\$2,332		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC59925(R01CA200709) VUMC67438(R01CA220581)	Case Western Reserve University	VUMC59925(R01CA200709) VUMC67438(R01CA220581)		\$49,155 \$18,668		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC67438(R01CA220581) VUMC68955(U01CA224276)	Vanderbilt University	VUMC67438(R01CA220581) VUMC68955(U01CA224276)		\$18,668 \$62,265		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCEL CAUGE AND THE VENTION RESEARCH	83.383	VOMICO0333(OUTCA224270)	International Agency for Research	VOINCO0333(0010A224210)		902,203	\$10,035,217 IXL	SEARCH AND DEVELOR MENT	\$343,000,030
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC71537(U19CA203654)	Cancer	VUMC71537(U19CA203654)		\$4,217	\$16,059,217 RE	SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC84234(R01CA247833)	Vanderbilt University	VUMC84234(R01CA247833)		\$90,895		SEARCH AND DEVELOPMENT	\$543,888,056
			Memorial Sloan-Kettering Cancer						
CANCER CAUSE AND PREVENTION RESEARCH	93.393	VUMC85652(R00CA230205)	Center	VUMC85652(R00CA230205)		\$4,817		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH CANCER CAUSE AND PREVENTION RESEARCH	93.393 93.393	VUMC91535(5U01CA250476) VUMC99724(R01CA262393)	Brigham and Women's Hospital Mayo Clinic Hospital	VUMC91535(5U01CA250476) VUMC99724(R01CA262393)		\$86,634 \$4,656		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER CAUSE AND PREVENTION RESEARCH CANCER DETECTION AND DIAGNOSIS RESEARCH	93.393	VUMC99724(R01CA262393) 1R01CA264508-01A1	мауд Сшис поэрцаг	VUINC99724(RUTCA262393)		\$4,656 \$1,875		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1R01CA269620-01				\$262,752		SEARCH AND DEVELOPMENT	\$543,888,056

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	ldentifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1R21CA252629-01A1 (Yr 2)			\$16,874	\$210,672	\$7.060.510. P	ESEARCH AND DEVELOPMENT	\$543.888.056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	1R21CA270731-01A1			\$10,074	\$7,650	\$7,060,510 R	ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394 93.394	1R21CA274545-01 2U01CA152662-11			\$48,091	\$153,775 \$425,815		ESEARCH AND DEVELOPMENT ESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	3U01CA152662-11 3U01CA152662-10S1			\$128.652	\$270.379		ESEARCH AND DEVELOPMENT	\$543.888.056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5D43CA270474-02			\$96,770	\$164,472		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394 93.394	5R01CA109106-16 5R01CA194024-05				\$255,859 \$275.937		ESEARCH AND DEVELOPMENT ESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5R01CA214494-06				\$159,408	\$7,060,510 R	ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5R01CA227133-05			\$195,843	\$819,580		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394 93.394	5R01CA250506-04 5R01CA252964-03			\$5,519 \$134,098	\$597,316 \$604.410		ESEARCH AND DEVELOPMENT ESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5R01CA253923-03			\$261,493	\$1,098,882		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394 93.394	5R01CA266233-02 5R21CA274426-02				\$271,699 \$96,000		ESEARCH AND DEVELOPMENT ESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5U01CA231840-03			\$4,145	\$4,145		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	5UM1CA183727-11				\$706,315		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394 93.394	7R01CA238686-03 UCA183727-06				\$21,410 \$21		ESEARCH AND DEVELOPMENT ESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
			New York University School of			*			
CANCER DETECTION AND DIAGNOSIS RESEARCH CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394 93.394	R01 CA159036 R01 CA193478	Medicine Childrens Hospital of Philadelphia	R01 CA159036 R01 CA193478		\$13,529 (\$437)		ESEARCH AND DEVELOPMENT ESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	R01 CA185476	Cedars-Sinai Medical Center	R01 CA218526		\$9.184		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	R01 CA239257	Stanford University	R01 CA239257		\$69,494		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394 93.394	R01 CA245134 R01 CA249992	Vanderbilt University Case Western Reserve University	R01 CA245134 R01 CA249992		\$20,724 \$1.196		ESEARCH AND DEVELOPMENT ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DE LECTION AND DIAGNOSIS RESEARCH	93.394	R01 CA249992	Fred Hutchinson Cancer Research	R01 CA249992		\$1,196	\$7,060,510 R	ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	U24 CA086368	Center	U24 CA086368	(\$20,967)	(\$33,446)		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394 93.394	U24 CA086368 U24 CA265879	Fred Hutchinson Cancer Center Lifespan Rhode Island Hospital	U24 CA086368 U24 CA265879	\$20,967	\$33,446 \$27,783		ESEARCH AND DEVELOPMENT ESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	UH3 CA232820	University of Alabama-Birmingham	UH3 CA232820		\$27,783 \$105.467		ESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	VUMC105623(UH3CA271377)	Cedars-Sinai Medical Center	VUMC105623(UH3CA271377)		\$38,258	\$7,060,510 R	ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	VUMC111245(U2CCA271854)	University of Michigan	VUMC111245(U2CCA271854)		\$42,907		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER DETECTION AND DIAGNOSIS RESEARCH CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394 93.394	VUMC65127(R01CA212147) VUMC68436(R01CA227466)	Vanderbilt University University of California-San Francisco	VUMC65127(R01CA212147) VUMC68436(R01CA227466)		\$35,533 \$68,587		ESEARCH AND DEVELOPMENT ESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
			Icahn School of Medicine at Mount	t '					
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	VUMC88214(U54CA260560)	Sinai	VUMC88214(U54CA260560)		\$219,913		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH CANCER TREATMENT RESEARCH	93.395 93.395	5R01CA213201-05 5R01CA227481-05			\$199,946 \$200,638	\$328,307 \$614,768		ESEARCH AND DEVELOPMENT ESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER TREATMENT RESEARCH	93.395	5R01CA248505-03			\$30,459	\$506,707		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	5R01CA262287-02				\$604,707		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH CANCER TREATMENT RESEARCH	93.395 93.395	5R03CA252807-02 5R21CA226562-02			\$8,567	\$56,140 \$11.999	\$4,824,275 R \$4,824,275 R	ESEARCH AND DEVELOPMENT ESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER TREATMENT RESEARCH	93.395	5U01CA253560-04			\$243,287	\$682,451	\$4,824,275 R	ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	5UG1CA233270-05				\$594,639		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH CANCER TREATMENT RESEARCH	93.395 93.395	U01 CA253166 U01 CA253166				\$38,921 \$56.924		ESEARCH AND DEVELOPMENT ESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:BRE S1418	ECOG-ACRIN - Eastern Cooperative Oncology Group	ECOG/NCTN:BRE S1418		(\$4,315)		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:MD FAY131	ECOG-ACRIN - Eastern Cooperative Oncology Group	ECOG/NCTN:MD EAY131		\$1,478	\$4 924 275 D	ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:MEL S1404	ECOG-ACRIN - Eastern Cooperative Oncology Group	ECOG/NCTN:MEL S1404		\$1,025		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:NRG-GI002	ECOG-ACRIN - Eastern Cooperative Oncology Group	ECOG/NCTN:NRG-GI002		(\$42)	64 004 075 D	ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	ECOG/NCTN:NRG-GI002 ECOG/NCTN:THO E4512 VUMC50421	ECOG-ACRIN - Eastern Cooperative Oncology Group	ECOG/NCTN:THO E4512 VUMC50421		(\$2,041)		ESEARCH AND DEVELOPMENT	\$543,888.056
ALLIAND THE THE THE PERSON HAVE		ECOG/NCTN:THO FA5142	ECOG-ACRIN - Eastern						
CANCER TREATMENT RESEARCH CANCER TREATMENT RESEARCH	93.395 93.395	ECOG/NCTN:THO EA5142 ECOG/NCTN:URO EA8141	Cooperative Oncology Group ECOG-ACRIN - Eastern Cooperative Oncology Group	ECOG/NCTN:THO EA5142 ECOG/NCTN:URO EA8141		\$876 \$146		ESEARCH AND DEVELOPMENT ESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER TREATMENT RESEARCH	93.395	P01 CA129243	Memorial Sloan-Kettering Cancer Center	P01 CA129243		\$6.604		ESEARCH AND DEVELOPMENT	\$543,888,056
			Memorial Sloan-Kettering Cancer			,			
CANCER TREATMENT RESEARCH	93.395	P01 CA129243	Center	P01 CA129243		\$36,496		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH CANCER TREATMENT RESEARCH	93.395 93.395	R00 CA218892 R01 CA214043	University of Hawaii Vanderbilt University	R00 CA218892 R01 CA214043		\$13,460 \$26,472		ESEARCH AND DEVELOPMENT ESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CANCER TREATMENT RESEARCH	93.395	R01 CA214043 R01 CA243326	Vanderbilt University	R01 CA214043 R01 CA243326		\$26,472 \$51,030		ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	R01 CA260958	Vanderbilt University	R01 CA260958		(\$6,330)	\$4,824,275 R	ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	R01 EB033822	Vanderbilt University Fred Hutchinson Cancer Research	R01 EB033822		\$9,767	\$4,824,275 R	ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U01 CA236229	Center Cancer Research	U01 CA236229		(\$1,522)	\$4.824.275 R	ESEARCH AND DEVELOPMENT	\$543.888.056
CANCER TREATMENT RESEARCH	93.395	U01 CA236229	Fred Hutchinson Cancer Center	U01 CA236229		\$2,354	\$4,824,275 R	ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA018082	ECOG-ACRIN - Eastern Cooperative Oncology Group ECOG-ACRIN - Eastern	U10 CA018082		(\$790)	\$4,824,275 R	ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	Cooperative Oncology Group	U10 CA180820		\$26,659	\$4,824,275 R	ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	Cooperative Oncology Group	U10 CA180820		\$9,799	\$4,824,275 R	ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	ECOG-ACRIN - Eastern Cooperative Oncology Group ECOG-ACRIN - Eastern	U10 CA180820		\$32,766	\$4,824,275 R	ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	Cooperative Oncology Group ECOG-ACRIN - Eastern	U10 CA180820		(\$190)	\$4,824,275 R	ESEARCH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	Cooperative Oncology Group	U10 CA180820		(\$2,135)	\$4,824,275 R	ESEARCH AND DEVELOPMENT	\$543,888,056

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Association Association with the	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Fede Sub-Recipients Expend		Federal Program Total	Cluster Name	Cluster Total
Federal Awarding Agency/Program Title	Number	Identification	Entity	Entity	Sub-Recipients Expend	litures	lotal	Name	Iotal
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	ECOG-ACRIN - Eastern Cooperative Oncology Group	U10 CA180820		(\$553)	\$4,824,275 RESEAR	CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	ECOG-ACRIN - Eastern Cooperative Oncology Group	U10 CA180820	\$	\$4,980	\$4,824,275 RESEAR	CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	ECOG-ACRIN - Eastern Cooperative Oncology Group ECOG-ACRIN - Eastern	U10 CA180820		(\$301)	\$4,824,275 RESEAR	CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	Cooperative Oncology Group ECOG-ACRIN - Eastern	U10 CA180820	\$	\$1,292	\$4,824,275 RESEAR	CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180820	Cooperative Oncology Group	U10 CA180820	(\$	\$5,952)	\$4,824,275 RESEAR	CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180868	NRG Oncology Foundation	U10 CA180868		\$12		CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	U10 CA180886	Public Health Institute	U10 CA180886		14,909		CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH CANCER TREATMENT RESEARCH	93.395 93.395	U10 CA180886 U10 CA180886	Public Health Institute Public Health Institute	U10 CA180886 U10 CA180886		10,318 35,442		CH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER TREATMENT RESEARCH	93.395	UCA186689-06	Yale University	UCA186689-06		(\$833)		CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UCA236229-04	FRED HUTCHINSON CANCER RESEARCH CENTER	UCA236229-04		\$1,487		CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828	(\$	\$4,008)	\$4,824,275 RESEAR	CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828	(\$	\$1,199)	\$4,824,275 RESEAR	CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group ECOG-ACRIN - Eastern	UG1 CA189828	(\$	\$1,844)	\$4,824,275 RESEAR	CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	Cooperative Oncology Group ECOG-ACRIN - Eastern	UG1 CA189828		\$163	\$4,824,275 RESEAR	CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	Cooperative Oncology Group ECOG-ACRIN - Eastern	UG1 CA189828	4	\$6,413	\$4,824,275 RESEAR	CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	Cooperative Oncology Group ECOG-ACRIN - Eastern	UG1 CA189828	\$	\$2,682	\$4,824,275 RESEAR	CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	Cooperative Oncology Group ECOG-ACRIN - Eastern	UG1 CA189828	,,	\$4,527)		CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	Cooperative Oncology Group ECOG-ACRIN - Eastern	UG1 CA189828		\$2,140		CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH CANCER TREATMENT RESEARCH	93.395 93.395	UG1 CA189828 UG1 CA189828	Cooperative Oncology Group ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828 UG1 CA189828		\$1,809) \$2.671)		CH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828	,,	\$2,541)		CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	ECOG-ACRIN - Eastern Cooperative Oncology Group	UG1 CA189828		\$3,806)		CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UG1 CA189828	Southwest Oncology Group	UG1 CA189828		(\$303)		CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	UM1 CA186689	Yale University	UM1 CA186689		(\$127)		CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH CANCER TREATMENT RESEARCH	93.395	UM1 CA228823 VUMC	Public Health Institute Yale University	UM1 CA228823 VUMC		13,696 \$5,741)		CH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER TREATMENT RESEARCH	93.395 93.395	VUMC	Yale University Yale University	VUMC		\$5,741) \$5,789)		CH AND DEVELOPMENT	\$543,888,056 \$543.888.056
O BOOK THE TIME IT THE SERVER	55.555	10110	Alliance for Clinical Trials in	romo	(4	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Q4,024,270 REGERAL	STAND DEVELOT METER	\$0.40,000,000
CANCER TREATMENT RESEARCH CANCER TREATMENT RESEARCH	93.395 93.395	VUMC(UG1CA233270) VUMC105266(R01CA258751)	Oncology Foundation University of Kentucky	VUMC(UG1CA233270) VUMC105266(R01CA258751)		33,694 \$3,884		CH AND DEVELOPMENT CH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER TREATMENT RESEARCH	93 395	VUMC107778(U10CA180888)	Oregon Health & Science Universit	tr \/LIMC107778/LI10CA180888\	e-	28 360	\$4.924.275 DESEAD	CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC108489(R01CA260958)	Vanderbilt University	VUMC108489(R01CA260958)		57.622		CH AND DEVELOPMENT	\$543,888.056
CANCER TREATMENT RESEARCH	93.395	VUMC44233(UM1CA186689)	Yale University	VUMC44233(UM1CA186689)		62,928		CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC61739(U10CA180868)	NRG Oncology Foundation	VUMC61739(U10CA180868)		\$4,733		CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395 93.395	VUMC74949(UG1CA233259) VUMC83991(R01CA116021)	Emory University Vanderbilt University	VUMC74949(UG1CA233259) VUMC83991(R01CA116021)		23,158 72 930		CH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC86613(R01CA243511)	University of Washington ECOG-ACRIN - Eastern	VUMC86613(R01CA243511)		35,562		CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC88742(U01CA180820)	Cooperative Oncology Group	VUMC88742(U01CA180820)		12,973		CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC91596(R41CA257262)	MTI BioTech National Marrow Donor Program	VUMC91596(R41CA257262)		80,768	* 1,000 1,000 110001111	CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH CANCER TREATMENT RESEARCH	93.395 93.395	VUMC91789(R01CA249211)(Mster VUMC63105) VUMC94398(U10CA180886)	(BeTheMatch Foundation) Public Health Institute	VUMC91789(R01CA249211)(Mster VUM VUMC94398(U10CA180886)		18,045 62,890		CH AND DEVELOPMENT CH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC94775(U10CA180886)	Public Health Institute	VUMC94775(U10CA180886)		13.366		CH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CANCER TREATMENT RESEARCH	93.395	VUMC95146(R37CA245157)	University of Alabama-Birmingham			25,367		CH AND DEVELOPMENT	\$543,888,056
CANCER TREATMENT RESEARCH	93.395	VUMC95223(R01CA260958)	Vanderbilt University	VUMC95223(R01CA260958)		39,335		CH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH CANCER BIOLOGY RESEARCH	93.396 93.396	1R01CA272687-01 1R01CA272875-01			\$11,731 \$70	06,954 03.188		CH AND DEVELOPMENT CH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CANCER BIOLOGY RESEARCH CANCER BIOLOGY RESEARCH	93.396	1R01CA272875-01 1R01CA278642-01A1				03,188 66.365		CH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CANCER BIOLOGY RESEARCH	93.396	1R01CA281732-01				16,225	\$6,929,316 RESEAR	CH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	2R01CA077955-27				59,556	\$6,929,316 RESEAR	CH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH CANCER BIOLOGY RESEARCH	93.396 93.396	2R01CA217987-06 3U01CA196405-06S1				70,549 40.180		CH AND DEVELOPMENT CH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CANCER BIOLOGY RESEARCH CANCER BIOLOGY RESEARCH	93.396	5R01CA196405-06S1 5R01CA193219-07				40,180 26.341		CH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER BIOLOGY RESEARCH	93.396	5R01CA211695-06			\$31	14,807	\$6,929,316 RESEAR	CH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396 93.396	5R01CA217987-05				83,064 05.512		CH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER BIOLOGY RESEARCH CANCER BIOLOGY RESEARCH	93.396 93.396	5R01CA227833-05S1 5R01CA235016-05				05,512 00.137	\$6,929,316 RESEAR \$6,929,316 RESEAR	CH AND DEVELOPMENT CH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CANCER BIOLOGY RESEARCH	93.396	5R01CA249424-04			\$171,488 \$59	99,422	\$6,929,316 RESEAR	CH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	5R01CA250051-04				79,842	\$6,929,316 RESEAR	CH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH CANCER BIOLOGY RESEARCH	93.396 93.396	5R35CA197570-07 5R37CA244970-04				71,211 82,535		CH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CANCER BIOLOGY RESEARCH	93.396	5R37CA244970-04 5R37CA263614-02				52,535 56.936		CH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CANCER BIOLOGY RESEARCH	93.396	5U24CA163056-11				68,464		CH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH CANCER BIOLOGY RESEARCH	93.396 93.396	RCA177681-03:06 P01 CA229123	Vanderbilt University	P01 CA229123		\$3,493 35,039		CH AND DEVELOPMENT CH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER BIOLOGY RESEARCH CANCER BIOLOGY RESEARCH	93.396 93.396	P01 CA268991	University of Miami	P01 CA268991		35,039 27,313		CH AND DEVELOPMENT	\$543,888,056 \$543,888,056

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity		Total Amount Provided to ub-Recipients	Federal	Federal Program Total	Cluster Name	Cluster Total
			•	•	ub-Recipients	-			
CANCER BIOLOGY RESEARCH CANCER BIOLOGY RESEARCH	93.396 93.396	R01 CA255446 R01 CA256054	Vanderbilt University Vanderbilt University University of Tennessee Health	R01 CA255446 R01 CA256054		\$5,175 \$29,289		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER BIOLOGY RESEARCH	93.396	U01 CA272541	Sciences Center University of Texas Health Sciences	U01 CA272541		\$44,517		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	VUMC59914(U24CA194215)	Center at Houston	VUMC59914(U24CA194215)		\$42,367		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH	93.396	VUMC71859(U01CA233581)	University of Alabama-Birmingham			\$65,142		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER BIOLOGY RESEARCH CANCER CENTERS SUPPORT GRANTS	93.396 93.397	VUMC77299(R01CA226833) 1U54CA274367-01	Vanderbilt University	VUMC77299(R01CA226833)	\$87,974	\$25,693 \$463,368		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER CENTERS SUPPORT GRANTS	93.397	2U54CA163072-12			\$235,640	\$1,751,502		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CENTERS SUPPORT GRANTS	93.397	3P30CA068485-27S1			\$1,161,594	\$7,890,244		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CENTERS SUPPORT GRANTS	93.397	5P50CA098131-21			\$386,182	\$2,439,547		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CENTERS SUPPORT GRANTS CANCER CENTERS SUPPORT GRANTS	93.397 93.397	5P50CA236733-05 U54 CA217450	Vanderbilt University	U54 CA217450	\$663,882	\$2,073,159 \$186,835	\$14,804,655 RES	SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER RESEARCH MANPOWER	93.398	1F32CA268703-01A1	variation of inversity	004 0/12/1/400		\$76,553		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	1F32CA268705-01				\$72,726		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	1K99CA277366-01				\$36,775		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER CANCER RESEARCH MANPOWER	93.398 93.398	5K00CA234920-06 5K07CA225404-05				\$104,334 \$111.017	\$2,585,617 RES	SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER RESEARCH MANPOWER	93.398	5K08CA240901-03				\$225,415		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	5K08CA241351-04				\$201,234		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER CANCER RESEARCH MANPOWER	93.398 93.398	5K12CA090625-21 5K12CA090625-23				\$20,429 \$699,454		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER RESEARCH MANPOWER CANCER RESEARCH MANPOWER	93.398	5K99CA248822-02				\$80,022		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	5R00CA215360-04				\$78,899		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	5T32CA106183-20				\$298,530		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER CANCER RESEARCH MANPOWER	93.398 93.398	5T32CA160056-11 5T32CA217834-05			\$1,500	\$128,554 \$285,335	\$2,585,617 RES	SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CANCER RESEARCH MANPOWER	93.398	KCA204726-01A1:05			\$1,500	(\$26)		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	KCA218247-03				(\$6,448)	\$2,585,617 RES	SEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	KCA218247-03	Manufact St. Halings In.			(\$4)		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER CANCER RESEARCH MANPOWER	93.398 93.398	T32 CA119925 VUMC103504(T32CA119925)	Vanderbilt University Vanderbilt University	T32 CA119925 VUMC103504(T32CA119925)		\$35,433 \$58,608		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER RESEARCH MANPOWER	93.398	VUMC104329(T32CA009582)	Vanderbilt University	VUMC104329(T32CA009582)		\$58,635		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER	93.398	VUMC113419(T32CA009582)	Vanderbilt University	VUMC113419(T32CA009582)		\$4,707		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER RESEARCH MANPOWER CANCER RESEARCH MANPOWER	93.398 93.398	VUMC68198(T32CA009582) VUMC76701(T32CA009592)	Vanderbilt University Vanderbilt University ECOG-ACRIN - Eastern	VUMC68198(T32CA009582) VUMC76701(T32CA009592)		\$4,863 \$10,572		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CANCER CONTROL	93.399	UG1 CA189828	Cooperative Oncology Group	UG1 CA189828		(\$5,943)	\$30,841 RES	SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CONTROL	93.399	UG1 CA189955	Public Health Institute	UG1 CA189955		\$8,471		SEARCH AND DEVELOPMENT	\$543,888,056
CANCER CONTROL STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATION'S HEALTH	93.399	UG1 CA189955 NU38OT000316	Public Health Institute The Task Force for Global Health	UG1 CA189955 NU38OT000316		\$28,313 \$45,483		SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
IMPROVING THE HEALTH OF AMERICANS THROUGH PREVENTION AND MANAGEMENT OF DIABETES AND HEART DISEASE AND STROKE	93.426	72501:ST TN	State of Tennessee	72501:ST TN		\$20,986	,	SEARCH AND DEVELOPMENT	\$543,888,056
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90RTEM0002	Vanderbilt University	90RTEM0002		\$4,002	\$10,885 RES	SEARCH AND DEVELOPMENT	\$543,888,056
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93,433	90RTEM003	Vanderbilt University	90RTEM003		\$6,883	\$40.00E DEG	SEARCH AND DEVELOPMENT	\$543,888,056
COVID-19 TESTING FOR THE UNINSURED	93.461	HRSA COVID UNINSURED	variable of iversity	30KTEW003		\$365,333	\$365,333 N/A		\$0
ALZHEIMER'S DISEASE PROGRAM INITIATIVE (ADPI)	93.470	VUMC75498(31602-20031)(Edison ID 65462)	State of Tennessee	VUMC75498(31602-20031)(Edison ID 6546	62)	\$50,411		SEARCH AND DEVELOPMENT	\$543,888,056
PREVENTING MATERNAL DEATHS: SUPPORTING MATERNAL			Tennessee Department of Health						
MORTALITY REVIEW COMMITTEES (B) COVID-19 PROVIDER RELIEF FUND AND AMERICAN RESCUE PLAN (ARP) RURAL DISTRIBUTION	93.478 93.498	VUMC78227(Edison ID 72869) PRF PERIODS 4 AND 5	Services TN Dept of Mental Health and	VUMC78227(Edison ID 72869)		\$84,834 \$68,077,081	\$84,834 N/A \$68,077,081 N/A		\$0 \$0
Temporary Assistance for Needy Families Child Care and Development Block Grant	93.558 93.575	VUMC91900(EDISON ID 74781) VUMC104101 (2101TNCSC6)	Substance Abuse Services (Changed 2012)	VUMC91900(EDISON ID 74781)		\$115,654 \$395,156	\$115,654 N/A \$395,156 CCI		\$0 \$395,156
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	31614-80423:ST TN	Tennessee Council on Developmental Disabilties	31614-80423:ST TN		\$69,179	\$679,203 N/A		\$0
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	73268:ST TN	Tennessee Council on Developmental Disabilties	73268:ST TN		\$10,004	\$679,203 N/A		\$0
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	77255:ST TN	TN Department of Intellectual and Developmental Disabilities Tennessee Council on	77255:ST TN		\$85,686	\$679,203 N/A		\$0
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	VUMC39643(Edison ID 79008)	Developmental Disabilties Cincinnati Children's Hospital	VUMC39643(Edison ID 79008)	\$44,296	\$514,334	\$679,203 N/A		\$0
DEVELOPMENTAL DISABILITIES PROJECTS OF NATIONAL SIGNIFICANCE	93.631	90D NHC0001	Medical Center	90D NHC0001		\$6,479	\$6,479 N/A		\$0
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90DDC50014-01-01				\$6,994	\$505,236 N/A		\$0
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632 93.632	90DDUC0077-01-00 90DDUC0077-02-00			(\$21,842) \$99,225	(\$21,842) \$101.102	\$505,236 N/A \$505,236 N/A		\$0 \$0
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90DDUC0077-03-01			900,223	\$410.016	\$505,236 N/A		\$0
UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE	93.632	90UCPH056-01-00				\$8,966	\$505,236 N/A		\$0
FOSTER CARE_TITLE IV-E MATERNAL OPIOID MISUSE MODEL (A)	93.658 93.687	56787:ST TN VUMC79773(Edison ID 65326)	State of Tennessee Department of Children's Services State of Tennessee	56787:ST TN VUMC79773(Edison ID 65326)	\$2,698	\$75,299 \$640,006	\$75,299 N/A \$640,006 RES	SEARCH AND DEVELOPMENT	\$0 \$543,888,056
MEDICAL ASSISTANCE PROGRAM	93.778	VUMC04952 (Edison ID 71331)	State of Tennessee - Bureau of Tenncare TN Dept of Mental Health and	VUMC04952 (Edison ID 71331)		\$1,150,969	\$5,876,757 MEI	DICAID CLUSTER	\$5,876,757
MEDICAL ASSISTANCE PROGRAM	93.778	VUMC32655(35910-02279)	Substance Abuse Services (Changed 2012) Tennessee Department of Health	VUMC32655(35910-02279)	\$53,441	\$3,265,076	\$5,876,757 MEI	DICAID CLUSTER	\$5,876,757
MEDICAL ASSISTANCE PROGRAM	93.778	VUMC34741(34347-37124)(Edison ID 78815)	Services	VUMC34741(34347-37124)(Edison ID 788	\$51,076	\$591,534	\$5,876,757 MEI	DICAID CLUSTER	\$5,876,757
MEDICAL ASSISTANCE PROGRAM	93.778	VUMC79162(Center of Excellence)	BlueCross/BlueShield of Tennessee	VUMC79162(Center of Excellence)	\$17,001	\$869,178	\$5,876,757 MEI	DICAID CLUSTER	\$5,876,757

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	ldentifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal	Federal Program Total	Cluster Name	Cluster Total
rederal Awarding Agency/Program Tide	Number	Identification	·	Entity	Sub-Recipients	Expenditures	Total	Name	Total
OPIOID STR	93.788	33901:ST TN	TN Dept of Mental Health and Substance Abuse Services (Changed 2012)	33901:ST TN		\$24,281	\$1,315,055 N/A		\$0
OPIOID STR	93.788	62292:ST TN - VUMC89917	TN Dept of Mental Health and Substance Abuse Services (Changed 2012)	62292:ST TN - VUMC89917		\$92.667	\$1.315.055 N/A		\$0
	33.700		TN Dept of Mental Health and Substance Abuse Services			,	. ,,		•
OPIOID STR	93.788	72607:ST TN - VUMC89917	(Changed 2012) TN Dept of Mental Health and Substance Abuse Services	72607:ST TN - VUMC89917		\$1,112,708	\$1,315,055 N/A		\$0
OPIOID STR	93.788	72660:ST TN	(Changed 2012)	72660:ST TN		\$85,399	\$1,315,055 N/A		\$0
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	1DP2HL152426-01 (Yr 4) 1F32HL165917-01				\$678,203 \$60,604		ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	1K01HL165020-01A1				\$20,880		ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	1K24HL165163-01A1 1R01HI 155197-01A1				\$2,786 \$766,476		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL155990-01				(\$124,333)	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCUI AR DISEASES RESEARCH	93.837 93.837	1R01HL159204-01A1 1R01HI 160863-01				\$3,906 \$540,004		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL161095-01				\$469,925	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	1R01HL161516-01 1R01HL164526-01A1			\$68,874	\$440,570 \$18.644		ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R01HL164909-01				\$192,917	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCUI AR DISEASES RESEARCH	93.837	1R01HL167110-01A1				\$101,725		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	1R38HL167237-01 1R56HL150186-01A1			\$143,893	\$161,459 \$179.804		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	1R61HL155810-01			\$34,192	\$163,354		ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCUI AR DISEASES RESEARCH	93.837 93.837	2R01HL094786-09 3K01HI 135461-05S1				\$33,674 \$10,517		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	4DP2HL137166-02				\$33,677	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	4R33HL155810-02 5K01HL140278-05			\$98,286	\$837,299 \$67.523	\$39,589,278 RESEA	ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5K01HL145345-04				\$93,919	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837	5K08HL145075-04 5K08HL153786-04				\$150,947 \$208,750		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5K08HL153786-04 5K08HL153956-03				\$208,750 \$160,072		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5K12HL133117-05				\$125,527		ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCUI AR DISEASES RESEARCH	93.837 93.837	5K23HL148640-04 5K23HI 151871-03				\$171,540 \$218,347		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5K23HL156759-03				\$160,805	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	5K99HL159594-02 5P01HL116263-08			\$654,695	\$89,651 \$2,873,948	\$39,589,278 RESEA	ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5P01HL128203-05			\$66,099	\$66,099	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCUI AR DISEASES RESEARCH	93.837 93.837	5P01HL129941-05 5R01HI 070715-17			\$510,060	\$417,281 \$172,151		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL094786-08				\$5,322		ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	5R01HL131977-05 5R01HI 133127-04			\$171,169	\$1,368,887 \$71,025		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL133727-04 5R01HL133786-04				\$44,792	\$39,589,278 RESEA	ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL134895-04				\$41	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	5R01HL135011-05 5R01HL140074-05			\$11,452	\$27,977 \$264,438		ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL140145-04			\$10,588	\$336,715	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCUI AR DISEASES RESEARCH	93.837 93.837	5R01HL141466-03 5R01HI 142583-03				(\$29,284) \$348,656	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL142856-05				\$475,227	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	5R01HL144568-03 5R01HI 144846-04			\$18,856	\$641,988 \$437,579		ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL144941-03				\$566,390	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	5R01HL144943-04 5R01HI 145293-03			\$40,922 \$22,490	\$376,497 \$141.622		ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL145721-05			\$22,490	\$283,815		ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCUI AR DISEASES RESEARCH	93.837	5R01HL146524-03 5R01HI 146654-04			\$23,605	\$199,902		ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	5R01HL148654-04 5R01HL148244-05			\$23,605	\$702,913 \$395.953		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL148661-03			\$490,086	\$1,144,613		ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	5R01HL149386-05 5R01HL149779-03			\$78,016	\$441,321 \$818,262	\$39,589,278 RESEA \$39,589,278 RESEA	ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL149826-03				\$631,650	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCUI AR DISEASES RESEARCH	93.837 93.837	5R01HL149948-04 5R01HI 151523-03			\$333,600	\$659,254 \$900.216		ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL153607-03			\$378,901	\$1,700,556	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	5R01HL155523-02 5R01HI 156021-03			\$246,424	\$492,668 \$696,310		ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL156021-03 5R01HL157378-03			\$246,424 \$4,036	\$596,942	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL157583-03			\$25,922	\$901,236		ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	5R01HL157584-03 5R01HL158884-03			\$235,964	\$796,682 \$551.022	\$39,589,278 RESEA \$39,589,278 RESEA	ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL158976-02			\$380,772	\$788,129	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	5R01HL159203-02 5R01HI 159487-03			\$44.882	\$678,786 \$727,251		ARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL160970-02			\$72,679	\$639,699	\$39,589,278 RESEA	ARCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	5R01HL160975-02 5R01HI 161212-02				\$691,105 \$549,990		ARCH AND DEVELOPMENT ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL161212-02 5R01HL163854-07			\$42,569	\$640,369		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
	,						,		

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	e Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients E	Federal	Federal Program Total	Cluster Name	Cluster Total
	Number		Entity	Enaty	Sub-Recipients E	xpenultures			iotai
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	5R01HL164327-02 5R01HL164675-02			\$211.722	\$534,992 \$984,340		RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837	5R01HL164975-02 5R01HL164995-02			\$211,722 \$184,792	\$464,233		RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R03HL154243-02			Q104,70E	\$10,998	\$39,589,278 RESEA	RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R03HL155041-02				\$63,400		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	5R21HL140382-02 5R25HL096223-11			\$7,728	\$3,236 \$111,650		RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837	5R25HL096223-11 5R34HL155400-03				\$353.943	\$39,589,278 RESEA \$39,589,278 RESEA	RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R35HL140016-06			\$72,453	\$751,168	\$39,589,278 RESEA	RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	5R35HL144980-03			\$23,835	\$1,036,564		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	5R38HL143619-04 5T32HL105334-11				\$12,062 \$1,350		RCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837	7R21HL147831-03				\$86,709		RCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CARDIOVASCULAR DISEASES RESEARCH	93.837	DHL137166-01				\$4,546		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	RHL081707-12A1				(\$11)	\$39,589,278 RESEA	RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	RHL121139-04:05				\$365		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	RHL140375-02 R01 HL134905	University of Pennsylvania	R01 HI 134905		(\$53) \$33,948	\$39,589,278 RESEA \$39,589,278 RESEA	RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL136679	University of Minnesota	R01 HL136679		\$126		RCH AND DEVELOPMENT	\$543,888,056
			University of North Carolina-Chape	el			,,		
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL142302	Hill	R01 HL142302		(\$3,107)		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	R01 HL147171 R01 HL147818	University of Cincinnati University of Pittsburgh	R01 HL147171 R01 HL147818		\$26,758 \$793		RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL147818 R01 HL147818	University of Pittsburgh University of Pittsburgh	R01 HL147818 R01 HL147818		\$793 \$232.121		RCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CARDIO VASCULAR DISEASES RESEARCH CARDIO VASCULAR DISEASES RESEARCH	93.837	R01 HL147818 R01 HL148137	Harvard School of Public Health	R01 HL147818 R01 HL148137		\$232,121 \$127.861		RCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL149680	Columbia University	R01 HL149680		\$34,743		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL150053	University of Minnesota	R01 HL150053	\$2,573	\$156,147		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL151223	Vanderbilt University	R01 HL151223		\$120,943		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL151659	University of Florida	R01 HL151659		\$70,422		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	R01 HL151838 R01 HL152081	Massachusetts General Hospital University of Kentucky	R01 HL151838 R01 HL152081		\$5,841 \$78.093		RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL152081	University of Cincinnati Medical	RU1 HL152081		\$78,093	\$39,589,278 KESEA	IRCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL153118	Center	R01 HL153118		\$60,241	\$39,589,278 RESEA	RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL156991	Washington University	R01 HL156991		\$94,081		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R01 HL159401	University of Rochester	R01 HL159401		\$1,284		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R25 HL105444	University of Miami	R25 HL105444		\$4,361	\$39,589,278 RESEA	RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R34 HL153566	University of California Los Angele University of Texas, Southwestern	s R34 HL153566		\$10,696	\$39,589,278 RESEA	RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	R56 HL158803	Med Center	R56 HL158803		\$27,813		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	T32 HL144446	Vanderbilt University	T32 HL144446		\$5,045		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	T32 HL144446	Vanderbilt University	T32 HL144446		\$1,084		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCUI AR DISEASES RESEARCH	93.837 93.837	T32 HL144446 T32 HL144446	Vanderbilt University Vanderbilt University	T32 HL144446 T32 HI 144446		\$59,112 \$61,992		RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CARDIOVASCI II AR DISFASES RESEARCH	93.637	U01 HI 123336	Massachusetts General Hospital	U01 HI 123336		\$17.988		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	U10 HL068270	New England Research Institute	U10 HL068270		(\$34,156)		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	U24 HL135691	New England Research Institute	U24 HL135691		(\$1,718)		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	U2C HL156291	Childrens Hospital of Philadelphia	U2C HL156291		\$245,100		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	UG3 HL153847	University of Pittsburgh	UG3 HL153847		\$3,150		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	UHL068270-15 VUMC	New England Reasearch Institutes University of Minnesota	UHL068270-15 VUMC		\$2,330 \$148.068		RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CARDIO VASCULAR DISEASES RESEARCH CARDIO VASCULAR DISEASES RESEARCH	93.837	VUMC104959(R01HL151152)	Fred Hutchinson Cancer Center	VUMC104959(R01HL151152)		\$30,241		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC105632(R01HL157247)	University of California-San Francisco	VUMC105632(R01HL157247)		\$28,562		RCH AND DEVELOPMENT	\$543,888,056
			University of California-San						
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	VUMC106924(R01HL155990) VUMC110315	Francisco Duke University	VUMC106924(R01HL155990) VUMC110315		\$207,200 \$358		RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC110513 VUMC110551(R44HL140669)	Volumetrix LLC	VUMC110513 VUMC110551(R44HL140669)		\$20.340		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC110664(R01HL145293)	Yale University	VUMC110664(R01HL145293)		\$288,797		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC111287(T32HL144446)	Vanderbilt University University of North Carolina-Chape	VUMC111287(T32HL144446)		\$14,121	\$39,589,278 RESEA	RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC112272(R01HL163262)	Hill	VUMC112272(R01HL163262)		\$846,631		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC50228(R01HL111821)	Massachusetts General Hospital	VUMC50228(R01HL111821)		\$20,413		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC71633(R01HL146134)	Boston Childrens Hospital	VUMC71633(R01HL146134)		\$52,987	\$39,589,278 RESEA	RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC86626(R01HL151604)	Cincinnati Children's Hospital Medical Center	VUMC86626(R01HL151604)		\$193.545	\$20 500 270 DESEA	RCH AND DEVELOPMENT	\$543.888.056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC87875(R01HL148439)	Brigham and Women's Hospital Cleveland Clinic Lerner College of	VUMC87875(R01HL148439)		\$98,902	\$39,589,278 RESEA	RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC91682(R01HL158071)	Medicine	VUMC91682(R01HL158071)		\$243,798		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC95796(R01HL153179)	University of Minnesota	VUMC95796(R01HL153179)		\$49,631		RCH AND DEVELOPMENT	\$543,888,056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837	VUMC96446(R01HL151841) VUMC97850(R01HL136685)	Massachusetts General Hospital University of Michigan	VUMC96446(R01HL151841) VUMC97850(R01HL136685)		\$131,213 \$3.981		RCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CARDIOVASCULAR DISEASES RESEARCH CARDIOVASCULAR DISEASES RESEARCH	93.837 93.837	VUMC97850(R01HL136685) VUMC97967(R01HL156034)	Vanderbilt University	VUMC97850(R01HL136685) VUMC97967(R01HL156034)		\$72,739		RCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
LUNG DISEASES RESEARCH	93.838	1R01HL155278-01A1	validerbilt Offiversity	VOINC97907(ICOTTE130034)		\$392,087		RCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	1R56HL149129-01A1				\$1,691	\$21,378,827 RESEA	RCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	1R61HL158941-01A1			\$45,971	\$414,729	\$21,378,827 RESEA	RCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	1U01HL163303-01				\$128,251	\$21,378,827 RESEA	RCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH LUNG DISEASES RESEARCH	93.838 93.838	1U01HL168412-01 1U01HI 168478-01				\$9,715 \$139,528	\$21,378,827 RESEA	RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
LUNG DISEASES RESEARCH LUNG DISEASES RESEARCH	93.838 93.838	1U01HL168478-01 2T32HL087738-17				\$139,528 \$565.204		RCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
LUNG DISEASES RESEARCH LUNG DISEASES RESEARCH	93.838	3K08HL136888-05S1				\$24,326		RCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	4R33HL151951-02				\$833,719	\$21,378,827 RESEA	RCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5K01HL149989-03				\$164,816		RCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH LUNG DISEASES RESEARCH	93.838 93.838	5K01HL157755-03 5K01HL161257-02				\$199,644 \$130.548		RCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
LUNG DISEASES RESEARCH	93.838	5K01HL161257-02 5K08HL143051-05				\$130,548		RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
LUNG DISEASES RESEARCH	93.838	5K12HL143956-05				\$374,782	\$21,378,827 RESEA	RCH AND DEVELOPMENT	\$543,888,056

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity		Total Amount Provided to b-Recipients E.	Federal xpenditures	Federal Program Total	Cluster Name	Cluster Total
LUNG DISEASES RESEARCH	93.838	5K23HI 141539-06				\$185.483	\$21 279 927 DE	SEARCH AND DEVELOPMENT	\$543.888.056
LUNG DISEASES RESEARCH	93.838	5K23HL143053-05				\$161,951	\$21,378,827 RE	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5K23HL148638-05 5K23HL153584-03				\$181,292		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
LUNG DISEASES RESEARCH	93.838 93.838	5K23HL153584-03 5K24HL127301-08				\$174,725 \$89,476		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
LUNG DISEASES RESEARCH	93.838	5K24HL155891-02			\$5,303	\$116,089	\$21,378,827 RE	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5P01HL092870-10				\$374,056		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH LUNG DISEASES RESEARCH	93.838 93.838	5P01HL108800-11 5P30DK020593-46			\$103,275 \$795,465	\$412,504 \$2,640,974		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL095797-13			\$7.50,400	\$362,661	\$21,378,827 RE	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL122554-09				\$788,104		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH LUNG DISEASES RESEARCH	93.838 93.838	5R01HL126176-06 5R01HL134802-05			\$18,656	\$242,852 \$380,264		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL134802-05 5R01HL136664-07				\$439,762		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL136748-04				\$15	\$21,378,827 RE	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL140231-04			\$107,323	\$113,581		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838 93.838	5R01HL142720-04 5R01HL146401-05				\$637,817 \$434,152		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL146588-04			\$293,898	\$514,707		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL150617-02			\$23,723	\$687,410		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH LUNG DISEASES RESEARCH	93.838 93.838	5R01HL151016-03 5R01HL153246-04			\$63,193	\$685,337 \$685,278	\$21,378,827 RE	SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
LUNG DISEASES RESEARCH	93.838	5R01HL157373-03			400,100	\$495.685		SEARCH AND DEVELOPMENT	\$543,888.056
LUNG DISEASES RESEARCH	93.838	5R01HL158906-02			\$54,150	\$1,009,804		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838 93.838	5R01HL160551-02 5R01HL163195-02			\$23,590	\$633,932 \$671,060		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL163960-02			\$85,559	\$479.981		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R01HL164937-02				\$324,000		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5R03HL154287-02				\$2,489		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH LUNG DISEASES RESEARCH	93.838 93.838	5R35HL150783-04 5T32HL087738-16			\$12,036 (\$42,629)	\$683,030 \$3.537		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
LUNG DISEASES RESEARCH	93.838	5T32HL094296-14			. , , ,	\$321,376	\$21,378,827 RE	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	5U01HL123033-07			\$57,502	\$0		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH LUNG DISEASES RESEARCH	93.838 93.838	RHL131906-02:04 UG1 HL139119				(\$1) \$32,457		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
LUNG DISEASES RESEARCH	93.838	K24 HL150312	Icahn School of Medicine at Mount Sinai	K24 HL150312		\$16,472	604 070 007 DE	SEARCH AND DEVELOPMENT	\$543.888.056
LUNG DISEASES RESEARCH	93.838	OT2 HL150312	Massachusetts General Hospital	OT2 HL156812		\$70,309		SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
LUNG DISEASES RESEARCH	93.838	OT2 HL156812	Massachusetts General Hospital	OT2 HL156812		\$7,232		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	OT2 HL156812	Duke University	OT2 HL156812		\$8,121	\$21,378,827 RE	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	OT2 HI 161847	Weill Medical College of Cornell University	OT2 HI 161847		\$125.381	\$21 279 927 DE	SEARCH AND DEVELOPMENT	\$543.888.056
	93.030	012 HE101047	Weill Medical College of Cornell			\$125,361	. ,,.		
LUNG DISEASES RESEARCH	93.838	OT2 HL161847	University Oklahoma Medical Research	OT2 HL161847		\$36,664	\$21,378,827 RE	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	R01 HL113326	Foundation	R01 HL113326		\$27,701	\$21.378.827 RE	SEARCH AND DEVELOPMENT	\$543.888.056
LUNG DISEASES RESEARCH	93.838	R01 HL130876	Washington University	R01 HL130876		\$8,904	\$21,378,827 RE	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	R01 HL135144	University of Pittsburgh	R01 HL135144		\$6,829		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH LUNG DISEASES RESEARCH	93.838 93.838	R01 HL142775 R01 HL152083	Southern Methodist University Stanford University	R01 HL142775 R01 HL152083		\$41,434 \$187,488		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
LUNG DISEASES RESEARCH	93.838	R01 HL157130	Dartmouth College	R01 HL157130		\$277.046		SEARCH AND DEVELOPMENT	\$543,888.056
LUNG DISEASES RESEARCH	93.838	R41 HL158393	MTI BioTech	R41 HL158393		\$33,723		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	R61 HL147833	Duke University	R61 HL147833		\$1,153		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	RHL132338-01A1:05	Mount Sinai School of Medicine University of California-San	RHL132338-01A1:05		(\$1,125)	\$21,378,827 RE	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	T32 HL160508	Francisco	T32 HL160508		\$91,924		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838 93.838	U01 HL123009 U01 HL123009	Massachusetts General Hospital Massachusetts General Hospital	U01 HL123009 U01 HI 123009	\$13,183	\$11,851 \$15,951		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
LUNG DISEASES RESEARCH	93.838 93.838	U01 HL123009 U01 HL123009	Massachusetts General Hospital	U01 HL123009 U01 HL123009		\$15,951 \$11		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
LUNG DISEASES RESEARCH	93.838	U01 HL123009	Massachusetts General Hospital	U01 HL123009		\$297,498	\$21,378,827 RE	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	U01 HL123009	Massachusetts General Hospital Cleveland Clinic Lerner College of	U01 HL123009		\$121,061	\$21,378,827 RE	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	U01 HL125177	Medicine	U01 HL125177		\$50,387	\$21,378.827 RF	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	U01 HL130045	Washington University	U01 HL130045		\$19,858		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	U01 HI 145561	Weill Medical College of Cornell University	U01 HI 145561		\$6.986	\$24 270 027 DE	SEARCH AND DEVELOPMENT	\$543 888 056
LUNG DISEASES RESEARCH	93.838	U01 HL145561 U01 HL152976	Boston University	U01 HL145561 U01 HL152976		\$6,986 \$158.063		SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
			University of North Carolina-Chapel				*=-,,		,
LUNG DISEASES RESEARCH	93.838	U24 HL138998	Hill	U24 HL138998		\$25,561	\$21,378,827 RE	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	UG1 HL139119	University of Kansas Medical Cente	r UG1 HL139119		\$41,660	\$21,378,827 RE	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	UH3 HL147011	Fred Hutchinson Cancer Research Center	UH3 HL147011		\$110	\$31 379 937 DE	SEARCH AND DEVELOPMENT	\$543.888.056
			University of California-San						,
LUNG DISEASES RESEARCH	93.838	VUMC100870(R01HL157533)	Francisco Dartmouth College	VUMC100870(R01HL157533)		\$100,519		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH LUNG DISEASES RESEARCH	93.838 93.838	VUMC102543(R01HL157130) VUMC105802(Master VUMC67453)(1OT2HL156812		VUMC102543(R01HL157130) VUMC105802(Master VUMC67453)(1OT2HL	156912\	\$247,436 \$315,113		SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
			University of California-San		.130012)				,
LUNG DISEASES RESEARCH	93.838	VUMC64624(R35HL140026)	Francisco Translational Genomics Research	VUMC64624(R35HL140026)		\$36,107	\$21,378,827 RE	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	VUMC71211(R01HL145372)	Institute	VUMC71211(R01HL145372)		\$318,485	\$21,378,827 RE	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	VUMC78663(R01HL149422)	Beth Israel Deaconess Medical Center (Harvard)	VUMC78663(R01HL149422)		\$60,569	\$21,378,827 RE	SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISFASES RESEARCH	93 838	VUMC86517(R01HL150070)	Johns Hopkins University School of Medicine	VUMC86517(R01HL150070)		(\$1,396)		SEARCH AND DEVELOPMENT	\$543.888.056
LUNG DISEASES RESEARCH	93.838	VUMC94285(U24HL145265)	University of Michigan	VUMC94285(U24HL145265)		\$3,743		SEARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	VUMC94854(R01HL159250)	Northwestern University	VUMC94854(R01HL159250)		\$3,651		SEARCH AND DEVELOPMENT	\$543,888,056

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

	Federal			Identifying Number	Total				
Federal Awarding Agency/Program Title	Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Assigned By Funder Pass-Through Entity S	Amount Provided to ub-Recipients	Federal Expanditures	Federal Program Total	Cluster Name	Cluster Total
recera Awarung Agencyrrogram ride	Number	identinication	•	Linuty	ab-recipients	Lxpenditures	Total	Hame	Total
LUNG DISEASES RESEARCH	93.838	VUMC95193(R01HL132338)	Icahn School of Medicine at Mount Sinai	VUMC95193(R01HL132338)		\$33,104	\$21.378.827 RES	EARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	VUMC96886(R01HL155159)	University of Pennsylvania	VUMC96886(R01HL155159)		\$39,936		EARCH AND DEVELOPMENT	\$543,888,056
LUNG DISEASES RESEARCH	93.838	VUMC97854(UH3HL151458)	Johns Hopkins University School of Medicine	VUMC97854(UH3HL151458)		\$4.271	\$21.378.827 RES	EARCH AND DEVELOPMENT	\$543.888.056
LUNG DISEASES RESEARCH	93.838	VUMC99273(5R01HL159886-02)	University of Pennsylvania	VUMC99273(5R01HL159886-02)		\$16,196		EARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH BLOOD DISEASES AND RESOURCES RESEARCH	93.839 93.839	1OT3HL147810-01 1R01HI 168179-01			\$48,521 \$74,257	\$48,521 \$202,331		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5K08HL150282-05			Q1-1,E01	\$135,204	\$4,138,538 RES	EARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH BLOOD DISEASES AND RESOURCES RESEARCH	93.839 93.839	5K23HL138291-05 5K24HL147017-04				\$15,490 \$104.020		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5R01HL124159-08				\$606,044		EARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH BLOOD DISEASES AND RESOURCES RESEARCH	93.839 93.839	5R01HL133559-04 5R01HL141943-04				\$132,661 \$322,216		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5R01HL155207-02				\$424,786	\$4,138,538 RES	EARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH BLOOD DISEASES AND RESOURCES RESEARCH	93.839 93.839	5R01HL158918-02 5R35HL140025-06			\$30,785	\$234,726 \$768.037		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	5U01HL156620-02			\$61,288	\$553,953	\$4,138,538 RES	EARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	R01 HL118979	University of Minnesota National Marrow Donor Program	R01 HL118979		\$20,881		EARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	R01 HL131731	(BeTheMatch Foundation)	R01 HL131731		\$2,593		EARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH BLOOD DISEASES AND RESOURCES RESEARCH	93.839 93.839	R01 HL144113 U01 HI 133815	Oregon Health & Science University University of Pittsburgh	/ R01 HL144113 U01 HL133815		\$62,974		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056
	93.839		ECOG-ACRIN - Eastern	001 HE133815		\$199	. , ,		\$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	U10 CA180820	Cooperative Oncology Group National Marrow Donor Program	U10 CA180820		(\$3,138)	\$4,138,538 RES	EARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	U24 HL138660	(BeTheMatch Foundation) National Marrow Donor Program	U24 HL138660		\$615	\$4,138,538 RES	EARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	U24 HL138660	(BeTheMatch Foundation) National Marrow Donor Program	U24 HL138660		\$8,996	\$4,138,538 RES	EARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	U24 HL138660	(BeTheMatch Foundation) National Marrow Donor Program	U24 HL138660		\$5,582	\$4,138,538 RES	EARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	VUMC101230(Master VUMC63105)	(BeTheMatch Foundation)	VUMC101230(Master VUMC63105)		\$2,970		EARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH BLOOD DISEASES AND RESOURCES RESEARCH	93.839 93.839	VUMC107464(R01HL156993) VUMC108481(R01HL157346)	University of Arizona Carnegie Mellon	VUMC107464(R01HL156993) VUMC108481(R01HL157346)		\$16,440 \$15,756		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
	93.039	VUMC100401(RUTHE13/340)	Icahn School of Medicine at Mount	VUNIC106461(RUTHE157346)		\$15,750	\$4,130,330 RES	EARCH AND DEVELOPMENT	\$343,000,000
BLOOD DISEASES AND RESOURCES RESEARCH BLOOD DISEASES AND RESOURCES RESEARCH	93.839 93.839	VUMC63541(UG1HL138645) VUMC72279(R01HL133896)	Sinai University of Alabama-Birmingham	VUMC63541(UG1HL138645) VUMC72279(R01HL133896)		\$22,671 \$20,000		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	VUMC75160(R01HL101972)	Oregon Health & Science University			\$64,570		EARCH AND DEVELOPMENT	\$543.888.056
BLOOD DISEASES AND RESOURCES RESEARCH BLOOD DISEASES AND RESOURCES RESEARCH	93.839	VUMC87270(U01HL133817)	Rutgers University	VUMC87270(U01HL133817)		\$27,061		EARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	VUMC93012(R61HL156508)	Stasys Medical Corporation Cleveland Clinic Lerner College of	VUMC93012(R61HL156508)		\$231,754	\$4,138,538 RES	EARCH AND DEVELOPMENT	\$543,888,056
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	VUMC96702(U01HL143402)	Medicine	VUMC96702(U01HL143402)		\$90,625	\$4,138,538 RES	EARCH AND DEVELOPMENT	\$543,888,056
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840 93.840	1R01HL157596-01 5K12HL137943-05			\$176,462	\$904,398 \$209.364		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	R01 HL146781	Ohio State University	R01 HL146781		\$209,364 \$12,483	\$18,094,387 RES	EARCH AND DEVELOPMENT	\$543,888,056
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	VUMC84189(OT2HL156812)(Master VUMC67453)	Research Triangle Institute	VUMC84189(OT2HL156812)(Master VUM	\$90,270	\$429,899		EARCH AND DEVELOPMENT	\$543,888,056
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	VUMC86800(R01HL154153)	University of Pittsburgh Seattle Institute for Biomedical and	VUMC86800(R01HL154153)		\$149,196	\$18,094,387 RES	EARCH AND DEVELOPMENT	\$543,888,056
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	VUMC87587(U01HL142103)	Clinical Research	VUMC87587(U01HL142103)		\$14,490		EARCH AND DEVELOPMENT	\$543,888,056
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS. TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS.	93.840 93.840	VUMC88227(UG3HL154297) VUMC91864(Master VUMC67453)(OT2HL156812)	Northwestern University Research Triangle Institute	VUMC88227(UG3HL154297) VUMC91864(Master VUMC67453)(OT2HL	\$10.871.902	\$22,235 \$16,352,322		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	1K08AR081405-01				\$129,203		EARCH AND DEVELOPMENT	\$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846 93.846	1R13AR078623-01 3K01AR072123-05S1				\$767 \$52,726	\$4,455,474 RES \$4,455,474 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5K08AR072757-05				\$181,951	\$4,455,474 RES	EARCH AND DEVELOPMENT	\$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846 93.846	5K08AR080808-02 5R01AR060846-09			\$314,719	\$130,127 \$570.843		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5R01AR063157-09			\$16,777	\$486,504	\$4,455,474 RES	EARCH AND DEVELOPMENT	\$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846 93.846	5R01AR073001-03 5R01AR073764-04				\$55,187 \$49,781	\$4,455,474 RES \$4,455,474 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5R01AR076516-04				\$494,727	\$4,455,474 RES	EARCH AND DEVELOPMENT	\$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846 93.846	5R01AR080629-02 5R21AR080372-02				\$259,576 \$151.524	\$4,455,474 RES \$4,455,474 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	5R21AR080387-02				\$128,992	\$4,455,474 RES	EARCH AND DEVELOPMENT	\$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846 93.846	5R21AR080914-02 7R01AR073196-05			\$43,227 \$119.658	\$123,151 \$425.590	\$4,455,474 RES \$4.455.474 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	7R21AR080233-00			*********	\$111,383	\$4,455,474 RES	EARCH AND DEVELOPMENT	\$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846 93.846	P50 AR060772 R01 AR055557	University of Alabama-Birmingham Brigham and Women's Hospital	P50 AR060772 R01 AR055557		(\$14,076) \$44,853		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	R01 AR073486	University of Southern California	R01 AR073486		\$14,435	\$4,455,474 RES	EARCH AND DEVELOPMENT	\$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846 93.846	R01 AR073773 R01 AR073874	Stanford University Emory University	R01 AR073773 R01 AR073874		\$9,936 \$82,392		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846 93.846	R21 AR079085 T32 AR059039	Masonic Medical Research Institute Vanderbilt University	R21 AR079085 T32 AR059039	\$3,575	\$40,043 \$5.577		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	T32 AR059039	Vanderbilt University	T32 AR059039		\$2,347	\$4,455,474 RES	EARCH AND DEVELOPMENT	\$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846 93.846	TAR059039-12 UG3 AR076387	Vanderbilt University University of Iowa	TAR059039-12 UG3 AR076387		(\$734) \$7.574		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	UG3 AR076387 UG3 AR076387	University of Iowa	UG3 AR076387 UG3 AR076387		\$93,436		EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	UH3 AR077360	Johns Hopkins University School of Medicine	UH3 AR077360		\$18,857	\$4.455.474 PEQ	EARCH AND DEVELOPMENT	\$543.888.056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	VUMC 109697 (5T32AR059039-12)	Vanderbilt University	VUMC 109697 (5T32AR059039-12)		\$32,452		EARCH AND DEVELOPMENT	\$543,888,056
ARTHRITIS. MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	VUMC104697(R01AR075777)	Cleveland Clinic Lerner College of Medicine	VUMC104697(R01AR075777)		\$10.274	\$4.455.474 RFS	EARCH AND DEVELOPMENT	\$543.888.056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	VUMC107611(P50AR070590)	Case Western Reserve University	VUMC107611(P50AR070590)		\$301,234	\$4,455,474 RES	EARCH AND DEVELOPMENT	\$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	VUMC108667(T32AR059039)	Vanderbilt University	VUMC108667(T32AR059039)		\$6,892	\$4,455,474 RES	EARCH AND DEVELOPMENT	\$543,888,056

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

	Federal Assistance	Additional	Name of Funder	Identifying Number	Total Amount		Federal		
	Assistance Listing	Additional Award	Name of Funder Pass-Through	Assigned By Funder Pass-Through	Amount Provided to	Federal	Program	Cluster	Cluster
Federal Awarding Agency/Program Title	Number	Identification	Entity	Entity	Sub-Recipients E	xpenditures	Total	Name	Total
			Cleveland Clinic Lerner College of						
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846 93.846	VUMC109295(R01AR075422) VUMC109409(R01AR078715)	Medicine Yale University	VUMC109295(R01AR075422) VUMC109409(R01AR078715)		\$98,456 \$232		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056
ARTHRITIS, MUSCULOSRELETAL AND SKIN DISEASES RESEARCH	93.846	VUMC109409(R01AR078715)	Cleveland Clinic Lerner College of			\$232	\$4,400,474 KES	SEARCH AND DEVELOPMENT	\$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	VUMC111671(AR075422S1)	Medicine	VUMC111671(AR075422S1)		\$67,726		SEARCH AND DEVELOPMENT	\$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	VUMC112702(T32AR059039-12)	Vanderbilt University Cleveland Clinic Lerner College of	VUMC112702(T32AR059039-12)		\$1,280	\$4,455,474 RES	SEARCH AND DEVELOPMENT	\$543,888,056
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	VUMC68489(R01AR074131)	Medicine	VUMC68489(R01AR074131)		\$69,339	\$4,455,474 RES	SEARCH AND DEVELOPMENT	\$543,888,056
ARTHRITIS MUSCUI OSKELETAL AND SKIN DISEASES RESEARCH	93 846	VUMC76553(R01AR075422)	Cleveland Clinic Lerner College of Medicine	VUMC76553(R01AR075422)		\$192.556	\$4 455 474 RES	SEARCH AND DEVELOPMENT	\$543.888.056
		,	University of Texas, Southwestern	1					
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.846 93.847	VUMC90548(R01AR074989) 1K08DK133691-01	Med Center	VUMC90548(R01AR074989)		\$18,361 \$111,389		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1K08DK135931-01				\$2,598	\$42,561,481 RES	SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	1K23DK135414-01 1R01DK126890-01A1			\$4,578	\$28,364 \$584.124		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK131070-01			\$4,570	\$387,304	\$42,561,481 RES	SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	1R01DK131104-01 1R01DK131129-01			\$314,192	\$519,034 \$836,965		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK131129-01 1R01DK131529-01			\$314,192	\$499,119		SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK133415-01A1				\$10,387		SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	1R01DK133442-01A1 1R01DK134692-01				\$4,085 \$51,211		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1R01DK135938-01				\$34,969	\$42,561,481 RES	SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	1R21DK127075-01 1R56DK131101-01				\$175,087 \$8,944		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1U01DK123821-01 (Yr 4)			\$339,443	\$686,759	\$42,561,481 RES	SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2R01DK095785-11A1				\$36,440		SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	2R01DK105550-11 2R25DK096999-12			\$2,007	\$310,253 \$7,409		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	2T35DK007383-44				\$133,524	\$42,561,481 RES	SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	3K01DK117969-03S1 3K23DK118118-04S1				\$4 \$159.805		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3P30DK020593-44S1			\$313,806	\$315,217		SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	3P30DK058404-20S1			\$1,067	(\$32,555) \$714.033		SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3R01DK115545-05S1 3R01DK127178-03S1			\$212,677 \$16,222	\$714,033 \$569.265		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	3T32DK007673-31S1				\$403,484	\$42,561,481 RES	SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	3U01DK135017-02S1 4R00DK119413-03			\$236,862	\$303,130 \$143,198		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5F32DK127679-02				\$9,799	\$42,561,481 RES	SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5F32DK128970-03 5K01DK120631-03				\$93,585 \$105.164		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5K01DK120631-03 5K01DK123495-04				\$115,544	\$42,561,481 RES	SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5K08DK132507-02				\$150,573		SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5K23DK114566-05 5K23DK118192-05				\$182,217 \$156,354		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5K23DK123392-03				\$165,475	\$42,561,481 RES	SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5K23DK129774-02 5K23DK131341-02				\$160,811 \$158.009		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5P20DK123967-02				\$4,204	\$42,561,481 RES	SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5P30DK058404-22 5P30DK092986-11			\$179,319 \$83,012	\$1,294,168 \$107,024		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DIGEASES EXTRAMURAL RESEARCH	93.847	5P30DK192986-11 5P30DK114809-05			\$72,922	\$753,757		SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK018381-52			\$21,887	\$564,498		SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5R01DK048370-28 5R01DK051265-26			\$174,258	\$751,498 \$498.716		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK051610-28			\$148,254	\$581,521		SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5R01DK056942-17 5R01DK058587-23				\$163,317 \$427,362		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK062794-19				\$473,666	\$42,561,481 RES	SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5R01DK066358-13 5R01DK069921-17			\$12,890	\$24,989 \$607.712		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK069921-17 5R01DK081134-13			\$78.262	\$377,759		SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK081646-13				\$27,634		SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5R01DK093501-13 5R01DK093660-11			\$386,666	\$912,705 \$393,221		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK095785-10				\$268,386	\$42,561,481 RES	SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5R01DK099467-10 5R01DK101332-08				\$357,580 \$1,379		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DIGEASES EXTRAMURAL RESEARCH	93.847	5R01DK101332-06 5R01DK101332-10				\$520,765		SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK103935-06			\$81,969	\$288,749		SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5R01DK105550-10 5R01DK109102-09			\$9,876 \$17,002	\$372,899 \$326.297		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK110166-05			\$202,203	\$627,193	\$42,561,481 RES	SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5R01DK111554-05 5R01DK111671-05				\$2,141 \$36,755		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK112262-06				\$43,003	\$42,561,481 RES	SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5R01DK113423-04 5R01DK116625-04				\$200,757 \$27,439		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK116625-04 5R01DK116957-05			\$903,445	\$27,439		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK116964-05				\$137,888	\$42,561,481 RES	SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5R01DK117144-05 5R01DK117875-04				\$465,589 \$8,150		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK118407-02				\$339,388	\$42,561,481 RES	SEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5R01DK119212-05 5R01DK119282-04			\$3,039 \$50.070	\$155,699 \$536.545		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DINDETES, DIGEOTIVE, AND NIDNET DIGENCES EXTRANSURAL RESEARCH	33.847	5.5.DK119202-04			\$30,070	φυσύ,040	ψ42,301,401 RES	SE WOLLDING DE VELOCINEIN	ψυ -1 0,000,000

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	ldentifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK120025-04				\$186,286	\$42 561 481 RESI	EARCH AND DEVELOPMENT	\$543 888 056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK120626-04				\$377,697	\$42,561,481 RESI	ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5R01DK120821-03 5R01DK121101-05			\$42,623	\$293,731 \$311,389		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK121101-03 5R01DK121316-04			\$82,629	\$386,681		EARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK122075-05				\$565,922		ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5R01DK122147-03 5R01DK124845-02			\$171,802 \$54,721	\$504,779 \$640,269	\$42,561,481 RESI \$42,561,481 RESI	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK125794-02			\$231,263	\$651,412	\$42,561,481 RESI	ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK125895-04 5R01DK126721-03			\$29,846	\$358,755 \$414,839		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5R01DK126721-03 5R01DK127912-03			\$9,071 \$167,469	\$414,839 \$351.426		EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK128190-03			*,	\$477,558	\$42,561,481 RESI	ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5R01DK128200-02 5R01DK128293-03			\$21.528	\$777,714		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMORAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMORAL RESEARCH	93.847	5R01DK128293-03 5R01DK129202-02			\$21,528 \$12,479	\$395,300 \$308.593		EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK131101-02				\$252,066	\$42,561,481 RESI	ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5R01DK132155-02 5R01DK132669-02			\$36,303 \$31.838	\$801,307 \$516,500		ARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R01DK133530-02			\$3,248	\$178,008	\$42,561,481 RESI	ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R03DK123489-02				(\$43)	\$42,561,481 RESI	ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5R03DK129559-02 5R18DK123373-05				\$30,794 \$790,510		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5R25DK096999-11				\$105,862	\$42,561,481 RESI	ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5T32DK007061-50 5T32DK007569-35			\$45,636	\$292,495 \$285,955		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5T35DK007569-35 5T35DK007383-43			\$45,636	\$285,955 \$97.658		EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5U01DK110804-06				(\$14)		ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5U01DK112271-05 5U01DK116093-05			\$157,581 (\$6,432)	\$415,670 \$283,685		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5U01DK116093-05 5U01DK123013-03			(\$6,432) \$388,229	\$283,685 \$506.368	\$42,561,481 RESI	EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	5U01DK123716-04			\$441,298	\$818,800	\$42,561,481 RESI	ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	5U01DK129989-02 5U34DK123895-02			\$258,870 \$110.556	\$588,076 \$121,191		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNET DISEASES EXTRAMURAL RESEARCH	93.847	DK103067-03:06			\$110,556	\$121,191		ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK103067-03:06				(\$27)		ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	R01DK129624-03 RDK048370-24			\$32,901	\$311,106 (\$15)		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	RDK051610-25				(\$2,691)	\$42,561,481 RESI	ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	RDK100694-04:06				(\$63)	\$42,561,481 RESI	ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	RDK103067-03:06 RDK126890.01				\$924 \$1.054		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	1U01 DK126654	University of Pennsylvania	1U01 DK126654		\$67,425		EARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	R01 DK087635	University of Pennsylvania	R01 DK087635		\$8,660		ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	R01 DK087635 R01 DK093094	University of Pennsylvania Columbia University	R01 DK087635 R01 DK093094		\$1,103 \$138.826		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	R01 DK105821	University of Pennsylvania	R01 DK105821		\$29.027		EARCH AND DEVELOPMENT	\$543,888,056
			University of Texas, Southwestern						
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	R01 DK108159	Med Center	R01 DK108159		\$85,368	. ,,.	EARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	R01 DK108438	University of California Los Angeles Johns Hopkins University School of			\$3	*,,	EARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	R01 DK110375 R01 DK113201	Medicine Dartmouth College	R01 DK110375 R01 DK113201	\$9.866	\$45,763 \$111,393		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	R01 DK113201 R01 DK114485	University at Buffalo	R01 DK113201	\$9,000	\$594		EARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVÉ, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	R01 DK114485	University of Florida	R01 DK114485		\$8,192		ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	R01 DK115392 R01 DK116898	Brigham and Women's Hospital	R01 DK115392 R01 DK116898		\$64,045 \$24,812		ARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	R01 DK116898 R01 DK119508	Brigham and Women's Hospital Vanderbilt University	R01 DK116898		\$24,812 \$16,479		EARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	R01 DK120598	Harvard Pilgrim Health Care	R01 DK120598		\$41,293		ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	R01 DK120814	Emory University University of California-San	R01 DK120814		\$293,010	. ,,.	EARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES. DIGESTIVE. AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	R01 DK122797 R01 DK123330	Francisco	R01 DK122797 R01 DK123330		\$158,378 \$3.632		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABET IES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETTES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMIRAL RESEARCH	93.847	R01 DK123330 R01 DK124063	University of Cincinnati University of Washington	R01 DK123330 R01 DK124063		\$3,632 \$248,787		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	R01 DK124385	Wistar Institute University of Texas Health Sciences	R01 DK124385		\$97,766	\$42,561,481 RESI	EARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	R01 DK127084	Center at Houston University of Texas, Southwestern	R01 DK127084		\$175,849	\$42,561,481 RESI	EARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	R01 DK127589	Med Center	R01 DK127589		\$7,121		ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	R01 DK128187 R01 DK129793	Baylor College of Medicine University of California, Davis	R01 DK128187 R01 DK129793		\$131,809 \$369,168		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES. DIGESTIVE. AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	R01 DK129793 R01 DK132338	Vanderbilt University	R01 DK129793 R01 DK132338		\$369,168		ARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	R01 DK133847	COM Affiliation, Inc. (Albert Einstein	R01 DK133847		\$28,897	\$42,561,481 RESI	EARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93 847	R18 DK118471	College of Medicine managed by Montefiore)	R18 DK118471		\$83,618	\$42.561.491.000	ARCH AND DEVELOPMENT	\$543 888 056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	T32 DK007563	Vanderbilt University	T32 DK007563		(\$734)		EARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	U01 DK100866	Nationwide Children's Hospital	U01 DK100866		\$2,685		ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	U01 DK100867 U01 DK103168		U01 DK100867 U01 DK103168		\$35,719 \$11.845		ARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
			Baylor College of Medicine Medical University of South Carolina				*,,		
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	U01 DK104833 U01 DK106993	Medical University of South Carolina University of South Florida	9 U01 DK104833 U01 DK106993		\$14 \$269.737		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	U01 DK120456	University of Miami	U01 DK120456	\$11,030	\$245,676	\$42,561,481 RESI	ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	U01 DK123743	Stanford University	U01 DK123743		\$141,896	\$42,561,481 RESI	ARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	U01 DK123812	University of Pittsburgh	U01 DK123812		\$8,297	\$42,561,481 RESI	EARCH AND DEVELOPMENT	\$543,888,056

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

	Federal Assistance Listing	Additional Award	Name of Funder Pass-Through	Identifying Number Assigned By Funder Pass-Through	Total Amount Provided to	Federal	Federal Program	Cluster	Cluster
Federal Awarding Agency/Program Title	Number	Identification	Entity	Entity	Sub-Recipients Ex	penditures	Total	Name	Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	U24 DK097771	Augusta University	U24 DK097771		(\$1,042)		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	U24 DK128851	Augusta University	U24 DK128851		\$49,266		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	U2C DK059637 U34 DK129924	Vanderbilt University Columbia University	U2C DK059637 U34 DK129924		\$68 \$7.823		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMORAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMORAL RESEARCH	93.847	UC2 DK126122	University of Pittsburgh	UC2 DK126924 UC2 DK126122		\$197,766		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	UDK098085-03	City of Hope	UDK098085-03		(\$1,290)	\$42,561,481	RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	UDK120429-04	University of California, San Diego	UDK120429-04		(\$10,850)		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	VUMC VUMC	University of Michigan Columbia University	VUMC		\$120,595 \$16,493		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC	University of Pennsylvania	VUMC		\$63,605		RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC100003(R01DK124719)	University of Utah	VUMC100003(R01DK124719)		\$146,346		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC100129(R01DK128710)	Vanderbilt University	VUMC100129(R01DK128710)		\$13,078		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC101213(U24DK098085)	City of Hope	VUMC101213(U24DK098085)		\$29,494		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	VUMC101213(U24DK098085) VUMC102910 (1R01DK132948-01)	City of Hope University of South Carolina	VUMC101213(U24DK098085) VUMC102910 (1R01DK132948-01)		\$305,193 \$317,267		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC103900(R01DK132151)	University of Pittsburgh COM Affiliation, Inc. (Albert Einsteir College of Medicine managed by	VUMC103900(R01DK132151)		\$32,490	\$42,561,481	RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	VUMC104120(P30DK020541) VUMC104709(T32DK101003)	Montefiore) Vanderbilt University	VUMC104120(P30DK020541) VUMC104709(T32DK101003)	\$10,530	\$52,314 \$64,148		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE AND KIDNEY DISEASES EXTRAMIRAL RESEARCH	93.847	VUMC104709(132DK101003) VUMC106157(R01DK130296)	University of Utah	VUMC104709(132DK101003) VUMC106157(R01DK130296)		\$64,148 \$28,723		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC106832(U24DK133700)	University of Florida	VUMC106832(U24DK133700)		\$6,107		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC107030(R56DK132629)	Vanderbilt University	VUMC107030(R56DK132629)		\$21,189		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC107790(R01DK128823)	Georgia State University	VUMC107790(R01DK128823)		\$57,143 \$51,661		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	VUMC108522(U01DK133766) VUMC110656(R01)	Vanderbilt University Vanderbilt University	VUMC108522(U01DK133766) VUMC110656(R01)		\$51,661 \$4,637		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
	au.047	7557 10030(NOT)	•			ψ4,03/	15#,10C,2#¢	ALGUANGI AND DEVELOPMENT	9040,000,000
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC111495(R01DK135308)	University of Kansas Medical Cente			\$11,664		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC38829(U01DK094157)	Case Western Reserve University	VUMC38829(U01DK094157)		\$154,691		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	VUMC53531(U01DK098246) VUMC55441(U01DK106993)	George Washington University University of South Florida	VUMC53531(U01DK098246) VUMC55441(U01DK106993)		\$15,094 \$94,718		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC64825(R01DK113980)				\$28,144		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC69125(U54DK118612)	University of Chicago	VUMC69125(U54DK118612)		\$143,136	\$42,561,481	RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	VUMC70520(R01DK117147) VUMC77982(RC2DK118640)	Vanderbilt University University of California Los Angeles	VUMC70520(R01DK117147)	\$18,261	\$180,401 \$692,546		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES. DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC81882(R01DK121709)	University of California Los Angeles University of Michigan	VUMC81882(R01DK121709)	\$18,261	\$29,397		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC82725(R01DK087635)	University of Pennsylvania	VUMC82725(R01DK087635)		\$1.550		RESEARCH AND DEVELOPMENT	\$543.888.056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC87856(R01DK050277)	Vanderbilt University	VUMC87856(R01DK050277)		\$112,551		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC88369(U24DK065176)	Duke University	VUMC88369(U24DK065176)		\$31,661		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	VUMC90549(R01DK103831) VUMC91813(R01DK088327)	Vanderbilt University Massachusetts General Hospital	VUMC90549(R01DK103831) VUMC91813(R01DK088327)		\$68,977 \$157.913		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC94705(R01DK080327)	Massachusetts General Hospital	VUMC91613(R01DR086327) VUMC94705(R01DK123019)		\$89,174		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC95204(R01DK116723)	Case Western Reserve University	VUMC95204(R01DK116723)		\$9,937		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC96416(U01DK112217)	University of Pennsylvania	VUMC96416(U01DK112217)	\$9,552	\$738,279		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC97597	Washington University	VUMC97597		\$13,435		RESEARCH AND DEVELOPMENT	\$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847 93.847	VUMC98798(R01DK128803) VUMC99864(T32DK007563)	University of California at San Diego Vanderbilt University	VUMC98798(R01DK128803) VUMC99864(T32DK007563)		\$7,896 \$36,857		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	VUMC99864(T32DK007563) VUMC99864(T32DK007563)	Vanderbilt University Vanderbilt University	VUMC99864(T32DK007563) VUMC99864(T32DK007563)		\$36,857 \$21,703		RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1K23NS126628-01	valide bilt of liversity	VOINCS3804(13251007303)		\$136,087		RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	1K23NS131592-01				\$44,323		RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853 93.853	1RF1NS126144-01 1UF1NS107666-01 (Yr 3)				\$356,651 \$172,367		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	2R01NS078680-12				\$10.956		RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	3R01NS123281-02S1				\$252,779	\$11,059,476	RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R01NS078680-11			\$7,246	\$391,640	\$11,059,476	RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853 93.853	5R01NS092961-08 5R01NS096127-06			\$2,865	\$538,718 \$22,289		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R01NS097763-05				\$326,252	\$11,059,476	RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R01NS100980-05				\$536,518		RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853 93.853	5R01NS107424-05 5R01NS108445-04			\$36,190	\$307,351 \$405,655		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R01NS109114-05			\$21,559	\$292,873	\$11,059,476	RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R01NS110130-05			\$39,147	\$469,634		RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853 93.853	5R01NS110661-04 5R01NS112252-05			\$300,310 \$314,370	\$888,168 \$662,573		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R01NS112252-05 5R01NS113171-05			\$684.279	\$1,298,826		RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R01NS113832-04			\$182,252	\$532,540	\$11,059,476	RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R01NS117816-03			\$5,288	\$358,530		RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853 93.853	5R01NS118483-04 5R01NS121718-02			\$425,021 \$8.937	\$767,910 \$552.878		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5R21NS107877-02			ψ0,007	\$27,158		RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	5T32NS007491-20				(\$3,349)		RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853 93.853	5U24NS107128-05 9U01NS134349-10				\$283,352 \$102.975		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	RNS092961-02:06				(\$185)	\$11,059,476	RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	RNS111486-01	University of California-San			\$14,615	\$11,059,476	RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	R01 NS096173	Francisco University of California-San	R01 NS096173		\$105,055		RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	R01 NS104094	Francisco	R01 NS104094		\$694		RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853 93.853	R01 NS104339 R01 NS105746 VUMC75791	University of Alabama-Birmingham Massachusetts General Hospital	R01 NS104339 R01 NS105746 VUMC75791		\$8,330 \$79,880		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	R01 NS105746 VUMC75791 R01 NS107281 VUMC75452	Washington University	R01 NS105746 VUMC75791 R01 NS107281 VUMC75452		\$79,880		RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	R01 NS110665	Vanderbilt University	R01 NS110665		\$4,097	\$11,059,476	RESEARCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	R01 NS118580	Vanderbilt University	R01 NS118580		\$224,500	\$11,059,476	RESEARCH AND DEVELOPMENT	\$543,888,056

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients E	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853 93.853	R01 NS120518 R01 NS121720	Vanderbilt University Stanford University	R01 NS120518 R01 NS121720		\$33,947 \$1,567		RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS		R44 NS117214	CND Life Sciences University of North Carolina-Chape	R44 NS117214		(\$6,360)		RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	RF1 NS113285	Hill	RF1 NS113285		\$136,168		RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	U01 NS080168	Mayo Clinic Hospital	U01 NS080168		\$3,946		RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	U01 NS088312	Massachusetts General Hospital	U01 NS088312		\$2,738		RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS		U01 NS088312	Massachusetts General Hospital University of California-San	U01 NS088312		\$66,937		RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS		U01 NS092764	Francisco University of Cincinnati Medical	U01 NS092764		\$4,503		RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	U01 NS095869	Center	U01 NS095869		(\$302)		RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	U01 NS100699	University of Cincinnati	U01 NS100699		\$2,610		RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853 93.853	U01 NS107486 U01 NS110728	University of Utah University of Cincinnati	U01 NS107486		\$28,636 \$922		RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	U01 NS110728 U01 NS122419	New York University	U01 NS110728 U01 NS122419		\$922 \$74,254		RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS		U24 NS114416	Duke University University of California-San	U24 NS114416		\$13,684		RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	VUMC102925(R01NS119896)	Francisco	VUMC102925(R01NS119896)		\$2,587	\$11.059.476 RESEA	RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	VUMC103884(R03NS125243)	Vanderbilt University	VUMC103884(R03NS125243)		\$19,134		RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	VUMC109035(R34NS127100)	Vanderbilt University	VUMC109035(R34NS127100)		\$13,179		RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	VUMC68327(R01NS102371)	Massachusetts General Hospital	VUMC68327(R01NS102371)		\$104,453		RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	VUMC83014(R01NS112171)	Loyola University Chicago	VUMC83014(R01NS112171)		\$6,553		RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	VUMC89879	Childrens Research Institute COM Affiliation, Inc. (Albert Einstei College of Medicine managed by	VUMC89879 in		\$16,035	\$11,059,476 RESEA	RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	VUMC90538(K12NS080223)	Montefiore) COM Affiliation, Inc. (Albert Einstei	VUMC90538(K12NS080223)		(\$232)	\$11,059,476 RESEA	RCH AND DEVELOPMENT	\$543,888,056
			College of Medicine managed by						
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	VUMC90538(K12NS080223)	Montefiore)	VUMC90538(K12NS080223)		\$76,124	\$11,059,476 RESEA	RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	VUMC96934(K23NS113858)	University of Cincinnati	VUMC96934(K23NS113858)		\$8,110		RCH AND DEVELOPMENT	\$543,888,056
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	VUMC98829(R41NS122656)	VasaMetrix LLC	VUMC98829(R41NS122656)		\$95,720	\$11,059,476 RESEA	RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1K99Al168483-01				\$95,847		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	1R01Al175245-01A1 1R01Al176521-01				\$34,301 \$45.055		RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1R21Al176219-01				\$32.195		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1U01AI172064-01				\$67,309		RCH AND DEVELOPMENT	\$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	1U19Al174999-01				\$204,716		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2R01Al101171-12A1			\$2,546	\$32,546		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	2R01Al131771-06				\$158,888	\$75,749,669 RESEA	RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	2T32Al007474-27A1 2T32Al095202-12				\$231,479 \$323,171		RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3F32AI161860-01S1				\$323,171	\$75,749,009 KESEA \$75,740,660 DESEA	RCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3R01Al101171-11S1			\$179,266	\$423,298		RCH AND DEVELOPMENT	\$543,888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3R01Al108197-10S1			\$599,295	\$857,520		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3R01Al108197-10S1			(\$199,414)	\$19,287		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3R01Al131722-05S1			\$5,826	\$184,614		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3R01Al131722-05S1			\$199,478	\$201,831		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	3R21Al142321-02S1 3U19Al095227-11S2				(\$285) \$216,790		RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3UM1AI148452-03				(\$479)	\$75,749,009 RESEA \$75,749,669 RESEA	RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3UM1AI148452-03S4			\$144,495	\$7.043.581		RCH AND DEVELOPMENT	\$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3UM1AI148452-03S4			\$922,891	\$2,062,951		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	3UM1AI148452-03S4			\$9,446,782	\$12,718,686		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5F32AI157215-03				\$10,964		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5F32Al169905-02 5K01Al131895-05				\$58,256 \$75,928		RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5K01AI131895-05 5K08AI150352-05			\$21,447	\$75,928 \$173.082	\$75,749,009 KESEA \$75,749,669 RESEA	RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5K08AI151100-03			ψ±1,1	\$11,600		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5K23AI141621-04				\$74,055		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5K23AI156132-03				\$188,857		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5K23Al168496-02 5K24Al148459-04				\$157,521 \$169,672		RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5K24Al148459-04 5K24Al150349-04				\$169,672 \$135,355		RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5P30Al110527-09			\$446,033	\$2,166,643		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al039657-25			\$79,761	\$244,565	\$75,749,009 RESEA \$75,749,669 RESEA	RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al051448-20			\$10,701	\$178,646		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al073843-14				\$564,226	\$75,749,669 RESEA	RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al077505-14			\$414,763	\$735,577		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al093234-10			\$191,253	\$333,481		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5R01Al118932-09 5R01Al120790-04			\$324,185 \$223	\$539,213 \$89,985		RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5R01Al124456-05			\$223	\$89,985 \$85		RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al125642-05			\$29,501	\$106,684		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al127828-05			\$67,872	\$231,722	\$75,749,669 RESEA	RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al130459-05				\$225,139	\$75,749,669 RESEA	RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al131771-05			\$365,967	\$543,779		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5R01Al132560-05 5R01Al136526-03			\$136.084	\$91,984 \$200,022		RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5R01Al136526-03 5R01Al137082-04						RCH AND DEVELOPMENT RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5R01Al137082-04 5R01Al138581-05			\$81,444 \$389,577	\$515,279 \$670,049		RCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al139046-04			φυυσ, <i>311</i>	\$407,600		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al139172-05				\$938,854	\$75,749,669 RESEA	RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al141448-03				\$310,484	\$75,749,669 RESEA	RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al142095-04				\$534,552		RCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al143710-05			\$146,307	\$409,612	\$75,749,669 RESEA	RCH AND DEVELOPMENT	\$543,888,056

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number		Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
	93 855			•	•		\$527 200			\$543 888 056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01AI145265-05 5R01AI145992-04				\$280,413	\$527,200 \$655,416		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al147765-05				\$275,485	\$739,215	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5R01AI149722-03 5R01AI150701-04					\$491,051 \$423.601	\$75,749,669 F	RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01AI150701-04				\$26,053	\$282,309		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al152693-03					\$1,251,108		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5R01Al153167-04 5R01Al155646-02				\$53.738	\$499,241 \$519,002		RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01AI155668-02				\$229,237	\$727,194		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al157843-03				\$198,974	\$687,943		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5R01AI158605-03 5R01AI164587-02				\$245,540	\$375,569 \$429,470		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01AI168302-02					\$429,470	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al168468-02					\$469,299	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R01Al172156-02				\$146,336	\$561,530	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5R03AI163835-02 5R03DK129626-0	2				\$60,581 \$99,039	\$75,749,669 F \$75,749,669 F	RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21Al145397-02					\$553	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21Al145686-02				\$38,851	\$126,359		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5R21AI146698-02 5R21AI149207-02					\$29,352 \$7.484		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21Al149262-02					\$120,413	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21Al150302-02				\$101,864	\$142,297		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5R21AI150384-02 5R21AI153769-02					\$146,469 \$112,960	\$75,749,669 F	RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21AI154016-02					(\$957)		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21AI154064-02				\$40,347	\$83,616		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5R21AI156292-02 5R21AI163586-02				\$8,234 \$15.632	\$172,846 \$249,222		RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21AI163586-02				\$15,632	\$249,222 \$149.334		RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21Al164760-02				***	\$188,558		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21Al166584-02					\$90,337		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5R21AI166870-02 5R21AI168832-02					\$206,290 \$104.827	\$75,749,669 F \$75,749,669 F	RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21Al171466-02					\$196,585	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5R21Al171901-02					\$285,625	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5R24AI124872-09 5R37AI095755-14				\$284,235	\$1,189,852 \$506.261		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5U01Al069923-19				\$1,516,145	\$3,014,509		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5U01AI150739-04				\$564,077	\$1,335,918		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5U01AI152967-04 5U01AI154659-04				\$164,355 \$528,838	\$838,575 \$3,167,434		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5U01AI155299-03					\$1,465,764	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	5U01Al167789-02				\$146,715	\$781,436		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	5U19AI095227-14 5UM1AI069439-17	,			\$337,585 \$711,575	\$1,851,758 \$2,694,610	\$75,749,669 F	RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	7K01Al138863-06				9711,373	\$44,402	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	Al007474-26					(\$188)	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	RAI073843-08:11 RAI118932-06					(\$33) (\$8,341)		RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	RAI147768-02					(\$26)		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	RAI69233-12:16					\$523		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	RAI95755-07:11 TAI095202-11					(\$3,586) \$16,903		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	U19 Al070535 VU	MC104886				\$108,739	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UAI069439-15					(\$4,249)	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	UAI125135-03 UCA183727-06					\$14,835 (\$361)	\$75,749,669 F	RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	P01 Al106695		University of California/Berkeley	P01 Al106695		\$35.902		RESEARCH AND DEVELOPMENT	\$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	P01 Al139449		MD Anderson Cancer Center	P01 Al139449		\$124,372		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	P30 Al117970		George Washington University	P30 Al117970		\$19,007		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	R01 Al073755 R01 Al077653		Washington University Indoor Biotechnologies, Inc.	R01 Al073755 R01 Al077653		\$123,278 \$77,320		RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 Al108884		University of Notre Dame	R01 Al108884		\$33,975		RESEARCH AND DEVELOPMENT	\$543,888,056
				University of North Carolina-Chapel	1					
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	R01 Al132178 R01 Al134430		Hill Boston University	R01 Al132178 R01 Al134430		\$244,912 \$31,434		RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY. IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	R01 Al134430 R01 Al134648		University of Alabama-Birmingham			\$31,434 (\$1.959)		RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 Al137523		Stanford University	R01 Al137523		\$304,669		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 Al139406		Emory University	R01 Al139406		\$8,952	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 Al141661		University of Texas Medical Branch at Galveston Weill Medical College of Cornell	R01 Al141661		\$428,330	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 Al143370		University	R01 Al143370		\$6,983		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 Al150295		Brigham and Women's Hospital	R01 Al150295		\$54,493		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	R01 Al153356 R01 Al153827		Vanderbilt University University of California Los Angeles	R01 Al153356 R01 Al153827		\$46,759 \$26,446	4,	RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 Al157037		Oregon Health & Science University			\$37,068		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 Al157155		Washington University	R01 Al157155		\$535,686	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 Al157827		Vanderbilt University	R01 Al157827		\$344,442		RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	R01 Al161022 R01 AL136740		Washington University Meharry Medical College	R01 Al161022 R01 AL136740		\$116,814 \$64.848		RESEARCH AND DEVELOPMENT RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY. IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R01 AL136740 R21 Al152869		University of Michigan	R21 Al152869		\$64,848 \$25.400		RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R24 Al067039		University of Alabama-Birmingham	R24 Al067039		\$517,983	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	R56 Al46096		Vanderbilt University	R56 Al46096		\$666	\$75,749,669 F	RESEARCH AND DEVELOPMENT	\$543,888,056

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	ldentifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients E	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	T32 Al138932	Vanderbilt University COM Affiliation, Inc. (Albert Einstein	T32 Al138932		\$123,656	\$75,749,669 RESEARCH AN	D DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	U01 Al096299	College of Medicine managed by Montefiore)	U01 Al096299		\$27,153	\$75,749,669 RESEARCH AN	D DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH		U19 Al070535 U19 Al142759	University of California at San Diego University of Alabama-Birmingham			\$1,577 \$249,698	\$75,749,669 RESEARCH AN \$75,749,669 RESEARCH AN		\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	U19 Al142785	University of Texas Medical Branch at Galveston Cincinnati Children's Hospital	U19 Al142785		\$1,183,224	\$75,749,669 RESEARCH AN	D DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	U54 Al117804 U54 Al150225	Medical Center University of Alabama-Birmingham	U54 AI117804 U54 AI150225		\$14,867 \$1,363	\$75,749,669 RESEARCH AN \$75,749,669 RESEARCH AN	D DEVELOPMENT D DEVELOPMENT	\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UM1 Al068614	Fred Hutchinson Cancer Research Center Fred Hutchinson Cancer Research	UM1 Al068614		(\$86)	\$75,749,669 RESEARCH AN	D DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	UM1 AI068614 UM1 AI068619	Center Family Health International	UM1 Al068614 UM1 Al068619	\$5.093	\$78,109 \$5,093	\$75,749,669 RESEARCH AN \$75,749,669 RESEARCH AN		\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UM1 AI104681	Duke University Benaroya Research Institute at	UM1 Al104681	******	\$39,952	\$75,749,669 RESEARCH AN	D DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UM1 Al109565	Virginia Mason Benaroya Research Institute at	UM1 Al109565		\$78,173	\$75,749,669 RESEARCH AN	D DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH		UM1 Al109565	Virginia Mason Benaroya Research Institute at	UM1 Al109565		(\$5,200)	\$75,749,669 RESEARCH AN		\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	UM1 Al109565 UM1 Al148684	Virginia Mason Emory University	UM1 Al109565 UM1 Al148684		\$34,971 \$64.065	\$75,749,669 RESEARCH AN \$75,749,669 RESEARCH AN	D DEVELOPMENT	\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH		UM1 AL148684	Emory University	UM1 AL148684		\$3,332	\$75,749,669 RESEARCH AN		\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	UMI AI068636	University of California Los Angeles	LIMI VIUEBESE		\$124,317	\$75.749.669 RESEARCH AN	D DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC100483(R01Al165327)	University of Calgary	VUMC100483(R01Al165327)		\$29,645	\$75,749,669 RESEARCH AN	D DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC102475(G11Al169624)	Aurum Institute, NPC Johns Hopkins University School of	VUMC102475(G11AI169624)		\$11,023	\$75,749,669 RESEARCH AN	D DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	VUMC102639(UM2AI130836) VUMC102933(U01AI169767)	Medicine University of Pennsylvania	VUMC102639(UM2AI130836) VUMC102933(U01AI169767)		\$378,412 \$310,971	\$75,749,669 RESEARCH AN \$75,749,669 RESEARCH AN		\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC103176 (UM1AI068636)	University of California Los Angeles	VUMC103176 (UM1AI068636)		\$4,453	\$75,749,669 RESEARCH AN	D DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC103176(UM1AI068636)	University of California Los Angeles			\$4,473	\$75,749,669 RESEARCH AN		\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMLINOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	VUMC103317(R01Al134036) VUMC103804(UM1Al068614)	Trustees of Indiana University Fred Hutchinson Cancer Center	VUMC103317(R01Al134036) VUMC103804(UM1Al068614)		\$136,662 \$48,173	\$75,749,669 RESEARCH AN \$75,749,669 RESEARCH AN		\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC103804(UM1Al068614)	Fred Hutchinson Cancer Center Fred Hutchinson Cancer Center	VUMC103804(UM1Al068614)		\$48,173 \$636.515	\$75,749,669 RESEARCH AN		\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC103972(R21Al171903)	Montana State University	VUMC103972(R21Al171903)		\$13,832	\$75,749,669 RESEARCH AN		\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC103994(U19Al171292)	University of North Carolina	VUMC103994(U19Al171292)		\$468,263	\$75,749,669 RESEARCH AN		\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	VUMC104353(R01Al170228) VUMC104795(U54Al170791)	Meharry Medical College University of Pittsburgh	VUMC104353(R01Al170228) VUMC104795(U54Al170791)		\$10,820 \$284.841	\$75,749,669 RESEARCH AN \$75,749,669 RESEARCH AN		\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC106166(U54AI170752)	Duke University	VUMC104795(U54AI170791)		\$85.882	\$75,749,669 RESEARCH AN		\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC106167(U54AI170752)	Duke University	VUMC106167(U54Al170752)		\$7,883	\$75,749,669 RESEARCH AN	D DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC106207(UM1Al068636)	University of California Los Angeles	,		\$50,679	\$75,749,669 RESEARCH AN		\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC106941(UM1Al068636)	University of California Los Angeles Centre for the Aids Program of			\$7,062	\$75,749,669 RESEARCH AN		\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	VUMC107241(R01Al152142) VUMC110799(U01Al176244)	Research in South Africa Oklahoma Medical Research Foundation	VUMC107241(R01Al152142) VUMC110799(U01Al176244)		\$11,799 \$5,709	\$75,749,669 RESEARCH AN \$75,749,669 RESEARCH AN		\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC113104(P01Al125181)	University of Maryland Johns Hopkins University School of	VUMC113104(P01Al125181)		\$71,469	\$75,749,669 RESEARCH AN		\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC33032(U01AI069918)	Medicine	VUMC33032(U01Al069918)		\$126,131	\$75,749,669 RESEARCH AN		\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC61674(T32Al112541)	Vanderbilt University Johns Hopkins University School of	VUMC61674(T32AI112541)		\$4,126	\$75,749,669 RESEARCH AN		\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	VUMC62474(R01Al127469) VUMC71248	Medicine	VUMC62474(R01AI127469)		\$1,405	\$75,749,669 RESEARCH AN		\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH			University of California Los Angeles			\$263,478	\$75,749,669 RESEARCH AN		\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	VUMC71248(UM1AI106701) VUMC72177(U19AI142764)	University of California Los Angeles Henry M Jackson Foundation	VUMC71248(UM1AI106701) VUMC72177(U19AI142764)	\$57.063	\$242,996 \$614.405	\$75,749,669 RESEARCH AN \$75,749,669 RESEARCH AN		\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC74801(U01Al136816)	Massachusetts General Hospital La Jolla Institute for Allergy and	VUMC74801(U01AI136816)	\$57,003	\$16,174	\$75,749,669 RESEARCH AN		\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	VUMC77449(U19Al142790) VUMC79241(UM1Al104815)	Immunology Duke University	VUMC77449(U19AI142790) VUMC79241(UM1AI104815)		\$680,251 \$39,952	\$75,749,669 RESEARCH AN \$75,749,669 RESEARCH AN		\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC81315(UM1AI068636)	University of California Los Angeles	VUMC81315(UM1AI068636)		\$5,825	\$75,749,669 RESEARCH AN	D DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC81315(UM1AI068636)	University of California Los Angeles			\$8,550	\$75,749,669 RESEARCH AN		\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC81970(R01Al148707)	The University of Cape Town Lung	VUMC81970(R01Al148707)		\$346,216	\$75,749,669 RESEARCH AN		\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	VUMC84464(R01Al152183) VUMC87191(U01Al135950)	Institute Stanford University	VUMC84464(R01AI152183) VUMC87191(U01AI135950)		\$78,827 \$703,098	\$75,749,669 RESEARCH AN \$75,749,669 RESEARCH AN		\$543,888,056 \$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	VUMC90144(R43Al149906)	Virtici, LLC	VUMC87191(U01AI135950) VUMC90144(R43AI149906)		\$703,098 \$16.236	\$75,749,669 RESEARCH AN \$75,749,669 RESEARCH AN		\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC94283(UM1A160040)	University of Wisconsin Madison	VUMC94283(UM1A160040)		\$38,464	\$75,749,669 RESEARCH AN	D DEVELOPMENT	\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC94896(R21Al164147)	University of Copenhagen	VUMC94896(R21AI164147)		\$123,972	\$75,749,669 RESEARCH AN		\$543,888,056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	VUMC97265 VUMC97265(UM1AI068636)	University of California Los Angeles University of California Los Angeles			\$5,032 \$4,288	\$75,749,669 RESEARCH AN \$75,749,669 RESEARCH AN		\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855 93.855	VUMC97265(UM1AI068636) VUMC97521(R01AI154470)	University of California Los Angeles Boston Childrens Hospital	VUMC97265(UM1AI068636) VUMC97521(R01AI154470)		\$4,288 \$17.676	\$75,749,669 RESEARCH AN \$75,749,669 RESEARCH AN		\$543,888,056 \$543.888.056
ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH	93.855	VUMC99812(R44AI152670)	Rise Therapeutics, LLC	VUMC99812(R44AI152670)		\$6,441	\$75,749,669 RESEARCH AN	D DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859 93.859	1F32GM142246-01 1K23GM150110-01				\$20,939 \$50,207	\$8,479,018 RESEARCH AN \$8,479,018 RESEARCH AN	D DEVELOPMENT	\$543,888,056 \$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859 93.859	1K23GM150110-01 3F32GM139303-02S1				\$50,207 \$73.066	\$8,479,018 RESEARCH AN \$8,479,018 RESEARCH AN		\$543,888,056 \$543,888,056
						,	, .,		,,

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

	Federal Assistance	Additional	Name of Funder	Identifying Number Assigned By Funder	Total Amount		Federal		
Federal Awarding Agency/Program Title	Listing Number	Award Identification	Pass-Through Entity	Pass-Through Entity	Provided to Sub-Recipients	Federal	Program Total	Cluster	Cluster Total
			Entity	Entity	Sub-Recipients			Name	
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859 93.859	3R01GM121711-05S1 3R35GM124685-05S1			\$18,280	(\$9,018) \$267,420	\$8,479,018 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859 93.859	3R35GM145375-02S1 3R35GM147470-02S1				\$230,836 \$557,890		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5K23GM129662-05				\$140,349		EARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859 93.859	5K23GM134482-04 5R01GM112871-06				\$173,275		EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM12871-06 5R01GM120484-05				(\$895) \$187,234		EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM120523-05				(\$28,073)	\$8,479,018 RES	EARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859 93.859	5R01GM124109-05 5R01GM126062-05			\$46,698	\$6,808 \$311,708		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM126535-05				\$231,598	\$8,479,018 RES	EARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859 93.859	5R01GM130791-05 5R01GM132204-05			\$77,611	\$458,391 \$258,569		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM132592-04			\$45,839	\$704,136	\$8,479,018 RES	EARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859 93.859	5R01GM133169-04 5R01GM138873-02			\$215,520	\$861,117 \$367,446		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R01GM139891-02				\$492,464	\$8,479,018 RES	EARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859 93.859	5R21GM144915-02 5R35GM131770-05			\$46,122	\$241,089 \$283,219	\$8,479,018 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R35GM131770-05 5R35GM138191-03			\$8.258	\$283,219 \$428,264		EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5R35GM141927-03				\$419,112	\$8,479,018 RES	EARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859 93.859	5T32GM007569-46 5T32GM007569-48				\$15,255 \$659,624	\$8,479,018 RES \$8,479,018 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	5T32GM108554-09				\$332,693	\$8,479,018 RES	EARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859 93.859	5T32GM135094-03 P50 Al150481	University of Pittsburgh	P50 AI150481		\$174,694 \$63.685		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	R01 GM119197	East Tennessee State University	R01 GM119197		\$203,707		EARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	R01 GM129783	Children's Mercy Hospital	R01 GM129783		\$25,067	\$8,479,018 RES	EARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859 93.859	R01 GM137083 R01 GM140464	Idaho State University University of Wisconsin	R01 GM137083 R01 GM140464		\$16,430 \$28,465		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	R25 GM134979	Vanderbilt University	R25 GM134979		\$13,371		EARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	R35 GM125028	Vanderbilt University	R35 GM125028		\$428	\$8,479,018 RES	EARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	R35 GM126943	Cincinnati Children's Hospital Medical Center	R35 GM126943		\$17.702	\$8.479.018 RES	EARCH AND DEVELOPMENT	\$543.888.056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	T32 GM139800	Vanderbilt University	T32 GM139800		\$7,945	\$8,479,018 RES	EARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859 93.859	T32 GM139800 T32 GM139800	Vanderbilt University Vanderbilt University	T32 GM139800 T32 GM139800		\$4,162 \$2.323		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
	93.639	132 GW139000	Sanford-Burnham Medical						\$343,000,030
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	VUMC105511(R01GM143583)	Research Institute	VUMC105511(R01GM143583)		\$34,410		EARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859 93.859	VUMC107257(R01GM147078) VUMC111475(R35GM125028)	Vanderbilt University Vanderbilt University	VUMC107257(R01GM147078) VUMC111475(R35GM125028)		\$11,854 \$1,136		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	VUMC64091(R01GM117473)	Duke University	VUMC64091(R01GM117473)		\$40,532	\$8,479,018 RES	EARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	VUMC90666(R01GM140287)	Scripps Research Institute	VUMC90666(R01GM140287)		\$87,167		EARCH AND DEVELOPMENT	\$543,888,056
BIOMEDICAL RESEARCH AND RESEARCH TRAINING BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859 93.859	VUMC98278(T32GM139800) VUMC98278(T32GM139800)	Vanderbilt University Vanderbilt University	VUMC98278(T32GM139800) VUMC98278(T32GM139800)		\$6,077 \$5,140		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1K08HD111664-01	,	VOINGSGE/ 0(1020111100000)		\$16,207	\$10,746,790 RES	EARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865 93.865	1K99HD108420-01				\$70,139 \$388.560		EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	1R01HD107695-02 1R21HD104983-01			\$25,677	\$248,802	\$10,746,790 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	3R01HD100458-03S1			\$132,342	\$1,031,675	\$10,746,790 RES	EARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865 93.865	5K12HD043483-21 5K12HD043483-23				\$9,786 \$504,476	\$10,746,790 RES \$10,746,790 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5K12HD087023-09				\$427,540	\$10,746,790 RES	EARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865 93.865	5K23HD104183-03 5P50HD103537-03			\$360,921	\$149,562 \$1,386,317		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5P50HD103537-03 5P50HD106446-02			\$13,187	\$1,369,771	\$10,746,790 RES	EARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865 93.865	5R01HD071089-09 5R01HD084500-06			\$138,483	\$395,095 \$239,692		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD084602-05			\$44,961	\$258,509		EARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD090061-05			\$8,066	\$20,343		EARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865 93.865	5R01HD093671-05 5R01HD094946-05			\$17,296	\$162,835 \$382,747	\$10,746,790 RES \$10,746,790 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD097344-04				\$446,358	\$10,746,790 RES	EARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865 93.865	5R01HD098213-05 5R01HD098719-03				\$348,444 \$859.851	\$10,746,790 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R01HD099777-04			\$21,539	\$499,652	\$10,746,790 RES	EARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865 93.865	5R21HD097992-02 5R21HD103348-02			\$69,316 \$28,920	\$46,030 \$118,242		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5R21HD103546-02 5R21HD106578-02			\$20,920	\$117,329		EARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	5U01HD076733-06			\$5,471	\$5,471		EARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865 93.865	HHSN275201000003I K12 HD047349	Duke University University of Utah	HHSN275201000003I K12 HD047349		\$21 \$12,580		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R01 HD024356	University of California, Davis	R01 HD024356		\$134,955	\$10,746,790 RES	EARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R01 HD083181	Baylor College of Medicine	R01 HD083181		\$1,426		EARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865 93.865	R01 HD089474 R01 HD092505	Vanderbilt University Augusta University	R01 HD089474 R01 HD092505		\$28,736 \$21,541		EARCH AND DEVELOPMENT	\$543,888,056 \$543.888,056
							* ,		
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865 93.865	R01 HD093933 R01 HD095060	University of Kansas Medical Cent Boston University	R01 HD095060		\$2,209 \$1,151		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R01 HD096147	Johns Hopkins University School of Medicine	f R01 HD096147		\$175,786	\$10.746.790 PES	EARCH AND DEVELOPMENT	\$543.888.056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R01 HD102752	Vanderbilt University	R01 HD102752		\$169,247	\$10,746,790 RES	EARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	R01 HD107002	Virginia Commonwealth University			\$34,823		EARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865 93.865	R21 HD100685 R33 HD099742	Iowa State University Washington University	R21 HD100685 R33 HD099742		\$325 \$105.641		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	UH3 HD069620	Northwestern University	UH3 HD069620		\$29,095	\$10,746,790 RES	EARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	UH3 HD096920	Northwestern University	UH3 HD096920		\$2,879	\$10,746,790 RES	EARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	UHD061222-13	University of Alabama at Birmingham	UHD061222-13		(\$12,039)	\$10,746,790 RES	EARCH AND DEVELOPMENT	\$543,888,056
			5	-			, .,		

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	ldentifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients	Federal Expenditures	Federal Program Cluster Total Name	Cluster Total
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	VUMC101098(R01HD107103)	Duke University	VUMC101098(R01HD107103)		\$124,969	\$10,746,790 RESEARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	VUMC101098(R01HD107103)	Duke University	VUMC101098(R01HD107103)		\$37,472	\$10,746,790 RESEARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	VUMC102957(R01HD104188)	Vanderbilt University	VUMC102957(R01HD104188)		\$346,023	\$10,746,790 RESEARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	VUMC107303(R01HD110107)	Harvard Pilgrim Health Care Miyazaki Enterprises, LLC	VUMC107303(R01HD110107) VUMC88785(R44HD084151)		\$3,575	\$10,746,790 RESEARCH AND DEVELOPMENT \$10,746,790 RESEARCH AND DEVELOPMENT	\$543,888,056
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH AGING RESEARCH	93.865 93.866	VUMC88785(R44HD084151) 1F32AG076276-01	Wilyazaki Efiterprises, EEC	VUMC88785(R44HD084151)		\$22,942 \$50,226	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
AGING RESEARCH	93.866	1R21AG070859-01				\$205,049	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	1R21AG075643-01				\$136,455	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	1R21AG080420-01 1R56AG074279-01A1			\$5,001	\$11,274 \$580,900	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
AGING RESEARCH	93.866	1RF1AG061351-01 (Yr 4)			\$487,652	\$792,198	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	1RF1AG075341-01A1				\$397,319	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	2R56AG047992-07A1 3K23AG045966-06S1			\$2,788,235	\$3,051,952 \$92,107	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
AGING RESEARCH	93.866	5K01AG058700-05				\$66.216	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	5K01AG066971-03				\$116,924	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	5K01AG073584-03 5K01AG077038-02				\$128,121 \$129,103	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
AGING RESEARCH	93.866	5K23AG070320-03				\$201.369	\$38 447 731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	5K23AG072030-03				\$165,798	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866 93.866	5K24AG046373-11 5K24AG064114-04				\$192,263	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
AGING RESEARCH AGING RESEARCH	93.866	5K25AG076864-02				\$218,799 \$100,785	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
AGING RESEARCH	93.866	5K76AG060001-05				\$229,738	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	5K76AG068436-03				\$219,277	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	5P20AG068082-03 5R01AG034962-10			(\$19,490) \$29,316	\$1,753,528 \$4,715,318	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
AGING RESEARCH	93.866	5R01AG048915-04			920,310	(\$1,225)	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	5R01AG053264-06				\$2,482	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	5R01AG056534-05 5R01AG058639-04			\$690,497	\$229,565 \$3,602,539	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
AGING RESEARCH	93.866	5R01AG058856-05			\$690,497	\$255,896	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	5R01AG059716-05			\$381,993	\$1,063,034	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	5R01AG061138-05 5R01AG061161-04			\$19.053	\$563,251 \$900,965	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
AGING RESEARCH AGING RESEARCH	93.866	5R01AG061518-04 5R01AG061518-04			\$19,053 \$473,469	\$1,173,342	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
AGING RESEARCH	93.866	5R01AG062499-05			\$25,054	\$760,190	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	5R01AG062574-02 5R01AG062826-04			\$11,983	\$337,532 \$973.581	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
AGING RESEARCH	93.866	5R01AG062826-04 5R01AG065249-03			\$11,983	\$973,581 \$792.114	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
AGING RESEARCH	93.866	5R01AG065550-04				\$559,580	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	5R01AG068606-04 5R01AG069795-04			\$26,709	\$401,854	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	5R01AG069795-04 5R01AG071439-03			\$95,988 \$440,997	\$378,231 \$733,441	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
AGING RESEARCH	93.866	5R01AG073439-03			\$358,997	\$1,033,359	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	5R01AG073633-02			\$28,742	\$387,772	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	5R01AG076785-02 5R03AG065643-02				\$481,346 (\$26)	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
AGING RESEARCH	93.866	5R21AG063126-02				\$130,856	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	5R56AG068026-02			\$121,539	\$1,002,840	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	5U24AG074855-02 7R21AG071975-02			\$4,327,016	\$5,459,430 \$24,286	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
AGING RESEARCH AGING RESEARCH	93.866	RAG035117-06				(\$1,241)	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
AGING RESEARCH	93.866	RAG059941-02				(\$117)	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	P01 AG027296	Brown University University of Southern California	P01 AG027296		\$40,879	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	P30 AG024968 R01 AG047992	University of Southern California University of Southern California	P30 AG024968 R01 AG047992		\$45,806 \$3.461	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
Ading RESEARCH	33.000	K01 A0047332	California Pacific Medical Center	101 AG047 882		45,401	\$30,997,731 RESEARCH AND DEVELOR WERE	\$343,000,030
AGING RESEARCH	93.866	R01 AG059417	Research Insitute	R01 AG059417		\$63,826	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	R01 AG059861 R01 AG060754	Ohio State University Vanderbilt University	R01 AG059861 R01 AG060754		\$23,497 \$40,710	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
AGING RESEARCH	93.866	NU1 AGU0U/04	University of Tennessee Health	NUT AG000704		\$40,710	\$30,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	R01 AG061325	Sciences Center	R01 AG061325		\$205,074	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	R01 AG064950	Vanderbilt University	R01 AG064950		\$7,063	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	R01 AG064950 R01 AG064950 VUMC#79115	Vanderbilt University Vanderbilt University	R01 AG064950 R01 AG064950 VUMC#79115		(\$369) \$33.726	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
Ading RESEARCH	33.000	K01 A0004330 VONIO#73113	Wake Forest University Health	101 AG004330 VOMC#73113		455,720	\$30,997,731 RESEARCH AND DEVELOR WERE	\$343,000,030
AGING RESEARCH	93.866	R01 AG071807	Sciences	R01 AG071807		\$1,957	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
			The Jackson Laboratory -					
AGING RESEARCH	93.866	R01 AG074012	Sacramento, CA The Jackson Laboratory -	R01 AG074012		\$243,808	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	R01 AG076129	Sacramento,CA	R01 AG076129		\$27.095	\$38.447.731 RESEARCH AND DEVELOPMENT	\$543.888.056
AGING RESEARCH	93.866	R21 AG071975	Vanderbilt University	R21 AG071975		\$6,803	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
101/2 2722221			University of Vermont and State					
AGING RESEARCH	93.866	R21 AG072101	Agricultural College Northern California Institute for	R21 AG072101		\$12,425	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	R24 AG064025	Research and Education	R24 AG064025		\$8,283	\$38.447.731 RESEARCH AND DEVELOPMENT	\$543.888.056
			Northern California Institute for			***	,	
AGING RESEARCH	93.866	R24 AG064025	Research and Education	R24 AG064025		\$74,907	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	R44 AG058268 R56 AG061522	Xyken, LLC Dartmouth College	R44 AG058268 R56 AG061522		\$13,493 \$48,988	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
AGING RESEARCH AGING RESEARCH	93.866	R61 AG066543 VUMC78417	University of Southern California	R61 AG066543 VUMC78417		\$40,966	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	RAG061325-02	University of Tennessee	RAG061325-02		(\$6,209)	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	RF1 AG063755	The Jackson Laboratory (Maine)	RF1 AG063755		\$27,327	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	T32 AG058524 T32 AG058524	Vanderbilt University Vanderbilt University	T32 AG058524 T32 AG058524		\$3,305 \$17.007	\$38,447,731 RESEARCH AND DEVELOPMENT \$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
AGING RESEARCH AGING RESEARCH	93.866	T32 AG058524 T32 AG058524	Vanderbilt University	T32 AG058524 T32 AG058524		\$62,416	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	T32 AG058524	Vanderbilt University	T32 AG058524		\$20,529	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	TAG058524-03	Vanderbilt University University of Southern California	TAG058524-03		(\$898)	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	U19 AG024904	University or Southern California	U19 AG024904		\$8,741	\$38,447,731 RESEARCH AND DEVELOPMENT	\$543,888,056

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

	Federal			Identifying Number	Total				
	Assistance Listing	Additional Award	Name of Funder Pass-Through	Assigned By Funder Pass-Through	Amount Provided to	Federal	Federal Program	Cluster	Cluster
Federal Awarding Agency/Program Title	Number	Award Identification	Pass-Inrougn Entity		Proviaea to ub-Recipients E		Program Total	Name	Total
			· ·	•		,			
AGING RESEARCH	93.866	U19 AG065188 U19 AG065188	Duke University	U19 AG065188 U19 AG065188		(\$10,878) \$92,778		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	U19 AG065188 U19 AG065188	Duke Clinical Research Institute Duke University	U19 AG065188 U19 AG065188		\$92,778 \$52,439		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
AGING RESEARCH AGING RESEARCH	93.866	VUMC104284(R01AG064950)	Vanderbilt University	VUMC104284(R01AG064950)		\$52,439 \$9.525		SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
AGING RESEARCH AGING RESEARCH	93.866	VUMC104354(R56AG047992)	University of Southern California	VUMC104264(R01AG064950) VUMC104354(R56AG047992)		\$123.197		SEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC104581(P30AG066619)	University of Chicago	VUMC104581(P30AG066619)		\$12,307		SEARCH AND DEVELOPMENT	\$543.888.056
AGING RESEARCH	93.866	VUMC107989(R01AG79118)	Augusta University	VUMC107989(R01AG79118)		\$9,855	\$38,447,731 RE	SEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC108492(R01AG074959)	Dartmouth College	VUMC108492(R01AG074959)		\$14,390	\$38,447,731 RE	SEARCH AND DEVELOPMENT	\$543,888,056
			Northern California Institute for						
AGING RESEARCH	93.866	VUMC108514(R24AG064025)	Research and Education	VUMC108514(R24AG064025)		\$18,542		SEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	VUMC72190(RF1AG059869) VUMC75015(R01AG064800)	Johns Hopkins University of Washington	VUMC72190(RF1AG059869) VUMC75015(R01AG064800)		\$166,741 \$19,998		SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
AGING RESEARCH	93.866	VUMC/5015(R01AG064800)	University of Vermont and State	VUMC/5015(R01AG064800)		\$19,998	\$38,447,731 RE	SEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC78764(R01AG066159)	Agricultural College	VUMC78764(R01AG066159)		\$781.159	\$38.447.731 RE	SEARCH AND DEVELOPMENT	\$543.888.056
AGING RESEARCH	93.866	VUMC84924(AG062685)	Vanderbilt University	VUMC84924(AG062685)		\$14.900	\$38 447 731 RE	SEARCH AND DEVELOPMENT	\$543.888.056
AGING RESEARCH	93.866	VUMC86263(R01AG054029)	University of Southern California	VUMC86263(R01AG054029)		\$6.581		SEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC86269(R01AG061848)	University of Southern California	VUMC86269(R01AG061848)		\$9,605		SEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC86541(P01AG032952)	Harvard University	VUMC86541(P01AG032952)		\$25,456	\$38,447,731 RE	SEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC87263(R61AG066543)	University of Southern California	VUMC87263(R61AG066543)		\$159,561		SEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC87897(U01AG068057)	University of Southern California	VUMC87897(U01AG068057)		\$8,971		SEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH	93.866	VUMC88959(R01053582)	Massachusetts General Hospital	VUMC88959(R01053582)		\$78,712		SEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	VUMC89194(P01AG032952) VUMC91810(U19AG063911)	Harvard University Mayo Clinic Hospital	VUMC89194(P01AG032952) VUMC91810(U19AG063911)		\$25,552		SEARCH AND DEVELOPMENT	\$543,888,056
		VUMC91810(U19AG063911) VUMC93653(R01AG069900)	Vanderbilt University	VUMC91810(U19AG063911) VUMC93653(R01AG069900)		\$438,643		SEARCH AND DEVELOPMENT	\$543,888,056
AGING RESEARCH AGING RESEARCH	93.866 93.866	VUMC96414(R21AG072188)	Vanderbilt University	VUMC93653(R01AG069900) VUMC96414(R21AG072188)		\$434,201 \$11.038		SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
AGING RESEARCH AGING RESEARCH	93.866	VUMC97851	University of Michigan	VUMC97851		\$71,166		SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	1R21EY032592-01			\$134,186	\$175,289	\$6,402,411 RE	SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	1R21EY032724-01			,	\$164,129	\$6,402,411 RE	SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	1R21EY033473-01				\$250,406		SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	1R21EY034313-01				\$95,395		SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH VISION RESEARCH	93.867 93.867	2R01EY024997-07A1 3R01EY022349-11S1			\$6.345	\$150,403 (\$5,635)		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
VISION RESEARCH	93.007	5K08EY027464-05			\$6,343	(\$5,635) \$3,092		SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5K08EY029006-05				\$195,504		SEARCH AND DEVELOPMENT	\$543,888.056
VISION RESEARCH	93.867	5K08EY032620-03				\$240,018		SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5P30EY008126-35			\$437,492	\$848,193		SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5R01EY013760-16				\$572,968		SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5R01EY017427-12				(\$32)		SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH VISION RESEARCH	93.867 93.867	5R01EY020894-11 5R01EY023397-09			\$18,017 \$6,931	\$333,158 \$411,058	\$6,402,411 RE	SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
VISION RESEARCH	93.867	5R01EY027746-05			90,331	\$101.863	\$6,402,411 RE	SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5R01EY028133-04			\$159,693	\$312.217	\$6,402,411 RE	SEARCH AND DEVELOPMENT	\$543.888.056
VISION RESEARCH	93.867	5R01EY029693-04				\$370,209	\$6,402,411 RE	SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5R01EY031315-02				\$435,425		SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	5U24EY029893-05			\$536,437	\$1,267,508		SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH VISION RESEARCH	93.867 93.867	REY024063-04 R01 EY013769	Vanderbilt University	R01 EY013769		(\$1,393) \$1.828		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
VISION RESEARCH VISION RESEARCH	93.867	R01 EY027729	Vanderbilt University Vanderbilt University	R01 EY013769 R01 EY027729		\$1,828 \$32,053		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
VISION RESEARCH	93.867	R01 EY030490	Vanderbilt University	R01 EY030490		\$1.828		SEARCH AND DEVELOPMENT	\$543,888.056
VISION RESEARCH	93.867	U10 EY011751	Jaeb Center for Health Research	U10 EY011751		\$24,237		SEARCH AND DEVELOPMENT	\$543,888,056
			New York University School of				, . ,		
VISION RESEARCH	93.867	U10 EY026869	Medicine	U10 EY026869		(\$452)	\$6,402,411 RE	SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	U24 EY029903	Stanford University	U24 EY029903		\$186,831		SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	U54 EY032442	Vanderbilt University	U54 EY032442		\$126,366		SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	UG1 EY011751	Jaeb Center for Health Research	UG1 EY011751		(\$7,099)		SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH VISION RESEARCH	93.867 93.867	UG1 EY011751 UG1 EY031651	Jaeb Center for Health Research University of Pittsburgh	UG1 EY011751 UG1 EY031651		(\$5,413) (\$14,677)		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
VISION RESEARCH	93.867	VUMC105698(R34EY034407)	Axonis	VUMC105698(R34EY034407)		\$76,812		SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	33.007	VOMC103030(N3421034407)	Johns Hopkins University School of			\$70,012	\$0,402,411 KL	SEARON AND DEVELOR MENT	4545,000,050
VISION RESEARCH	93.867	VUMC73899(UG1EY028091)	Medicine	VUMC73899(UG1EY028091)		\$4.045	\$6.402.411 RE	SEARCH AND DEVELOPMENT	\$543.888.056
VISION RESEARCH	93.867	VUMC73899(UG1EY028091)	Johns Hopkins	VUMC73899(UG1EY028091)		\$5,636	\$6,402,411 RE	SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	VUMC80507(R01EY002686)	Vanderbilt University	VUMC80507(R01EY002686)		\$10,720		SEARCH AND DEVELOPMENT	\$543,888,056
VISION RESEARCH	93.867	VUMC93134(R01EY032670)	Vanderbilt University	VUMC93134(R01EY032670)		\$37,448	\$6,402,411 RE	SEARCH AND DEVELOPMENT	\$543,888,056
19901			University of California-San						
VISION RESEARCH MEDICAL LIBRARY ASSISTANCE	93.867	VUMC94576(UG1EY029658)	Francisco	VUMC94576(UG1EY029658)		\$2,473 \$81.537		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MEDICAL LIBRARY ASSISTANCE MEDICAL IIBRARY ASSISTANCE	93.879 93.879	1K99LM014097-01 1R01I M013995-01			\$5.888	\$81,537 \$196.710		SEARCH AND DEVELOPMENT SEARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
MEDICAL LIBRARY ASSISTANCE MEDICAL LIBRARY ASSISTANCE	93.879	5R01LM010685-13			\$3,000	\$670.167		SEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	5R01I M012854-03				\$385,662		SEARCH AND DEVELOPMENT	\$543,888.056
MEDICAL LIBRARY ASSISTANCE	93.879	5R21LM013807-02				\$167,179	\$2,357,344 RE	SEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	7R01LM012964-04			\$350,470	\$472,033	\$2,357,344 RE	SEARCH AND DEVELOPMENT	\$543,888,056
MERCAL URDANY ASSISTANCE	00	Dod I Modorato	Helensky down	- Dot I Motorto			eo or=	OF ADOLLAND DELTH COLUMN	Apr
MEDICAL LIBRARY ASSISTANCE	93.879	R01 LM013712	University of California at San Dieg Meharry Medical College			\$14,107		SEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE MEDICAL LIBRARY ASSISTANCE	93.879 93.879	R25 LM014216 T15 I M007450	Meharry Medical College Vanderbilt University	R25 LM014216 T15 LM007450		\$31,431 \$34,258		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MEDICAL LIBRARY ASSISTANCE MEDICAL LIBRARY ASSISTANCE	93.879	T15 LM007450	Vanderbilt University Vanderbilt University	T15 LM007450		\$34,258 \$1.100		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MEDICAL LIBRARY ASSISTANCE MEDICAL LIBRARY ASSISTANCE	93.879	T15 LM007450 T15 LM007450	Vanderbilt University	T15 LM007450 T15 LM007450		\$1,100		SEARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MEDICAL LIBRARY ASSISTANCE MEDICAL LIBRARY ASSISTANCE	93.879	T15 LM007450	Vanderbilt University	T15 LM007450		\$6,459	\$2,357,344 RF	SEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	T15 LM007450	Vanderbilt University	T15 LM007450		\$6,459		SEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	VUMC103206(T15LM007450)	Vanderbilt University	VUMC103206(T15LM007450)		\$6,459		SEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	VUMC104026(T15LM007450)	Vanderbilt University	VUMC104026(T15LM007450)		\$58,406		SEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	VUMC104848(2T15LM007450-21)	Vanderbilt University	VUMC104848(2T15LM007450-21)		\$59,497		SEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	VUMC105193(T15LM007450)	Vanderbilt University	VUMC105193(T15LM007450)		\$62,208		SEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	VUMC111788	Yale University University of Texas Health Science	VUMC111788		\$14,734	\$2,357,344 RE	SEARCH AND DEVELOPMENT	\$543,888,056
MEDICAL LIBRARY ASSISTANCE	93.879	VUMC96199/R01I M012806)	Center at Houston	VUMC96199(R01I M012806)		\$31.907	\$2.357.34/ DE	SEARCH AND DEVELOPMENT	\$543 888 056
MEDICAL LIBRARY ASSISTANCE PRIMARY CARE TRAINING AND ENHANCEMENT	93.884	VUMC90245(T0BHP33102)	Meharry Medical College	VUMC90199(K01EM012006) VUMC90245(T0BHP33102)		\$24.258		SEARCH AND DEVELOPMENT	\$543,888,056
PAIMWAN I CARE I RAINING AND ENVIAUCEMENT I NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	34307-30922:ST TN 262980 - VUMC44193	State of Tennessee	34307-30922:ST TN 262980 - VUMC44193		\$24,250	\$24,256 RE \$28,269 N/		\$343,000,036
***							,		**

70 2312-4393418

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	Identifying Number Total Assigned By Funder Amoun Pass-Through Provided Entity Sub-Recipi		Federal Program Total	Cluster Name	Cluster Total
			Tennessee Department of Health					
CANCER PREVENTION AND CONTROL PROGRAMS FOR STATE, TERRITORIAL AND TRIBAL ORGANIZATIONS	93.898	65897:ST TN	Services Metropolitan Nashville & Davidson	65897:ST TN \$26,3		***************************************	EARCH AND DEVELOPMENT	\$543,888,056
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	42015:METRO	County Metropolitan Nashville & Davidson	42015:METRO	\$596,631	\$812,138 N/A		\$0
HIV EMERGENCY RELIEF PROJECT GRANTS	93.914	6485124:METRO	County Tennessee Department of Health	6485124:METRO	\$215,507	\$812,138 N/A		\$0
HIV CARE FORMULA GRANTS COVID-19 GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE HIV DEMONSTRATION, RESEARCH, PUBLIC AND PROFESSIONAL EDUCATION PROJECTS Cooperative Agreements to Support State-Based Safe Motherhood and Infant Health Initiative Programs	93.917 93.918 93.941 93.946	VUMC39267(Ryan White Part B)(Edison ID 77195) 2H76HA30761-08-00 5U01PS005240-02-00 6NU58DP007307-01-01	Services TN Dept of Mental Health and	VUMC39267(Ryan White Part B)(Edison ID 77195) \$950,1	\$872,937 \$649,097 931 \$1,262,071 \$134,588		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$0 \$0 \$543,888,056 \$543,888,056
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES	93.958	70822:ST TN	Substance Abuse Services (Changed 2012) TN Dept of Mental Health and Substance Abuse Services	70822:ST TN	\$30,064	\$107,721 N/A		\$0
BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES PPHF GERIATRIC EDUCATION CENTERS	93.958 93.969	72568:ST TN U1QHP33085-05-00	(Changed 2012)	72568:ST TN \$403,	\$77,657 517 \$796,289	\$107,721 N/A \$796.289 RES	EARCH AND DEVELOPMENT	\$0 \$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	1D43TW012468-01			\$3,505	\$2,481,328 RES	EARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989 93.989	3D43TW009337-11S2 5D43TW009745-09		\$575, \$165.		\$2,481,328 RES \$2,481,328 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5D43TW011544-04		\$133,	356 \$377,829	\$2,481,328 RES	EARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989 93.989	5D43TW011949-03 5D43TW012268-02		\$26,: \$35 :			EARCH AND DEVELOPMENT FARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5G11TW011529-03		\$29,	857 \$95,229	\$2,481,328 RES	EARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989 93.989	5G11TW011819-03 5R21TW011327-02		\$29, \$27.		\$2,481,328 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	5R25TW009722-10		\$53,	323 \$99,231	\$2,481,328 RES	EARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989 93.989	5U2RTW011248-04 RTW010899-01:02		\$181,	985 \$241,516 (\$150)		EARCH AND DEVELOPMENT FARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	D43 TW009744	University of Zambia	D43 TW009744	\$90,313		EARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	D43 TW010559	University of Cape Town	D43 TW010559	(\$3,720)		EARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989 93.989	D43 TW010559 VUMC110943(G11TW011529)	University of Cape Town Tulane University	D43 TW010559 VUMC110943(G11TW011529)	\$20,586 \$6,079		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989	VUMC111538(U2RTW011248)	Tulane University	VUMC111538(U2RTW011248)	\$4,984	\$2,481,328 RES	EARCH AND DEVELOPMENT	\$543,888,056
INTERNATIONAL RESEARCH AND RESEARCH TRAINING MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.989 93.994	VUMC112100(D43TW009745) VUMC04734(Edison ID 65891)	Tulane University State of Tennessee	VUMC112100(D43TW009745) VUMC04734(Edison ID 65891)	\$4,344 \$237,481		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	VUMC06072(34352-45321)(Edison ID 67188)	State of Tennessee	VUMC06072(34352-45321)(Edison ID 67188)	\$424,165	\$661,646 N/A	EARCH AND DEVELOPMENT	\$0
AUTISM AND OTHER DEVELOPMENTAL DISABILITIES, SURVEILLANCE, RESEARCH, AND PREVENTION AUTISM AND OTHER DEVELOPMENTAL DISABILITIES. SURVEILLANCE, RESEARCH, AND PREVENTION	93.998 93.998	1NUR3DD000107-01-00 6NU53DD000010-04-01			\$141,528 \$158.895	\$300,423 N/A \$300,423 N/A		\$0 \$0
AUTISM AND OTHER DEVELOPMENTAL DISABILITIES, SURVEILLANCE, RESEARCH, AND PREVENTION Department of Health and Human Services	93.998 93.RD	6NU53DD000010-04-01 200-2012-50430			\$158,895 \$347,082	\$31.071.275 RES	EARCH AND DEVELOPMENT	\$0 \$543,888,056
Department of Health and Human Services	93.RD 93.RD	75D30120C07637			\$461	\$31,071,275 RES	EARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services Department of Health and Human Services	93.RD 93.RD	75D30120C07637:COVID-19 75D30121C10094			(\$724) \$1,796,514	\$31,071,275 RES \$31,071,275 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
Department of Health and Human Services	93.RD	75D30121C11513			\$261,435	\$31,071,275 RES	EARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services Department of Health and Human Services	93.RD 93.RD	75N91021P00873 75N91022P00216			\$16,551 \$35.980	\$31,071,275 RES \$31.071.275 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
Department of Health and Human Services	93.RD	HHS-CAOD-2021-NHLBI-001			\$17,949	\$31,071,275 RES	EARCH AND DEVELOPMENT FARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
Department of Health and Human Services Department of Health and Human Services	93.RD 93.RD	HHSN272201300023I VUMC103100(75N91022P00943)			\$89,111 \$4,488		EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
Department of Health and Human Services Department of Health and Human Services	93.RD 93.RD	VUMC105199(75D30122C14944) VUMC106147(75D30122E00006)(TO6)		\$4,381,	587 \$7,939,802 \$1,150,620		EARCH AND DEVELOPMENT FARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
Department of Health and Human Services Department of Health and Human Services	93.RD 93.RD	VUMC106147(75D30122F00006)(1O6) VUMC106248(75P00122C00034)		\$5.1			EARCH AND DEVELOPMENT	\$543,888,056 \$543.888.056
Department of Health and Human Services Department of Health and Human Services	93.RD	VUMC76957(75N95D22P00141) VUMC78931(75N93019C00074)		\$66	\$5,676 762 \$1,202,721		EARCH AND DEVELOPMENT FARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
Department of Health and Human Services Department of Health and Human Services	93.RD 93.RD	VUMC78931(75N93019C00074) VUMC93226(75D30121C11656)		\$66, \$2,738,			EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
Department of Health and Human Services	93.RD	VUMC97370(75D30122C12914)(IVY 4)		\$2,478,		\$31,071,275 RES	EARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services Department of Health and Human Services	93.RD 93.RD	VUMC99463(75D30122C13379) 75D30120C07725	Boston Childrens Hospital	\$27, 75D30120C07725	153 \$3,247,084 \$57.565		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
Department of Health and Human Services	93.RD	75D30120C07986	Westat, Inc. Johns Hopkins University School of	75D30120C07986	\$182,288	\$31,071,275 RES	EARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75D30120C08171	Medicine Public Health Institute at Denver	75D30120C08171	\$8,657		EARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75D30121C10166	Health	75D30121C10166	\$40,079		EARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services Department of Health and Human Services	93.RD 93.RD	75F40119D10037 75F40119D10037	Harvard Pilgrim Health Care Harvard Pilgrim Health Care	75F40119D10037 75F40119D10037	\$9,190 \$15.815		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
Department of Health and Human Services	93.RD	75F40119D10037	Harvard Pilgrim Health Care	75F40119D10037	(\$842)	\$31,071,275 RES	EARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services Department of Health and Human Services	93.RD 93.RD	75FCMC19D0093 75N3019C00055	Rand Corporation, Headquarters University of Maryland	75FCMC19D0093 75N3019C00055	\$64,436 \$40,947	\$31,071,275 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
Department of Health and Human Services Department of Health and Human Services	93.RD 93.RD	75N91020C00046	Outcomes4Me	75N3019C00055 75N91020C00046	\$40,947 \$562		EARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75N91021C00046	Kitware	75N91021C00046	\$2,802		EARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services Department of Health and Human Services	93.RD 93.RD	75N93019C00052 75N93019C00055	University of Georgia University of Maryland	75N93019C00052 75N93019C00055	\$3,835 \$734		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056
Department of Health and Human Services	93.RD	75N93019C00055	University of Maryland	75N93019C00055	\$399,802	\$31,071,275 RES	EARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75N93019C00062	Washington University Integral Molecular	75N93019C00062	\$548,646		EARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services Department of Health and Human Services Department of Health and Human Services	93.RD 93.RD 93.RD	75N93019C00073 75N93019D00031 75Q8012DD00018	Johns Hopkins University School o Medicine National Opinion Research Center	75N93019C00073 f 75N93019D00031 75080120D00018	\$244,367 \$547,894 \$219,954	\$31,071,275 RES	EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056 \$543,888,056
Department of Health and Human Services Department of Health and Human Services	93.RD 93.RD	VUMC (75D30121C10166)	Denver Health and Hospital Authority	VUMC (75D30121C10166)	\$219,954		EARCH AND DEVELOPMENT	\$543,888.056
Department of Health and Human Services Department of Health and Human Services	93.RD 93.RD	VUMC102712(Master VUMC86922) (75F40119D10037/75F40119F19002)(WO2015)	Harvard Pilgrim Health Care	VUMC102712(Master VUMC86922)(75F40119D1003	. ,		EARCH AND DEVELOPMENT	\$543,888.056
Department of Health and Human Services	93.RD	VUMC102712(Master VUMC86922) (75F40119D10037/75F40119F19002)(WO2015)	Harvard Pilgrim Health Care	VUMC102719(Master VUMC86922)(75F40119D1003			EARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC103591(75D30121C10168)		na VUMC103591(75D30121C10168)	\$15,502	\$31,071,275 RES	EARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC103743(75N91019D00024) VUMC105465(75N91019D00024)	Leidos Biomedical Research, Inc. Leidos Biomedical Research, Inc.	VUMC103743(75N91019D00024) \$139,3		\$31,071,275 RES	EARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services Department of Health and Human Services	93.RD 93.RD	VUMC105465(75N91019D00024) VUMC106117(75N91019D00024)	Leidos Biomedical Research, Inc. University of Minnesota	VUMC105465(75N91019D00024) VUMC106117(75N91019D00024)	\$360,823 \$15,412		EARCH AND DEVELOPMENT EARCH AND DEVELOPMENT	\$543,888,056 \$543,888,056

71 2312-4393418

Schedule of Expenditures of Federal Awards and State Financial Assistance (Continued)

Fiscal Period 7/1/2022 - 6/30/2023

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Identification	Name of Funder Pass-Through Entity	ldentifying Number Assigned By Funder Pass-Through Entity	Total Amount Provided to Sub-Recipients E	Federal Expenditures	Federal Program Cluster Total Name	Cluster Total
Department of Health and Human Services	93.RD	VUMC106140	Boston Childrens Hospital	VUMC106140		\$261.090	\$31.071.275 RESEARCH AND DEVELOPMENT	\$543.888.056
Department of Health and Human Services Department of Health and Human Services	93.RD	VUMC107712(WDR5-MLL1)	Vanderbilt University	VUMC107712(WDR5-MLL1)		\$7.327	\$31.071.275 RESEARCH AND DEVELOPMENT	\$543,888.056
Department of Health and Human Services	93.RD	VUMC107713 VUMC108939(Master VUMC86922)	Vanderbilt University	VUMC107713		\$22,883	\$31,071,275 RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	(75F40119D10037)(75F40119F19002)(WO2020) VUMC109524(Master VUMC86922)	Harvard Pilgrim Health Care	VUMC108939(Master VUMC86922)(75F40119D10037)(75	\$122,220	\$31,071,275 RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	(75F40119D10037)(75F40119F19002)(WO2022) VUMC89882(Master VUMC86922)	Harvard Pilgrim Health Care	VUMC109524(Master VUMC86922)(75F40119D10037)(75	\$42,624	\$31,071,275 RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	75F40119D10037)(75F40119F19002)(WO2000.3) VUMC89883(Master VUMC86922)75F40119D10037/75F40119F19002)	Harvard Pilgrim Health Care	VUMC89882(Master VUMC86922)(7	5F40119D10037)(75f	\$29,603	\$31,071,275 RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	(WO2021) VUMC93894(Master VUMC86922)	Harvard Pilgrim Health Care	VUMC89883(Master VUMC86922)(7	5F40119D10037/75F	\$16,592	\$31,071,275 RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	(75F40119D10037/75F40119F19002)(WO2006) VUMC93909(Master VUMC86922)	Harvard Pilgrim Health Care	VUMC93894(Master VUMC86922)(7	5F40119D10037/75F	\$230,209	\$31,071,275 RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	(75F40119D10037/75F40119F19002)(WO2005)	Harvard Pilgrim Health Care	VUMC93909(Master VUMC86922)(7)	5F40119D10037/75F	\$123,563	\$31,071,275 RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services	93.RD	VUMC96364(75N93020C00027) VUMC99420(Master VUMC86922)	IDBiologics, LLC	VUMC96364(75N93020C00027)		\$17,575	\$31,071,275 RESEARCH AND DEVELOPMENT	\$543,888,056
Department of Health and Human Services TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES	93.RD	(75F40119D10037/75F40119F19002)(WO2010)	Brigham and Women's Hospital	VUMC99420(Master VUMC86922)(79	5F40119D10037/75F \$105,582,118	\$76,018 \$646,772,442	\$31,071,275 RESEARCH AND DEVELOPMENT	\$543,888,056
U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT USAID POPEIGN ASSISTANCE FOR PROGRAMS OVERSEAS USAID DEVELOPMENT PARTIRESHIPS FOR UNIVERSITY COOPERATION AND DEVELOPMENT	98.001 98.012	720-656-18-C-00001 720-0AA-18-CA-00019	Chemonics International, Inc.	720-656-18-C-00001	\$11.854	(\$5) \$93.893	(\$5) N/A \$366.039 N/A	\$0 \$0
USAID DEVELOPMENT PARTNERSHIPS FOR UNIVERSITY COOPERATION AND DEVELOPMENT TOTAL U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT	98.012	720-0AA-21-CA-00010	Yale University	720-0AA-21-CA-00010	\$11,854	\$272,146 \$366,034	\$366,039 N/A	\$0
TOTAL EXPENDITURE OF FEDERAL AWARDS					\$109,215,571	\$669,834,888		

Please Note: Italicized award lines indicate pass-through funding

The accompanying Notes to the Schedule of Expenditures of Federal Awards and State Financial Assistance are an integral part of the schedule.

Schedule of Expenditures of Federal Awards and State Financial Assistance

Fiscal Period 7/1/2022 - 6/30/2023

	Assistance Listing	Additional Award	Name of Funder Pass-Through	Identifying Number Assigned By Funder Pass-Through	Total Amount Provided to	Federal	Federal Program	Cluster	Cluster
Federal Awarding Agency/Program Title	Number	Identification	Entity	Entity	Sub-Recipients	Expenditures	Total	Name	Total
TOTAL EXPENDITURE OF FEDERAL AWARDS					\$109,215,571	\$669,834,888			
STATE FINANCIAL ASSISTANCE									
PSYLTDHDDFET MW				6442:STTN BOP		\$116,731			
DOC (BOP) RISK ASSESSMENTS				6442:STTN BOP		\$164,881			
COMMUNITY FORENSIC-JUV CT EVALUATIONS				6442:STTN CFJCE		\$4,790			
30994:PROVIDE ACCESS TO THE VISUAL ENVIRONMEN	T (PAVE)			30994:ST TN		\$289,027			
233330:QUALITY IMPROVEMENT COLLABORATIVE FOR	COVID-19			233330:ST TN		\$442,197			
75756:COMPREHENSIVE CARE CLINIC FOR STATE APP.	ROVED CLIENTS			75756:ST TN		\$105,300			
215466:THE ENHANCEMENT GOALS OF CARE DISCUSS	IONS IN TN LTC FA	CIL		215466:ST TN		\$64,839			
56787:CPS ASSESSMENT TRACK TRAINING ACADEMY				56787:ST TN		\$85,923			
65891:GENETIC SCREENING, TESTING, COUNSELING-S	TATE FUND			65891:ST TN		\$735,031			
34001-99205:CLOVER BOTTOM NEUROLOGY SPASTICIT	Y CLINICS			34001-9925:ST TN		\$9,385			
62967:MED-ASSISTED TREATMENT SERVICES				62967:MED-ASSISTED TRT		\$10,067			
67188:POISON CONTROL SERVICES				67188:ST TN		\$409,452			
74585:SAFE BABY COURTS-STATE				74585:ST TN		\$78,463			
74876:TENNESSEE INTEGRATED COURT SCREENING A	ND REFERRAL PRO	OJ		74876:ST TN		\$56,879			
64491:STRATEGIC TRAINING, ANALYSIS AND RESOURCE	ES FOR			64491:ST TN		\$87,117			
INTERNAL CAR SEAT PROGRAM				STATE OF TENNESSEE		-\$401			
TOTAL STATE FINANCIAL ASSISTANCE					\$0	\$2,659,680			
TOTAL EXPENDITURE OF FEDERAL AWARDS AND STATE FIN	ANCIAL ASSISTAN	CE			\$109,215,571	\$672,494,568			

Please Note:
The accompanying Notes to the Schedule of Expenditures of Federal Awards and State Financial Assistance are an integral part of the schedule.

Notes to the Schedule of Expenditures of Federal Awards and State Financial Assistance

For the Year Ended June 30, 2023

1. Significant Accounting Policies Used in Preparing the Schedule of Expenditures of Federal Awards and State Financial Assistance

The accompanying Schedule of Expenditures of Federal Awards and State Financial Assistance (the Schedule) includes the activity of Vanderbilt University Medical Center (VUMC) under programs of the federal government and of the State of Tennessee for the year ended June 30, 2023. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance) and the State of Tennessee Audit Manual. For purposes of the Schedule, federal and state awards include all grants, contracts, and similar agreements entered into directly between VUMC and agencies and departments of the federal government and all subawards to VUMC by organizations pursuant to federal grants, contracts, and similar agreements, and agencies and departments of the Tennessee state government, including federal awards passed through by the state of Tennessee.

2. 10% De Minimis Cost Rate

VUMC did not use the de minimis cost rate.

3. Summary of Significant Accounting Policies for the Schedule

For purposes of the Schedule, expenditures for federal and state programs are recognized on the accrual basis, which is consistent with accounting principles generally accepted in the United States of America. Expenditures for federal and state awards of VUMC are determined using the cost accounting principles and procedures set forth in the Uniform Guidance and the State of Tennessee Audit Manual. Under these cost principles, certain expenditures are not allowable or are limited as to reimbursement. Negative amounts represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.

4. COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution (Assistance Listing No. 93.498) Reporting Periods 4 and 5

The Schedule includes \$68.1 million received from the Department of Health and Human Services (HHS) between July 1, 2021 and June 30, 2022 under the Provider Relief Fund (PRF) program Assistance Listing No. 93.498. In accordance with guidance from HHS, the amounts in the Schedule were reported in Reporting Periods 4 and 5 in the HHS Reporting Portal. Such amounts were recognized as other operating revenue in VUMC's consolidated financial statements in the accompanying consolidated statement of operations and changes in net assets for the year ended June 30, 2023. Due to the PRF Reporting Portal requirements, these amounts are not the total PRF received and/or recognized by VUMC as other operating revenue in VUMC's consolidated financial statements for the year ended June 30, 2023.

2312-4393418 74

Notes to the Schedule of Expenditures of Federal Awards and State Financial Assistance (continued)

4. COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution (Assistance Listing No. 93.498) Reporting Periods 4 and 5 (continued)

The amount presented on the Schedule for PRF is for the fiscal year ended June 30, 2023. The amount presented reconciles to the PRF information reported to HHS as follows:

Name of Reporting Entity for HHS	Reporting Entity Tax		Total Lost	
Reporting Periods 4 and 5 Provider Relief Fund Report	Identification Number (TIN)	Type of Distribution	Revenues Reported	Total
·		PRF	•	
Vanderbilt University Medical Center	35-2528741	General PRF	\$ 405,501	\$ 405,501
Vanderbilt University Medical Center	35-2528741	General	44,405,967	44,405,967
Vanderbilt University Medical Center	35-2528741	ARP Rural	22,420,733	22,420,733
Vanderbilt Integrated Providers	62-1650124	ARP Rural	93,145	93,145
VIP MidSouth, LLC	62-1654580	ARP Rural	569,864	569,864
Spring Hill Surgery Center, LLC	46-2325870	ARP Rural	23,198	23,198
Vanderbilt Health and Williamson Medical			,	,
Center Clinics and Services, LLC	62-1864145	ARP Rural	29,740	29,740
One Hundred Oaks Imaging, LLC	26-3762022	ARP Rural	45,931	45,931
Williamson Imaging, LLC	62-1855535	ARP Rural	29,439	29,439
Vanderbilt Imaging Services, LLC	62-1787098	ARP Rural	53,564	53,564
			\$ 68,077,082	\$ 68,077,082

2312-4393418 75

Uniform Guidance Reports and Schedule



Ernst & Young LLP Suite 2100 222 2nd Avenue South Nashville, TN 37201 Tel: +1 615 252 2000 ev.com

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards

Senior Management and the Board of Directors Vanderbilt University Medical Center

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the consolidated financial statements of Vanderbilt University Medical Center (VUMC), which comprise the consolidated balance sheet as of June 30, 2023 and the related consolidated statements of operations, changes in net assets and cash flows for the year then ended, and the related notes (collectively referred to as the "financial statements"), and have issued our report thereon dated September 29, 2023.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered VUMC's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of VUMC's internal control. Accordingly, we do not express an opinion on the effectiveness of VUMC's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether VUMC's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst & Young LLP

September 29, 2023



Ernst & Young LLP Suite 2100 222 2nd Avenue South Nashville, TN 37201 Tel: +1 615 252 2000 ev.com

Report of Independent Auditors on Compliance for Each Major Federal Program and Report on Internal Control Over Compliance Required by the Uniform Guidance

Senior Management and the Board of Directors Vanderbilt University Medical Center

Report of Independent Auditors on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Vanderbilt University Medical Center's (VUMC) compliance with the types of compliance requirements identified as subject to audit in the U.S. Office of Management and Budget (OMB) Compliance Supplement that could have a direct and material effect on each of VUMC's major federal programs for the year ended June 30, 2023. VUMC's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, VUMC complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2023.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of VUMC and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on compliance for each major federal program. Our audit does not provide a legal determination of VUMC's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to VUMC's federal programs.

2312-4393418 78



Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on VUMC's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about VUMC's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, Government Auditing Standards, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design
 and perform audit procedures responsive to those risks. Such procedures include examining, on a
 test basis, evidence regarding VUMC's compliance with the compliance requirements referred to
 above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of VUMC's internal control over compliance relevant to the audit in order
 to design audit procedures that are appropriate in the circumstances and to test and report on
 internal control over compliance in accordance with the Uniform Guidance, but not for the purpose
 of expressing an opinion on the effectiveness of VUMC's internal control over compliance.
 Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance, which is required to be reported in accordance with the Uniform Guidance and which is described in the accompanying schedule of findings and questioned costs as 2023-001 related to the R&D Cluster and Equipment. Our opinion on the major federal program is not modified with respect to this matter.

Government Auditing Standards requires the auditor to perform limited procedures on VUMC's response to the noncompliance finding identified in our audit described in the accompanying schedule of findings and questioned costs. VUMC's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.



Report on Internal Control Over Compliance

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance, and therefore, material weaknesses or significant deficiencies may exist that were not identified. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, as discussed below, we did identify a deficiency in internal control over compliance that we consider to be a significant deficiency.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance. We consider the deficiency in internal control over compliance described in the accompanying schedule of findings and questioned costs as 2023-001 related to the R&D Cluster and Equipment to be a significant deficiency.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

Government Auditing Standards requires the auditor to perform limited procedures on VUMC's response to the internal control over compliance finding identified in our audit described in the accompanying schedule of findings and questioned costs. VUMC's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Ernst + Young LLP

February 20, 2024

Schedule of Findings and Questioned Costs

For the Year Ended June 30, 2023

Section I—Summary of Auditor's Results

Financial Statements

Type of report the auditor issued on wheth statements audited were prepared in account	P:		Unm	odified			
Internal control over financial reporting: Material weakness(es) identified? Significant deficiency(ies) identified? Noncompliance material to financial stater	ments noted?		yes yes yes	X X X	no none reported no		
Federal Awards							
Internal control over major federal program Material weakness(es) identified? Significant deficiency(ies) identified?	ns:	X	yes yes	X	no none reported		
Type of auditor's report issued on complia federal programs:	nce for major	Unmod	lified				
Any audit findings disclosed that are requireported in accordance with 2 CFR 200.		X	yes		no		
Identification of major federal programs:							
Assistance Listing number(s)	Nam	e of fede	eral prog	ram or o	cluster		
Various	Research & Development Cluster						
84.027	Special Education Cluster (IDEA)						
93.067	Global AIDS						
93.498	COVID-19 Provider Relief Fund and American Rescue Pla (ARP) Rural Distribution						
93.778	Medical Assistar	nce Prog	ram				
Dollar threshold used to distinguish between Type A and Type B programs:	\$ 3,000,000						
Auditee qualified as low-risk auditee?			yes	X	no		

Schedule of Findings and Questioned Costs (continued)

Section II—Financial Statement Findings

None noted.

2312-4393418 82

Schedule of Findings and Questioned Costs (continued)

Section III—Federal Award Findings and Questioned Costs

Finding 2023-001

Information on the Federal Program: Research & Development Cluster

Assistance Listing No.: 93.110, 93.113, 93.121, 93.172, 93.242, 93.279, 93.389, 93.393, 93.394, 93.395, 93.396, 93.837, 93.846, 93.847, 93.849, 93.853, 93.855, 93.865, 93.RD

Award Number: 5R01HL131977-05; Assistance Listing No. 93.837. The remaining Assistance Listing Numbers relate to equipment purchased in prior years and are not on the June 30, 2023 Schedule of Expenditures of Federal Awards.

Federal Grantor: United States Department of Health and Human Services

Award Year: July 1, 2022 through June 30, 2023

Pass-Through Award Period of Performance: July 1, 2022 through June 30, 2023

Criteria or Specific Requirement (Including Statutory, Regulatory, or Other Citation):

Section 200.303 of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance) states the following regarding internal control:

"The non-Federal entity must:

(a) Establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in "Standards for Internal Control in the Federal Government" issued by the Comptroller General of the United States or the "Internal Control Integrated Framework", issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)."

Section 200.313(d)(2) and (3) of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance) states the following regarding compliance:

"A physical inventory of the property must be taken and the results reconciled with the property records at least once every two years."

"A control system must be developed to ensure adequate safeguards to prevent loss, damage, or theft of the property. Any loss, damage, or theft must be investigated."

Schedule of Findings and Questioned Costs (continued)

Section III—Federal Award Findings and Questioned Costs (continued)

Section 200.313(e) of Title 2 U.S. *Code of Federal Regulations* Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance) states the following regarding compliance:

"Disposition. When original or replacement equipment acquired under a Federal award is no longer needed for the original project or program or for other activities currently or previously supported by a Federal awarding agency, except as otherwise provided in Federal statutes, regulations, or Federal awarding agency disposition instructions, the non-Federal entity must request disposition instructions from the Federal awarding agency if required by the terms and conditions of the Federal award. Disposition of the equipment will be made, in accordance with Federal awarding agency disposition instructions."

Condition:

- 1. VUMC performed a physical inventory, however; not all count sheets sent out to the R&D departments were returned to conclude if the inventory was on hand.
- 2. During our physical inventory testing, we identified one item that could not be located by VUMC.
- 3. VUMC's internal controls over the disposition of equipment do not include formal documentation of the criteria assessed to determine how VUMC concluded on the appropriateness of the disposition of equipment. In addition, the value used in the assessment of the disposition of equipment is based on the net book value of the asset, versus the fair market value required by Section 200.313(e).

Cause:

VUMC's internal controls over the physical inventory are not designed sufficiently to follow up on items where no response was received from the department to confirm the existence of equipment items.

VUMC's disposal form does not include the required documentation of the disposition criteria in Section 200.313(e).

Questioned Costs:

Unknown

Context:

As of June 30, 2023, VUMC had 1,739 equipment items and 638 inventory count sheets were not returned. As of June 30, 2023, the cost of these items was \$6,640,261 and the net book value is \$1,716,407.

Schedule of Findings and Questioned Costs (continued)

Section III—Federal Award Findings and Questioned Costs (continued)

We performed an inventory inspection of 25 items of equipment with an original cost of \$906,905 and a net book value of \$398,768. We could not locate one item with an original cost of \$15,000 and a net book value of \$0.

We performed a test of 21 dispositions with a total original cost of \$319,391 and a net book value of \$15,182. Total dispositions for the year ended June 30, 2023 had an original cost of \$1,167,770 and a net book value of \$55,268.

Total federal expenditures for the R&D Cluster was \$543,888,056 for the year ended June 30, 2023.

Effect or Potential Effect:

Physical inventory was not performed in a manner to properly support the federal physical equipment listing.

Federal physical equipment may be overstated.

Equipment may not be disposed in accordance with the criteria required under section 200.313(e)

Identification as a Repeat Finding, if Applicable

This is not a repeat finding.

Recommendation:

VUMC should implement internal controls to ensure physical inventory is performed thoroughly to ensure all equipment recorded is safeguarded and maintained.

VUMC should design and implement internal controls to ensure disposal compliance requirements are met before equipment is disposed.

Management's Response:

VUMC did perform a physical inventory during fiscal year 2023, but our documentation did not adequately support the existence of all fixed assets. VUMC will improve the internal controls around our fixed asset physical inventory procedures by ensuring that we document the location and existence of all fixed assets ensuring completeness of the physical inventory performed and allowing for reperformance by our auditors. VUMC will also improve the documentation for disposals ensuring that the required criteria under section 200.313(e) are met and can be evidenced to allow for reperformance by our auditors.

EY | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2024 Ernst & Young LLP. All Rights Reserved.

ey.com



VUIVIC FINANCE

Vanderbilt University Medical Center Management's Corrective Action Plan For the Year Ended June 30, 2023

Finding 2023-001

Federal Grantor: U.S. Department of Health and Human Services (HHS)

Research & Development Cluster

Assistance Listing No.: 93.110, 93.113, 93.121, 93.172, 93.242, 93.279, 93.389, 93.393, 93.394, 93.395, 93.396, 93.837, 93.846, 93.847, 93.849, 93.853, 93.855, 93.865, 93.RD.

VUMC did perform a physical inventory during fiscal year 2023, but our documentation did not adequately support the existence of all fixed assets. VUMC will improve the internal controls around our fixed asset physical inventory procedures by ensuring that we document the location and existence of all fixed assets ensuring completeness of the physical inventory performed and allowing for reperformance by our auditors. VUMC will also improve the documentation for disposals ensuring that the required criteria under section 200.313(e) are met and can be evidenced to allow for reperformance by our auditors. Paula Yarbrough, VUMC Director – Grants and Contracts will be responsible for implementation by fiscal year-end 2024.

VUMC Finance

Summary Schedule of Prior Year Audit Findings FOR THE Year Ended June 30, 2022 and 2021

Finding 2022-001

Federal Grantor: United States Department of Health and Human Services, Health Resources

and Services Administration (HRSA)

Assistance Listing No.: 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured

Program and the COVID-19 Coverage Assistance Fund

Management agrees with this finding and performed a review of claims submitted to the HRSA COVID-19 Uninsured Program identifying payments for ineligible services and refunded the entire overpayment amount. In March 2022, HRSA announced the discontinuance of the HRSA COVID-19 Uninsured Program and therefore remediation of internal controls is no longer applicable.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year end 2023.

Status: The corrective action plan was taken.

Finding 2022-002

Federal Agency: U.S. Department of Health and Human Services

Assistance Listing No.: 93.067, Global AIDS **Award Number:** 6 NU2GGH001943-05-09

VUMC is a prime recipient of funding from The Centers for Disease Control and Prevention related to the Global Aids grant and made first tier subawards of greater than \$30,000. VUMC reported the subaward from VUMC, the prime, to Friends in Global Health, the subrecipient as a single report in the Federal Funding Accountability and Transparency Act Subaward Reporting System (FSRS) instead of filing a separate report for each subaward. Procedures and internal controls were in place for first tier subawards.

VUMC has changed procedures and internal controls to report each Global Aid subaward separately in FSRS. All subawards have been reported in FY23 in compliance with the Transparency Act.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year end 2023.

Status: The corrective action plan was taken.

Finding 2022-003

Federal Agency: U.S. Department of Health and Human Services (HHS) Health Resources and

Services Administration (HRSA)

Assistance Listing No.: 93.498 COVID-19 Provider Relief Fund and American Rescue Plan (ARP)

Rural Distribution

All expenditures included by VUMC Management (Management) in its submissions in the Department of Health and Human Services (HHS) portal were verified against HHS guidance to ensure allowability. Management understands that additional audit evidence must be retained at a detailed enough level to allow the auditor to meet their

reperformance standard. Management believes that our control risk is mitigated by the fact that our lost revenues far exceed any provider relief funding received. However, should management need to report any future eligible



VUMC Finance

expenses in the HHS portal, we will retain additional audit evidence to enable auditor reperformance of the controls regarding allowability of expenditures.

Management also established appropriate review and approval controls surrounding the performance and review of the lost revenue analytic and the subsequent reporting of lost revenue in the HHS portal. Management retained documentation to support execution of this control, however, management understand that additional audit evidence supporting the reviews was not available to the auditor to evidence execution of this control. Management will retain additional audit evidence to allow the auditor to reperform execution of this control for future HHS portal submissions.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year end 2023.

Status: The corrective action plan was taken.

Finding 2021-001

Federal Grantor: United States Department of Health and Human Services, Health Resources

and Services Administration (HRSA)

Assistance Listing No.: 93.461, COVID-19 HRSA COVID-19 Claims Reimbursement for the Uninsured

Program and the COVID-19 Coverage Assistance Fund

Management agrees with this finding and performed a review of claims submitted to the HRSA COVID-19 Uninsured Program identifying payments for ineligible services and refunded the entire overpayment amount. In March 2022, HRSA announced the discontinuance of the HRSA COVID-19 Uninsured Program and therefore remediation of internal controls is no longer applicable.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year end 2023.

Status: Refunds were paid in fiscal year 2023.

Finding 2021-002

Federal Agency: U.S. Department of Health and Human Services

Assistance Listing No.: 93.067, Global AIDS **Award Number:** 6 NU2GGH001943-05-09

VUMC is a prime recipient of funding from The Centers for Disease Control and Prevention related to the Global Aids grant and made first tier subawards of greater than \$30,000. VUMC reported the subaward from VUMC, the prime, to Friends in Global Health, the subrecipient as a single report in the Federal Funding Accountability and Transparency Act Subaward Reporting System (FSRS) instead of filing a separate report for each subaward. Procedures and internal controls were in place for first tier subawards.

VUMC has changed procedures and internal controls to report each Global Aid subaward separately in FSRS. All subawards have been reported in FY23 in compliance with the Transparency Act.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year end 2023.

Status: The corrective action plan was taken in 2023.

Finding 2021-003

Federal Agency: U.S. Department of Health and Human Services (HHS) Health Resources and

Services Administration (HRSA)

VUMC Finance

Assistance Listing No.: 93.498 COVID-19 Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution

All expenditures included by VUMC Management (Management) in its submissions in the Department of Health and Human Services (HHS) portal were verified against HHS guidance to ensure allowability. Management understands that additional audit evidence must be retained at a detailed enough level to allow the auditor to meet their reperformance standard. Management believes that our control risk is mitigated by the fact that our lost revenues far exceed any provider relief funding received. However, should management need to report any future eligible expenses in the HHS portal, we will retain additional audit evidence to enable auditor reperformance of the controls regarding allowability of expenditures.

Management also established appropriate review and approval controls surrounding the performance and review of the lost revenue analytic and the subsequent reporting of lost revenue in the HHS portal. Management retained documentation to support execution of this control, however, management understand that additional audit evidence supporting the reviews was not available to the auditor to evidence execution of this control. Management will retain additional audit evidence to allow the auditor to reperform execution of this control for future HHS portal submissions.

Paula Yarbrough, VUMC Director – Grants and Contracts, will be responsible for implementation by fiscal year end 2023.

Status: The corrective action plan was taken in 2023.